UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                    FORM 10-Q

                                   (Mark One)

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE 
                                  ACT OF 1934

                For the quarterly period ended September 30, 2006

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
                                   ACT OF 1934

                        For the transition period from to

                           COMMISSION FILE NO. 0-26224

                    INTEGRA LIFESCIENCES HOLDINGS CORPORATION

             (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

                  DELAWARE                        51-0317849
---------------------------------------     -------------------------------
     (STATE OR OTHER JURISDICTION OF           (I.R.S. EMPLOYER
     INCORPORATION OR ORGANIZATION)            IDENTIFICATION NO.)

          311 ENTERPRISE DRIVE
          PLAINSBORO, NEW JERSEY                     08536
---------------------------------------     --------------------------------
          (ADDRESS OF PRINCIPAL                    (ZIP CODE)
           EXECUTIVE OFFICES)

         REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: (609) 275-0500

Indicate by check mark whether the registrant: (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
   Yes [X]  No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an
accelerated filer or a non-accelerated filer.  See definition of "accelerated 
filer and large accelerated filer" in Rule 12b-2 of the Exchange Act. 
(Check one):
Large accelerated filer [ ]   Accelerated filer [X]   Non-accelerated filer [ ]

Indicate by check mark whether the registrant is a shell company (as defined in 
Rule 12b-2 of the Exchange Act).   
   Yes [ ]  No [X]

The number of shares of the registrant's Common Stock, $.01 par value,
outstanding as of November 6, 2006 was 27,771,327.

                                       1

<PAGE>


                    INTEGRA LIFESCIENCES HOLDINGS CORPORATION

                                     INDEX

                                                                    Page Number

PART I.   FINANCIAL INFORMATION


Item 1.  Financial Statements
Condensed Consolidated Statements of Operations for the three and 
nine months ended September 30, 2006 and 2005 (Unaudited)......................3

Condensed Consolidated Balance Sheets as of September 30, 2006 and 
December 31, 2005 (Unaudited)..................................................4

Condensed Consolidated Statements of Cash Flows for the nine 
months ended September 30, 2006 and 2005 (Unaudited)...........................5

Notes to Unaudited Condensed Consolidated Financial Statements.................6


Item 2.  Management's Discussion and Analysis of Financial Condition 
         and Results of Operations............................................20


Item 3.  Quantitative and Qualitative Disclosures About Market Risk...........35


Item 4.  Controls and Procedures..............................................36



PART II.                   OTHER INFORMATION


Item 1.  Legal Proceedings....................................................37


Item 1A. Risk Factors.........................................................38


Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds..........41


Item 6.  Exhibits.............................................................42



SIGNATURES....................................................................43



EXHIBITS......................................................................44


                                       2


<PAGE>




PART I.  FINANCIAL INFORMATION


Item 1.  Financial Statements

<TABLE>
<CAPTION>
                                                   INTEGRA LIFESCIENCES HOLDINGS CORPORATION
                                                 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                                                                  (UNAUDITED)

(In thousands, except per share amounts)


                                                    Three Months Ended September 30,  Nine Months Ended September 30,
                                                         2006             2005             2006            2005
                                                         ----             ----             ----            ----
<s>                                                    <c>               <c>             <c>             <c>
Total Revenue..................................        $116,647          $69,334         $293,903       $204,951
Costs and Expenses:
Cost of product revenues.......................          47,559           26,394          116,869         78,423

Research and development ......................          10,991            3,110           20,518          9,256

Selling, general and administrative ...........          43,431           22,653          111,770         72,610

Intangible asset amortization .................           2,852            1,085            6,150          3,470
                                                        -------          -------         --------         ------

     Total costs and expenses .................         104,833           53,242          255,307        163,759

Operating income ..............................          11,814           16,092           38,596         41,192

Interest income ...............................             375              952            1,993          2,813

Interest expense ..............................          (4,362)          (1,345)          (8,117)        (3,094)

Other income (expense), net ...................          (1,765)              (4)          (1,832)          (638)
                                                        -------          -------         --------         -------

Income before income taxes ....................           6,062           15,695           30,640          40,273

Income tax expense ............................           3,468            5,213           11,364          13,693
                                                        -------          -------         --------         -------

Net income.....................................         $ 2,594          $10,482         $ 19,276        $ 26,580
                                                        =======          =======         ========        ========

Basic net income per share ....................          $ 0.09           $ 0.35           $ 0.65          $ 0.88

Diluted net income per share ..................          $ 0.09           $ 0.33           $ 0.64          $ 0.82

Weighted average common
shares outstanding :
     Basic ....................................          29,193           30,039           29,457          30,334

     Diluted ..................................          29,867           34,297           30,162          34,727
</TABLE>


The accompanying notes are an integral part of these condensed consolidated
financial statements.


                                       3

<PAGE>



                    INTEGRA LIFESCIENCES HOLDINGS CORPORATION
                      CONDENSED CONSOLIDATED BALANCE SHEETS
                                   (UNAUDITED)

(In thousands)

<TABLE>
<CAPTION>
                                                                             September 30, 2006        December 31, 2005
<s>                                                                             <c>                   <c>
ASSETS
Current Assets:
     Cash and cash equivalents.........................................         $  24,322             $  46,889
     Short-term investments ...........................................                --                80,327
     Accounts receivable, net of allowances of
         $4,520 and $3,508 ............................................            76,715                49,007
     Inventories, net .................................................            93,773                67,476
     Deferred tax assets...............................................            11,337                10,842
     Prepaid expenses and other current assets ........................            13,352                11,411
                                                                                ---------             ---------

         Total current assets .........................................           219,499               265,952

Non-current investments................................................                --                16,168
Property, plant, and equipment, net ...................................            40,659                27,451
Identifiable intangible assets, net ...................................           178,354                64,569
Goodwill...............................................................           158,243                68,364
Other assets ..........................................................             7,705                 5,928
                                                                                ---------             ---------

Total assets ..........................................................         $ 604,460             $ 448,432
                                                                                =========             =========

LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities:
     Borrowings under senior credit facility...........................            87,000                    --
     Convertible securities............................................           115,205                    --
     Accounts payable, trade ..........................................            16,255                 8,978
     Income taxes payable .............................................                --                   715
     Deferred revenue .................................................             4,986                    88
     Accrued expenses and other current liabilities ...................            32,010                21,506
                                                                                ---------             ---------

         Total current liabilities ....................................           255,456                31,287

Long-term debt ........................................................             4,889               118,378
Deferred tax liabilities ..............................................            33,094                 2,520
Other liabilities......................................................             5,540                 6,429
                                                                                ---------             ---------

Total liabilities .....................................................           298,979               158,614

Commitments and contingencies (see Footnote 11)                                        --                    --

Stockholders' Equity:
     Common stock; $0.01 par value; 60,000 authorized shares; 
         31,190 and 29,823 issued at September 30, 2006 and 
         December 31, 2005, respectively ..............................               312                   298

     Additional paid-in capital .......................................           353,415               333,179
     Treasury stock, at cost; 3,226 and 2,368 shares at
         September 30, 2006 and December 31, 2005, respectively .......          (107,640)              (75,815)
     Accumulated other comprehensive income (loss):
         Unrealized loss on available-for-sale securities, net of tax .                --                  (801)
         Foreign currency translation adjustment ......................             5,010                (2,300)
         Minimum pension liability adjustment, net of tax .............            (1,821)               (1,672)
     Retained earnings.................................................            56,205                36,929
                                                                                ---------             ---------

         Total stockholders' equity ...................................           305,481               289,818
                                                                                ---------             ---------

Total liabilities and stockholders' equity ............................         $ 604,460             $ 448,432
                                                                                =========             =========
</TABLE>

The accompanying notes are an integral part of these condensed consolidated
financial statements.


                                       4


<PAGE>

                    INTEGRA LIFESCIENCES HOLDINGS CORPORATION
                 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                                   (UNAUDITED)

<TABLE>
<CAPTION>
(In thousands)

                                                                                 Nine Months Ended September 30,
                                                                                    2006                  2005
                                                                                    ----                  ----
<s>                                                                             <c>                     <c>
OPERATING ACTIVITIES:
Net income ............................................................         $ 19,276                $ 26,580
Adjustments to reconcile net income to net cash provided by
   operating activities:
         Depreciation and amortization ................................           13,181                   8,488
         Deferred income tax provision (benefit) ......................           (7,821)                 10,004
         Amortization of discount/premium on investments ..............              364                   1,543
         Loss of sale of assets/ investments ..........................            1,112                      --
         Amortization of bond issuance costs...........................            1,910                     611
         Share-based compensation .....................................           10,499                      77
         Excess tax benefits from stock-based compensation arrangements             (730)                     --
         In-process research and development...........................            5,600                     500
         Other, net ...................................................              200                      40
     Changes in assets and liabilities, net of business acquisitions:..
         Accounts receivable ..........................................          (18,373)                  2,975
         Inventories ..................................................             (527)                (11,505)
         Prepaid expenses and other current assets ....................             (460)                 (5,139)
         Other non-current assets .....................................             (114)                    144
         Accounts payable accrued expenses and other liabilities.......            4,215                  (1,337)
         Income taxes payable .........................................             (316)                   (869)
         Deferred revenue .............................................            4,776                     (72)
         Other accrued expenses and current liabilities................            7,781                   9,677
         Deferred tax liabilities......................................           10,409                      --
         Other non-current liabilities.................................             (214)                    170
                                                                                ---------               --------

Net cash provided by operating activities .............................           50,768                  41,887
                                                                                ---------               --------

INVESTING ACTIVITIES:
Cash used in business acquisition, net of cash acquired ...............         (227,114)                (50,527)
Proceeds from sales/maturities of investments..........................          109,872                  39,477
Purchases of available-for-sale investments ...........................          (13,074)                (36,724)
Purchases of property and equipment ...................................           (7,236)                 (6,632)
                                                                                ---------               ---------

Net cash used in investing activities .................................         (137,552)                (54,406)
                                                                                ---------               ---------

FINANCING ACTIVITIES:
Borrowings under senior credit facility................................          140,000                      --
Repayment of loans ....................................................          (54,463)                   (270)
Proceeds from exercised stock options..................................            9,155                   5,368
Excess tax benefits from stock-based compensation arrangements ........              730                      --
Purchases of treasury stock ...........................................          (31,825)                (24,650)
                                                                                ---------               ---------

Net cash provided by (used in) financing activities ...................           63,597                 (19,552)
                                                                                --------                ---------

Effect of exchange rate changes on cash and cash equivalents...........              620                    (432)
                                                                                --------                -------- 
Net decrease in cash and cash equivalents .............................          (22,567)                (32,503)

Cash and cash equivalents at beginning of period ......................           46,889                  69,855
                                                                                --------                --------

Cash and cash equivalents at end of period ............................         $ 24,322                $ 37,352
                                                                                ========                ========
</TABLE>

The accompanying notes are an integral part of these condensed consolidated
financial statements.

                                       5


<PAGE>

                    INTEGRA LIFESCIENCES HOLDINGS CORPORATION
         NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1.       BASIS OF PRESENTATION

General

In the opinion of management, the September 30, 2006 unaudited condensed
consolidated financial statements contain all adjustments (consisting only of
normal recurring adjustments) necessary for a fair statement of the financial
position, results of operations and cash flows of the Company. Certain
information and footnote disclosures normally included in financial statements
prepared in accordance with generally accepted accounting principles have been
condensed or omitted in accordance with the instructions to Form 10-Q and Rule
10-01 of Regulation S-X. These unaudited condensed consolidated financial
statements should be read in conjunction with the Company's consolidated
financial statements for the year ended December 31, 2005 included in the
Company's Annual Report on Form 10-K. The December 31, 2005 condensed
consolidated balance sheet was derived from audited financial statements but
does not include all disclosures required by accounting principles generally
accepted in the United States. Operating results for the three- and nine-month
periods ended September 30, 2006 are not necessarily indicative of the results
to be expected for the entire year.

The preparation of consolidated financial statements in conformity with
accounting principles generally accepted in the United States requires
management to make estimates and assumptions that affect the reported amount of
assets and liabilities, the disclosure of contingent liabilities, and the
reported amounts of revenues and expenses. Significant estimates affecting
amounts reported or disclosed in the consolidated financial statements include
allowances for doubtful accounts receivable and sales returns, net realizable
value of inventories, estimates of future cash flows associated with long-lived
asset valuations, depreciation and amortization periods for long-lived assets,
fair value estimates of stock-based compensation awards, valuation allowances
recorded against deferred tax assets, estimates of amounts to be paid to
employees and other exit costs to be incurred in connection with the
restructuring of our operations and loss contingencies. These estimates are
based on historical experience and on various other assumptions that are
believed to be reasonable under the current circumstances. Actual results could
differ from these estimates.

Certain reclassifications have been made to the prior year financial statements
to conform to the current year's presentation.

We revised our presentation of cost of product revenues in 2006 to include
amortization of product technology-based intangible assets. Previously, this
amortization was included in intangible asset amortization in the condensed
consolidated statement of operations. We have revised prior period amounts to
conform to the current year's presentation. This revision increased cost of
product revenues by $380,000 and $1,138,000 for the three and nine-month periods
ended September 30, 2005, respectively.

Recently Adopted Accounting Standard

The Company adopted Statement of Financial Accounting Standards No. 123(R)
"Share-Based Payment" on January 1, 2006 using the modified prospective method
which requires companies (1) to record the unvested portion of previously issued
awards that remain outstanding at the initial date of adoption and (2) to record
compensation expense for any awards issued, modified or settled after the
effective date of the statement. As a result of the adoption of Statement
123(R), the Company began expensing stock options in the 2006 first quarter
using the fair value method prescribed by Statement 123(R). Stock-based
compensation cost is measured at the grant date based on the fair value of an
award and is recognized on a straight-line basis as an expense over the
requisite service period, which is the vesting period. Certain of these costs
are capitalized into inventory and will be recognized as an expense when the
related inventory is sold. The Company's income before income taxes and net
income for the nine months ended September 30, 2006 were $10.3 million and $3.3
million lower, respectively, than if it had continued to account for share-based
compensation under APB No. 25.

The Company recognizes stock-based compensation expense in the consolidated
statement of operations based on the awards that are expected to vest.
Accordingly, the Company's recognized stock-based compensation expense is net of

                                       6

<PAGE>

the impact of estimated forfeitures. Statement 123(R) requires forfeitures to be
estimated at the time of grant and revised, if necessary, in subsequent periods
if actual forfeitures differ from those estimates. The Company estimates
forfeitures based on historical experience.

Statement 123(R) supercedes the Company's previous accounting under Accounting
Principals Boards Opinion No. 25 "Accounting for Stock Issued to Employees" for
periods subsequent to December 31, 2005. In March 2005, the Securities and
Exchange Commission issued Staff Accounting Bulletin No. 107, which provides
interpretive guidance in applying the provisions of Statement 123(R). The
Company has applied the provisions of SAB 107 in its adoption of Statement
123(R). Had compensation cost for the Company's stock option plans been
determined based on the fair value of the award at the grant date consistent
with Statement 123, the Company's net income and basic and diluted net income
per share for the three and nine months ended September 30, 2005 would have been
as follows (in thousands, except per share amounts):

<TABLE>
<CAPTION>
                                                                   Three Months Ended     Nine Months Ended
                                                                   September 30, 2005     September 30, 2005
                                                                   ------------------     ------------------
     <s>                                                                 <c>                    <c>
     Net income, as reported...........................                  $10,482                $26,580
     Add back:  Total stock-based employee compensation
                expense determined under the intrinsic 
                value-based method for all awards, net of                   30                       53
                related tax effects...................
     Less:      Total stock-based employee compensation 
                expense determined under the fair 
                value-based method for all awards, net of 
                related tax effects....................                   (1,897)                (5,383)
                                                                        --------                -------

         Pro forma ....................................                  $ 8,615                $21,250
                                                                         =======                =======

     Net income per share:
         Basic:
         As reported ..................................                  $  0.35                $  0.88
         Pro forma ....................................                  $  0.29                $  0.70

         Diluted:
         As reported ..................................                  $  0.33                $  0.82
         Pro forma ....................................                  $  0.28                $  0.67
</TABLE>

Statement 123(R) did not change the accounting for stock-based awards granted to
non-employees.


Recently Issued Accounting Standards and Other Matters

In September 2006, the Financial Accounting Standards Board (FASB) issued SFAS
No. 158, Employer's Accounting for Defined Benefit Pension and Other
Postretirement Plans--an amendment of FASB Statements No. 87, 88, 106 and 132(R)
. SFAS No. 158 requires the Company to (a) recognize a plan's funded status in
its statement of financial position, (b) measure a plan's assets and its
obligations that determine its funded status as of the end of the employer's
fiscal year, and (c) recognize changes in the funded status of a defined
postretirement plan in the year in which the changes occur through other
comprehensive income. The requirement to recognize the funded status of a
benefit plan and the disclosure requirements are effective for the Company for
the fiscal year ending December 31, 2006. The Company believes the
implementation of this provision will not have a material impact on its 
financial position or results of operations.

In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements. This
Statement defines fair value, establishes a framework for measuring fair value
in generally accepted accounting principles (GAAP), and expands disclosures
about fair value measurements. SFAS No. 157 is effective for financial
statements issued for fiscal years beginning after November 15, 2007. The
Company is currently assessing the impact this provision may have on its
financial position or results of operations.

In September 2006, the SEC issued Staff Accounting Bulletin No. 108, Considering
the Effects of Prior Year Misstatements when Quantifying Misstatements in
Current Year Financial Statements (SAB 108), to address diversity in practice in
quantifying financial statement misstatements. SAB 108 requires the
quantification of misstatements based on their impact to both the balance sheet
and the income statement to determine materiality. The guidance provides for a
one-time cumulative effect adjustment to correct for misstatements for errors
that were not deemed material under a company's prior approach but are material
under the SAB 108 approach. SAB 108 is effective for the fiscal year ending
December 31, 2006. The Company believes the implementation of this
provision will not have a material impact on its financial position or results 
of operations.

                                       7

<PAGE>

In July 2006, the FASB issued FASB Interpretation 48, "Accounting for
Uncertainty in Income Taxes - An Interpretation of FASB Statement No. 109" (FIN
48). FIN 48 clarifies the accounting for uncertainty in income tax recognition
in a company's financial statements in accordance with FASB Statement No. 109,
Accounting for Income Taxes, by defining the criterion that an individual tax
position must meet in order to be recognized in the financial statements. FIN 48
requires that the tax effects of a position be recognized only if it is
"more-likely-than-not" to be sustained based solely on the technical merits as
of the reporting date. FIN 48 further requires that interest that the tax law
requires to be paid on the underpayment of taxes should be accrued on the
difference between the amount claimed or expected to be claimed on the return
and the tax benefit recognized in the financial statements. FIN 48 also requires
additional disclosures of unrecognized tax benefits, including a reconciliation
of the beginning and ending balance. The provisions of FIN 48 are effective
January 1, 2007. The Company is currently assessing the impact that the adoption
of FIN 48 will have on its financial position or results of operations.


2.       BUSINESS ACQUISITIONS

Newdeal Technologies SAS

In January 2005, the Company acquired all of the outstanding capital stock of
Newdeal Technologies SAS ("Newdeal Technologies") for $51.9 million in cash paid
at closing, a $0.7 million working capital adjustment paid in January 2006, and
$0.8 million of acquisition related expenses. Additionally, the Company agreed
to pay the sellers up to an additional 1.3 million Euros if the sellers were to
continue their employment with the Company through January 3, 2006. This
additional payment was accrued to selling, general and administrative expense on
a straight-line basis in 2005 over the one-year employment requirement period
and was paid in January 2006.

Radionics

On March 3, 2006, the Company acquired the assets of the Radionics Division of
Tyco Healthcare Group, L.P. for approximately $74.5 million in cash paid at
closing, subject to certain adjustments, and $3.2 million of acquisition-related
expenses in a transaction treated as a business combination. Radionics, based in
Burlington, Massachusetts, is a leader in the design, manufacture and sale of
advanced minimally invasive medical instruments in the fields of neurosurgery
and radiation therapy. Radionics' products include the CUSA EXcel(R) ultrasonic
surgical aspiration system, the CRW(R) stereotactic system, the XKnife(R)
stereotactic radiosurgery system, and the OmniSight(R) EXcel image-guided
surgery system.

The following summarizes the fair value of the assets acquired and liabilities
assumed:

<TABLE>
         <s>                                                                     <c>              <c>
         Inventory ..................................................             $ 8,201

         Property, plant and equipment ..............................               1,365         Wtd. Avg. Life
                                                                                                  --------------

         Intangible assets:
              Tradename .............................................              18,100           Indefinite
              Customer relationships ................................              20,900            7 years
              Technology ............................................              10,000            10 years
         Goodwill ...................................................              21,054
         Other assets ...............................................                  72
                                                                                  -------

              Total assets acquired .................................              79,692
                                                                                  -------

         Accrued expenses and other current liabilities .............                 425

         Deferred revenue ...........................................               1,605
                                                                                  -------
              Total liabilities assumed .............................               2,030
                                                                                  -------

         Net assets acquired ........................................             $77,662
                                                                                  =======
</TABLE>

                                       8

<PAGE>

Management determined the fair value of assets acquired with the assistance of a
third-party valuation firm. Certain adjustments were finalized in the second
quarter of 2006 relating to the Radionics valuation, which primarily resulted in
an increase to intangible assets and a reduction in goodwill of $4 million. The
adjustment was related to the finalization of certain assumptions in the
valuation of identifiable intangible assets. Additional direct costs of
approximately $450,000 were paid in the third quarter and have been added to
goodwill. The goodwill recorded in connection with this acquisition is based on
the benefits the Company expects to generate from the synergy between Radionics'
ultrasonic aspirator product line and the Company's ultrasonic aspirator product
lines. The goodwill acquired in the Radionics acquisition is expected to be
deductible for tax purposes.

Miltex

On May 12, 2006, the Company acquired all of the outstanding capital stock of
Miltex Holdings, Inc. ("Miltex") for $102.7 million in cash paid at closing,
subject to certain adjustments, and $0.6 million of transaction-related costs.
Miltex, based in York, Pennsylvania, is a leading provider of surgical and
dental hand instruments to alternate site facilities, which includes physician
and dental offices and ambulatory surgery care sectors. Miltex sells products
under the Miltex(R), Meisterhand(R), Vantage(R), Moyco(R), Union Broach(R), and
Thompson(R) trade names in over 65 countries, using a network of independent
distributors. Miltex operates a manufacturing and distribution facility in York,
Pennsylvania and also operates a leased facility in Tuttlingen, Germany, where
Miltex's staff coordinates design, production and delivery of instruments.

The following summarizes the preliminary allocation of the purchase price based
on the fair value of the assets acquired and liabilities assumed (in thousands):

<TABLE>
         <s>                                                                     <c>              <c>
         Inventory ..................................................            $ 16,775

         Other current assets .......................................               7,935

         Property, plant and equipment ..............................               7,699

         Intangible assets:                                                                       Wtd. Avg. Life
                                                                                                  --------------
              Customer relationships ................................              13,100            15 years
              Tradename (Miltex).....................................              13,500           Indefinite
              Tradename (Moyco, Union Branch, Thompson)..............                 300             4 years
              Tradename (other product lines)........................                 600            15 years
              Technology ............................................               1,100            10 years
              Supplier relationships.................................              29,300            30 years
         Goodwill ...................................................              40,431
         Other assets ...............................................                 219
                                                                                 --------

              Total assets acquired .................................             130,959
                                                                                 --------

         Accrued expenses and other current liabilities .............               5,066

         Deferred tax liabilities ...................................              22,588
                                                                                 --------

              Total liabilities assumed .............................              27,654
                                                                                 --------

         Net assets acquired ........................................            $103,305
                                                                                 ========
</TABLE>


Management determined the preliminary fair value of assets acquired with the
assistance of a third-party valuation firm. Certain adjustments were made in the
third quarter of 2006 relating to the Miltex valuation. The most significant of
which resulted in the recognition of a $29.3 million supplier relationship
intangible asset, a decrease of $1.9 million in the customer relationship
intangible asset, a decrease in goodwill of $13.8 million and an increase in
deferred tax liabilities of $11.7 million. A portion of the goodwill acquired in
the Miltex acquisition is expected to be deductible for tax purposes. Certain
elements of the purchase price allocation are considered preliminary,
particularly as they relate to the final valuation of certain identifiable
intangible assets. Additional changes are not expected to be significant as the
allocations are finalized.

                                       9

<PAGE>


Canada Microsurgical, Ltd.

On July 5, 2006, the Company acquired all of the outstanding capital stock of
Canada Microsurgical, Ltd. ("CML") for $5.8 million in cash paid at closing,
subject to certain adjustments, and $0.1 million of transaction-related costs.
In addition, the Company may pay up to an additional 2.1 million Canadian
dollars over the next three years, depending on the performance of the business.
If and when such amounts are paid, then those payments will be added to
goodwill. CML, a long-standing distributor for the Company, has eight sales
representatives covering each province in Canada.

The following summarizes the preliminary allocation of the purchase price based
on the fair value of the assets acquired and liabilities assumed (in thousands):

<TABLE>
         <s>                                                                       <c>           <c>
         Inventory ..................................................              $1,576

         Other current assets .......................................               1,121

         Intangible assets:                                                                       Wtd. Avg. Life
                                                                                                  --------------
              Customer relationships ................................               2,994            6 years
              Tradename .............................................               2,140            15 years
              Non-compete............................................                  90            5 years
         Goodwill ...................................................                 610
         Other assets ...............................................                  21
                                                                                   ------

              Total assets acquired .................................               8,552
                                                                                   ------

         Accrued expenses and other current liabilities .............                 686

         Deferred tax liabilities ...................................               1,963
                                                                                   ------

              Total liabilities assumed .............................               2,649
                                                                                   ------

         Net assets acquired ........................................              $5,903
                                                                                   ======
</TABLE>


Management determined the preliminary fair value of assets acquired. Certain
elements of the purchase price allocation are considered preliminary,
particularly as they relate to the final valuation of certain identifiable
intangible assets. Additional changes are not expected to be significant as the
allocations are finalized.

Kinetikos Medical, Inc.

On July 31, 2006, the Company acquired all of the outstanding capital stock of
Kinetikos Medical, Inc. ("KMI") for $39.5 million in cash paid at closing,
subject to certain adjustments, and $1.1 million of transaction-related costs.
In addition, the Company may pay up to an additional $20 million over the next
two years, depending on the performance of the business. If and when such
amounts are paid, then those payments will be added to goodwill. Subsequent to
closing, the Company implemented certain changes in the KMI business, including
eliminating approximately one-half of the positions located in the Carlsbad,
California facility. In addition, the Company plans to discontinue operating
under the name of KMI before the end of this year and to exit the Carlsbad
facility and move the remaining operations to its San Diego facility during
2007. A restructuring provision of $360,000 has been set up on the opening
balance sheet in connection with these plans as part of the purchase price
allocation.

KMI, based in Carlsbad, California, was a leading developer and manufacturer of
innovative orthopedic implants and surgical devices for small bone and joint
procedures involving the foot, ankle, hand, wrist and elbow. KMI marketed
products that addressed both the trauma and reconstructive segments of the
extremities market. KMI's reconstructive products are largely focused on
treating deformities and arthritis in small joints of the upper and lower
extremity, while its trauma products are focused on the treatment of fractures
of small bones most commonly found in the extremities. The Company has
integrated the KMI product line into its U.S. direct sales force while
maintaining seven former KMI independent sales agencies. The Company plans to
increase sales of KMI products internationally through its well-established
Newdeal infrastructure.

                                       10

<PAGE>


The following summarizes the preliminary allocation of the purchase price based
on the fair value of the assets acquired and liabilities assumed (in thousands):

<TABLE>
         <s>                                                                      <c>            <c>
         Inventory ..................................................             $ 2,208

         Other current assets .......................................               2,451

         Property, plant and equipment ..............................               1,646

         Intangible assets:                                                                        Wtd. Avg. Life
                                                                                                   --------------
              Customer relationships ................................               6,100            3.5 years
              Tradename (MBA, UNI2) .................................                 300             5 years
              Developed technology patents...........................               2,000             15 years
              In-process research and development....................               5,600       Expensed immediately
         Goodwill ...................................................              23,624
         Other assets ...............................................               1,260
                                                                                  -------

              Total assets acquired .................................              45,189
                                                                                  -------

         Accrued expenses and other liabilities .....................               1,933

         Deferred tax liabilities ...................................               2,684
                                                                                  -------

              Total liabilities assumed .............................               4,617
                                                                                  -------

         Net assets acquired ........................................             $40,572
                                                                                  =======
</TABLE>


Management determined the preliminary fair value of assets acquired with the
assistance of a third-party valuation firm. The Company recorded an in-process
research and development charge of $5.6 million in the third quarter of 2006 in
connection with this acquisition. Certain elements of the purchase price
allocation are considered preliminary, particularly as they relate to the final
valuation of certain identifiable intangible assets. Additional changes are not
expected to be significant as the allocations are finalized.

The results of operations of each of the acquired businesses have been included
in the condensed consolidated financial statements since their respective dates
of acquisition.

The following unaudited pro forma financial information summarizes the results
of operations for the three months and nine months ended September 30, 2006 and
2005 as if the acquisitions had been completed as of the beginning of 2005. The
pro forma results are based upon certain assumptions and estimates, and they
give effect to actual operating results prior to the acquisitions and
adjustments to reflect increased interest expense, depreciation expense,
intangible asset amortization, and income taxes at a rate consistent with the
Company's statutory rate in each year. No effect has been given to cost
reductions or operating synergies. As a result, these pro forma results do not
necessarily represent results that would have occurred if the acquisitions had
taken place on the basis assumed above, nor are they indicative of the results
of future combined operations.


<TABLE>
<CAPTION>
                                                    Three Months Ended September 30,   Nine Months Ended September
                                                                                                    30,

(in thousands, except per share amounts)                 2006             2005             2006            2005
                                                         ----             ----             ----            ----
<s>                                                    <c>              <c>              <c>             <c>
Total Revenue..................................        $117,768         $103,357         $337,692        $305,932

Net income .....................................          7,777           12,286           22,568          23,754
Net income per share:
     Basic .....................................          $0.27            $0.41            $0.77           $0.78

     Diluted ...................................          $0.26            $0.38             $0.75           $0.74
</TABLE>


                                       11

<PAGE>

3.       INVENTORIES

<TABLE>
<CAPTION>
Inventories, net consisted of the following (in thousands):

                                                           September 30, 2006    December 31, 2005
<s>                                                                <c>                  <c>
Raw materials........................................              $15,138              $13,175
Work-in process......................................               14,331                9,801
Finished goods.......................................               64,304               44,500
                                                                  --------             --------

                                                                   $93,773              $67,476
                                                                   =======              =======
</TABLE>


The Company capitalizes inventory costs associated with certain products prior
to regulatory approval, based on management's judgment of probable future
commercialization. The Company could be required to expense previously
capitalized costs related to pre-approval inventory upon a change in such
judgment, due to, among other potential factors, a denial or delay of approval
by necessary regulatory bodies or a decision by management to discontinue the
related development program.

In June 2006, the Company recorded a $1.2 million charge to research and
development related to pre-approval inventory associated with a project to
develop an ultrasonic aspirator system. The Company discontinued this project in
June 2006 following management's review of the Company's existing technology and
the ultrasonic aspirator technology acquired in the Radionics acquisition.
Management determined that there was no future, alternative use for the
pre-approval inventory in any other development project.

4.       GOODWILL AND OTHER INTANGIBLE ASSETS

Changes in the carrying amount of goodwill for the nine months ended September
30, 2006, were as follows:

<TABLE>
<s>                                                                                             <c>
Balance at December 31, 2005 ...............................................................      $ 68,364
Radionics acquisition ......................................................................        21,054
Newdeal working capital adjustment..........................................................           694
Miltex acquisition (based on preliminary allocation) .......................................        40,431
Canada Microsurgical Ltd. acquisition (based on preliminary allocation) ....................           610
Kinetikos Medical, Inc. acquisition (based on preliminary allocation) .................... .        23,624
Foreign currency translation ...............................................................         3,466
                                                                                                  --------
Balance at September 30, 2006 ..............................................................      $158,243
                                                                                                  ========
</TABLE>



<TABLE>
<CAPTION>
The components of the Company's identifiable intangible assets were as follows
(in thousands):

                                                                          September 30, 2006         December 31, 2005

                                                           Weighted
                                                            Average                 Accumulated               Accumulated
                                                             Life         Cost      Amortization    Cost      Amortization
<s>                                                        <c>          <c>          <c>          <c>          <c>
Completed technology ..............................          12 years   $ 32,816     $ (7,669)    $ 18,921     $ (5,691)
Customer relationships ............................          12 years     66,085       (8,705)      22,550       (4,823)
Trademarks/brand names ............................        Indefinite     31,600           --           --           --
Trademarks/brand names ............................          34 years     34,726       (3,700)      31,175       (2,802)
Noncompetition agreements..........................           5 years      7,109       (3,711)       6,943       (2,607)
Supplier relationships.............................          30 years     29,300         (375)          --           --
All other .........................................          15 years      1,620         (742)       2,233       (1,330)
                                                                        --------     ---------    --------     ---------

                                                                        $203,256     $(24,902)    $ 81,822     $(17,253)

Accumulated amortization ..........................                      (24,902)                  (17,253)
                                                                        ---------                 ---------
                                                                        $178,354                  $ 64,569
                                                                        ========                  ========
</TABLE>


                                       
                                       12

<PAGE>

Annual amortization expense is expected to approximate $11.7 million in 2006,
$14.3 million in 2007, $14.0 million in 2008, $12.5 million in 2009, and $10.8
million in 2010. Identifiable intangible assets are initially recorded at fair
market value at the time of acquisition generally using an income or cost
approach.

5.       RESTRUCTURING ACTIVITIES

In June 2005, management announced plans to restructure the Company's European
operations. The restructuring plan included closing the Company's Integra ME
production facility in Tuttlingen, Germany and reducing various positions in the
Company's production facility located in Biot, France, both of which were
substantially completed in December 2005. The Company transitioned the
manufacturing operations of Integra ME to its production facility in Andover,
UK. The Company also eliminated some duplicative sales and marketing positions,
primarily in Europe. The Company terminated 68 individuals under the European
restructuring plan.

During the nine months ended September 30, 2006, the Company terminated four
employees in connection with the transfer of certain manufacturing packaging
operations from its plant in Plainsboro, New Jersey to its plant in Anasco,
Puerto Rico. The Company may terminate approximately ten additional employees
over the next nine to twelve months in connection with this transfer; however no
final decision has been made.

In connection with these restructuring activities, the Company has recorded the
following charges during the three and nine months ended September 30, 2006 (in
thousands):

<TABLE>
<CAPTION>
                                                                               Research      Selling
                                                                   Cost of       and        General and
                                                                    Sales     Development  Administrative   Total
                                                                   -------    -----------  --------------   -----
<s>                                                                <c>          <c>           <c>           <c>
Involuntary employee termination costs:
Three months ended September 30, 2006..........................      $  63           --           --        $   63
Nine months ended September 30, 2006...........................      $ 418         $ 22           --         $ 440
</TABLE>


Below is a reconciliation of the restructuring accrual activity recorded during
2006 (in thousands):

<TABLE>
<CAPTION>

                                                                                        Employee    Facility
                                                                                       Termination   Exit
                                                                                          Costs      Costs      Total
<s>                                                                                      <c>         <c>       <c>
Balance at December 31, 2005 ........................................................     $2,420     $ 124     $2,544
Additions............................................................................        268        --        268
Change in estimate...................................................................        (18)       --        (18)
Payments ............................................................................     (1,991)     (115)    (2,106)
Effects of Foreign Exchange .........................................................        108         5        113
                                                                                          ------     -----     ------

Balance at September 30, 2006 .......................................................     $  787     $  14     $  801
                                                                                          ======     =====     ======
</TABLE>


The Company expects to pay all of the remaining costs by the end of 2007.

6.       STOCK-BASED COMPENSATION

As of September 30, 2006, the Company had stock options, restricted stock
awards, performance stock awards, contract stock awards and restricted stock
unit awards outstanding under seven plans, the 1993 Incentive Stock Option and
Non-Qualified Stock Option Plan (the 1993 Plan), the 1996 Incentive Stock Option
and Non-Qualified Stock Option Plan (the 1996 Plan), the 1998 Stock Option Plan
(the 1998 Plan), the 1999 Stock Option Plan (the 1999 Plan), the 2000 Equity
Incentive Plan (the 2000 Plan), the 2001 Equity Incentive Plan (the 2001 Plan),
and the 2003 Equity Incentive Plan (the 2003 Plan, and collectively, the Plans).
No new awards may be granted under the 1993 Plan or the 1996 Plan.

Stock options issued under the Plans become exercisable over specified periods,
generally within four years from the date of grant for officers, employees and
consultants, and generally expire six years from the grant date. The transfer
and non-forfeiture provisions of restricted stock issued under the Plans lapse
over specified periods, generally at three years after the date of grant.

                                       13

<PAGE>

Prior to the adoption of Statement 123(R), the Company presented all tax
benefits resulting from the exercise of stock options as operating cash flows
(reflected in accrued taxes). Statement 123(R) requires the cash flows resulting
from excess tax benefits (tax deductions realized in excess of the compensation
costs recognized for the options exercised) from the date of adoption of
Statement 123(R) to be classified as financing cash flows. Therefore, as of
January 1, 2006, excess tax benefits for the nine months ended September 30,
2006, have been classified as financing cash flows.

At September 30, 2006, there were 6,697,371 shares authorized for issuance under
the Plans, with 1,537,024 shares available for grant under the Plans.

Employee stock-based compensation expense recognized under FAS 123(R) was as
follows (in thousands, except for per share data):

<TABLE>
<CAPTION>
                                                                              Three Months Ended   Nine Months Ended
                                                                              September 30, 2006   September 30, 2006
<s>                                                                                  <c>                 <c>      
Research and development expense............................................           $  168              $   452
Selling, general and administrative.........................................            3,529                9,613
Amortization of amounts previously capitalized to inventory.................              112                  217
                                                                                       ------              -------
Total employee stock-based compensation expense.............................            3,809               10,282
Tax benefit related to employee stock-based compensation expense............           (1,212)              (3,253)
                                                                                       -------             --------
Net effect on net income....................................................           $2,597              $ 7,029
                                                                                       ======              =======

Effect on earnings per share:
         Basic..............................................................           $  .09              $   .24
         Diluted............................................................           $  .09              $   .21
</TABLE>


As of September 30, 2006, $111,000 of stock-based compensation costs remain
capitalized in inventory based on the underlying employees receiving the awards.

Stock Options

The following is a summary of stock option activity for the nine-month period
ended September 30, 2006 (shares in thousands):

<TABLE>
<CAPTION>
                                                                                                    Wtd. Avg.
                                                                                                    Remaining     Aggregate
                                                                                       Wtd. Avg.   Contractual    Intrinsic
                                                                     Stock Options     Ex. Price   Term Years       Value
<s>                                                                        <c>         <c>             <c>       <c>
Outstanding, December 31, 2005..................................           4,001        $27.50
Granted ........................................................              73         35.85
Exercised ......................................................            (436)        21.31
Cancelled ......................................................             (87)        33.30
                                                                           -----         -----

Outstanding, September 30, 2006.................................           3,551        $28.28         4.3      $32.7 million
                                                                          ======
                                      
Options exercisable at September 30, 2006.......................           2,146        $25.06         3.4      $26.6 million
</TABLE>


The intrinsic value of options exercised during the nine-month periods ended
September 30, 2006 and 2005 was $7.7 million and $8.7 million, respectively. The
weighted-average per share fair value of stock options granted during the nine
months ended September 30, 2006 and 2005 was $15.35 and $14.49, respectively.

As of September 30, 2006, there was approximately $18.2 million of total
unrecognized compensation costs related to unvested stock options. These costs
are expected to be recognized over a weighted-average period of approximately
2.8 years.

The fair value of options granted prior to October 1, 2004 was calculated using
the Black-Scholes model, while the fair value of options granted on or after
October 1, 2004 was calculated using the binomial distribution model. Expected
volatilities are based on historical volatility of the Company's stock price
with forward-looking assumptions. The expected life of stock options is
estimated based on historical data on exercises of stock options, post-vesting
forfeitures and other factors to estimate the expected term of the stock options
granted. The risk-free interest rates are derived from the U.S. Treasury yield

                                       14

<PAGE>

curve in effect on the date of grant for instruments with a remaining term
similar to the expected life of the options. In addition, the Company applies an
expected forfeiture rate when amortizing stock-based compensation expenses. The
estimate of the forfeiture rate is based primarily upon historical experience of
employee turnover. As individual grant awards become fully vested, stock-based
compensation expense is adjusted to recognize actual forfeitures. The Company
used the following weighted-average assumptions to calculate the fair value for
stock options granted during the following periods:

<TABLE>
<CAPTION>
                                                    Three Months Ended September 30,  Nine Months Ended September 30,

                                                         2006             2005             2006            2005
                                                         ----             ----             ----            ----
<s>                                                    <c>               <c>              <c>             <c>
Dividend yield.................................           0%               0%               0%               0%
Expected volatility ............................         43%              43%              43%              43%
Risk free interest .............................        4.3%             3.4%             3.4%             3.4%
Expected life of option from grant date.........        5.4 years        5.4 years        5.4 years        5.4 years
</TABLE>


The Company received proceeds of $9.2 million and $5.4 million from stock option
exercises for the nine months ended September 30, 2006 and 2005, respectively.

Awards of Restricted Stock, Performance Stock and Contract Stock

The following is a summary of awards of restricted stock, performance stock and
contract stock for the nine-month period ended September 30, 2006 (shares in
thousands):

<TABLE>
<CAPTION>
                                                                                           Performance Stock and
                                                        Restricted Stock Awards            Contract Stock Awards

                                                                      Wtd. Avg. Fair                  Wtd. Avg. Fair
                                                        Shares       Value Per Share     Shares      Value Per Share
<s>                                                      <c>             <c>              <c>          <c>
Unvested, December 31, 2005....................           19             $ 35.08            --              --
Grants .........................................         168               38.43           218         $ 35.41
Vested .........................................         ---                  --            --              --
Cancellations...................................          (6)              37.68            --              --
                                                         ---                               ---            

Unvested, September 30, 2006....................         181             $ 38.11           218         $ 35.41
                                                         ===                               ===
</TABLE>


Performance stock awards have performance features associated with them.
Performance stock, restricted stock and contract stock awards generally have
requisite service periods of three years. The fair value of these awards is
being expensed on a straight-line basis over the vesting period. As of September
30, 2006, there was approximately $11.2 million of total unrecognized
compensation costs related to unvested awards. These costs are expected to be
recognized over a weighted-average period of approximately 2.8 years. The
Company granted 13,496 restricted stock awards with a weighted average fair
value of $34.08 during the nine months ended September 30, 2005.

The Company has no formal policy related to the repurchase of shares for the
purpose of satisfying stock-based compensation obligations. Independent of these
programs, the Company does have a practice of repurchasing shares, from time to
time, in the open market.

The Company also maintains an Employee Stock Purchase Plan (the ESPP), which
provides eligible employees of the Company with the opportunity to acquire
shares of common stock at periodic intervals by means of accumulated payroll
deductions. The ESPP was amended in 2005 to eliminate the look-back option and
to reduce the discount available to participants to five percent. Accordingly,
the ESPP is a non-compensatory plan under Statement 123(R).

                                       15

<PAGE>



7.       RETIREMENT BENEFIT PLANS

The Company maintains defined benefit pension plans that cover employees in its
manufacturing plants located in Andover, United Kingdom and its former
manufacturing plant in Tuttlingen, Germany. Net periodic benefit costs for the
Company's defined benefit pension plans included the following amounts (in
thousands):

<TABLE>
<CAPTION>
                                                                         Three Months Ended       Nine Months Ended
                                                                           September 30,            September 30,
                               
                                                                          2006         2005        2006       2005
                                                                          ----         ----        ----       ----
     <s>                                                                  <c>          <c>        <c>         <c>
     Service cost ..............................................          $ 53         $ 61       $ 157       $ 185
     Interest cost .............................................           142          103         424         313
     Expected return on plan assets ............................          (124)         (85)       (370)       (260)
     Recognized net actuarial loss..............................            54           34         162         106
                                                                         -----        -----       -----       -----

     Net periodic benefit cost .................................         $ 125        $ 113       $ 373       $ 344
                                                                         =====        =====       =====       =====
</TABLE>


The Company made $126,000 and $167,000 of contributions to its defined benefit
pension plans for the nine months ended September 30, 2006 and 2005
respectively.

8.       COMPREHENSIVE INCOME

Comprehensive income was as follows (in thousands):

<TABLE>
<CAPTION>
                                                                Three Months Ended            Nine Months Ended
                                                                   September 30,                September 30,

                                                               2006            2005           2006          2005
                                                               ----            ----           ----          ----
<s>                                                           <c>           <c>             <c>          <c>
Net income ..............................................     $2,594        $10,482         $19,276      $26,580
Foreign currency translation adjustment .................      1,312           (232)          7,310       (9,978)
Unrealized holding gains (losses) on
     available-for-sale securities, net of tax...........        522             --             784         (163)
Reclassification adjustment for losses included in net
     income, net of tax..................................       (237)            --              17           18
                                                              
Minimum pension liability adjustment, net of tax.........        (55)            --            (149)          --
                                                              ------        -------         -------      -------
Comprehensive income ....................................     $4,136        $10,250         $27,238      $16,457
                                                              ======        =======         =======      =======
</TABLE>


                                       16

<PAGE>

9.       NET INCOME PER SHARE

Basic and diluted net income per share was as follows (in thousands, except per
share amounts):

<TABLE>
<CAPTION>
                                                               Three Months Ended             Nine Months Ended
                                                                 September 30,                  September 30,

                                                              2006           2005           2006            2005
                                                              ----           ----           ----            ----
<s>                                                         <c>          <c>               <c>            <c>
Basic net income per share:

Net income.........................................         $ 2,594      $10,482           $19,276        $26,580

Weighted average common shares outstanding ........          29,193       30,039            29,457         30,334

Basic net income per share ........................         $  0.09      $  0.35           $  0.65        $  0.88

Diluted net income per share:

Net income ........................................
                                                            $ 2,594      $10,482           $19,276        $26,580
Add back: Interest expense and other income/(expense)
          related to convertible notes payable, net
          of tax ..................................              --          800                --          1,832
                                                            -------      -------           -------        -------

Net income applicable to common stock..............         $ 2,594      $11,282           $19,276        $28,412
                                                            =======      =======           =======        =======

Weighted average common shares outstanding - Basic           29,193       30,039            29,457         30,334
Effect of dilutive securities:
     Stock options and restricted stock............             674          744               705            879
     Shares issuable upon conversion of notes payable
                                                                 --        3,514                --          3,514
                                                            -------      -------           -------         ------
Weighted average common shares for diluted earnings
per share..........................................          29,867       34,297            30,162         34,727
                                                             ======       ======            ======         ======
Diluted net income per share.......................         $  0.09       $ 0.33           $  0.64         $ 0.82
</TABLE>


Options outstanding at September 30, 2006 and 2005 to acquire approximately 1.8
million shares and 921,000 shares of common stock, respectively, were excluded
from the computation of diluted net income per share for the three months ended
September 30, 2006 and 2005, respectively, because their effects would be
anti-dilutive. Options outstanding at September 30, 2006 and 2005 to acquire
approximately 1.9 million shares and 624,000 shares of common stock,
respectively, were excluded from the computation of diluted net income per share
for the nine months ended September 30, 2006 and 2005, respectively, because
their effects would be anti-dilutive. The Company excluded from the computation
of diluted earnings per share for the three months and nine months ended
September 30, 2006 approximately 3.5 million shares issuable upon conversion of
its convertible notes payable because their effects would be anti-dilutive.

                                       17

<PAGE>


10.      SEGMENT AND GEOGRAPHIC INFORMATION

The Company's management reviews financial results and manages the business on
an aggregate basis. Therefore, financial results are reported in a single
operating segment, the development, manufacture and marketing of medical devices
for use in neurosurgery, reconstructive surgery and general surgery.

In 2006, the Company revised the manner in which it presents its revenues. The
Company now presents its revenues in two categories: Neurosurgical / Orthopedic
Implants and Medical / Surgical Equipment. This change better aligns our product
categories by functional product characteristic and intended use. The Company's
revenues were as follows (in thousands):

<TABLE>
<CAPTION>
                                                          Three Months Ended              Nine Months Ended
                                                             September 30,                  September 30,
                                                          2006           2005           2006           2005
                                                          ----           ----           ----           ----
<s>                                                     <c>            <c>            <c>            <c>
Revenue:
     Neurosurgical and Orthopedic Implants ........     $ 43,136       $ 33,516       $118,778       $ 99,219
     Medical Surgical Equipment....................       73,511         35,818        175,125        105,732
                                                          ------         ------        -------        -------

Total Revenue .....................................     $116,647       $ 69,334       $293,903       $204,951
                                                        ========       ========       ========       ========
</TABLE>


Certain of the Company's products, including the DuraGen(R) and NeuraGen(TM)
product families and the INTEGRA(R) Dermal Regeneration Template and
wound-dressing products, contain material derived from bovine tissue. Products
that contain materials derived from animal sources, including food as well as
pharmaceuticals and medical devices, are increasingly subject to scrutiny from
the press and regulatory authorities. These products constituted 23% and 32% of
total revenues in each of the three-month periods ended September 30, 2006 and
2005, respectively, and 26% and 31% of total revenues in each of the nine-month
periods ending September 30, 2006 and 2005, respectively. Accordingly,
widespread public controversy concerning collagen products, new regulation, or a
ban of the Company's products containing material derived from bovine tissue
could have a material adverse effect on the Company's current business or its
ability to expand its business.


Total revenues by major geographic area are summarized below (in thousands):

<TABLE>
<CAPTION>
                                                                  United                 Asia       Other
                                                                  States     Europe     Pacific    Foreign    Total
<s>                                                             <c>        <c>         <c>        <c>       <c>
Three months ended September 30, 2006.......................    $ 88,740   $ 21,165    $ 2,815    $ 3,927   $116,647
Three months ended September 30, 2005.......................      53,504     10,443      2,662      2,725     69,334


Nine months ended September 30, 2006........................    $220,393   $ 56,884    $ 8,809    $ 7,817   $293,903
Nine months ended September 30, 2005........................     152,623     36,187      8,443      7,698    204,951
</TABLE>


11.      COMMITMENTS AND CONTINGENCIES

In consideration for certain technology, manufacturing, distribution and selling
rights and licenses granted to the Company, the Company has agreed to pay
royalties on the sales of products that relate to those granted rights and
licenses. Royalty payments under these agreements by the Company were not
significant for any of the periods presented.

Various lawsuits, claims and proceedings are pending or have been settled by the
Company. The most significant of those are described below.

In May 2006, Codman & Shurtleff, Inc. ("Codman"), a division of Johnson &
Johnson, commenced an action in the United States District Court for the
District of New Jersey for declaratory judgment against Integra LifeSciences
Corporation with respect to United States Patent No. 5,997,895 (the "'895
Patent") held by Integra. Integra's patent covers dural repair technology
related to Integra's Duragen(R) family of duraplasty products.

The action seeks declaratory relief that Codman's DURAFORM(TM) product does not
infringe Integra's patent and that Integra's patent is invalid and
unenforceable. Codman does not seek either damages from Integra or injunctive

                                       18

<PAGE>

relief to prevent Integra from selling the Duragen(R) Dural Graft Matrix.
Integra has filed a counterclaim against Codman, alleging that Codman's
DURAFORM(TM) product infringes the '895 Patent, seeking injunctive relief
preventing the sale and use of DURAFORM(TM), and seeking damages, including
treble damages, for past infringement.

In July 1996, the Company sued Merck KGaA, a German corporation, seeking damages
for patent infringement. The patents in question are part of a group of patents
granted to The Burnham Institute and licensed by Integra that are based on the
interaction between a family of cell surface proteins called integrins and the
arginine-glycine-aspartic acid ("RGD") peptide sequence found in many
extracellular matrix proteins.

The case has been tried, appealed and returned to the trial court. Most
recently, in September 2004, the trial court ordered Merck KgaA to pay Integra
$6.4 million in damages. Merck KGaA filed a petition for a writ of certiorari
with the United States Supreme Court seeking review of the Circuit Court's
decision, and the Supreme Court granted the writ in January 2005.

On June 13, 2005, the Supreme Court vacated the June 2003 judgment of the
Circuit Court. The Supreme Court held that the Circuit Court applied an
erroneous interpretation of 35 U.S.C. ss.271(e)(1) when it rejected the
challenge of Merck KGaA to the jury's finding that Merck KGaA failed to show
that its activities were exempt from claims of patent infringement under that
statute. On remand, the Circuit Court was to have reviewed the evidence under a
reasonableness test that does not provide categorical exclusions of certain
types of activities. The hearing before the Circuit Court occurred in June 2006,
and a ruling is expected by the end of this year. Further enforcement of the
trial court's order has been stayed. We have not recorded any gain in connection
with this matter, pending final resolution and completion of the appeals
process.

In addition to these matters, the Company is subject to various claims, lawsuits
and proceedings in the ordinary course of its business, including claims by
former employees, distributors and competitors and with respect to our products.
In the opinion of management, such claims are either adequately covered by
insurance or otherwise indemnified, or are not expected, individually or in the
aggregate, to result in a material adverse effect on the Company's financial
condition. However, it is possible that the Company's results of operations,
financial position and cash flows in a particular period could be materially
affected by these contingencies.

12.      CONTINGENT CONVERTIBLE NOTES

On September 27, 2006, the Company exchanged of $115.2 million (out of a total
of $120.0 million) of its 2 1/2% Contingent Convertible Subordinated Notes due
2008 (the "old notes")for the equivalent amount of 2 1/2% Contingent Convertible
Subordinated Notes due 2008 (the "new notes"). The terms of the new notes are
substantially similar to those of the old notes, except that the new notes have
a net share settlement feature and include "takeover protection," whereby the
Company will pay a premium to holders who convert their notes upon the
occurrence of designated events, including a change in control. The net share
settlement feature requires that, upon conversion of the new notes, the Company
will pay holders in cash for up to the principal amount of the converted new
notes, with any amounts in excess of this cash amount settled, at the election
of the Company, in cash or shares of our common stock. Holders who exchanged
their old notes in the exchange offer received an exchange fee of $2.50 per
$1,000 principal amount of their old notes.

In addition, since the closing price of the Company's stock on the issuance date
of the new notes was higher than the market price trigger of the new notes, the
holders have the option to convert their notes into cash, and if applicable,
shares of our common stock at any time. As a result, $115.2 million of
contingent convertible notes have been classified as current liabilities on the
balance sheet. The Company recorded a $1.2 million write-off of the unamortized
debt issuance costs and $0.3 million of fees associated with the old notes that
were exchanged.

13.      SUBSEQUENT EVENT

In October 2006, the Company exchanged an additional $4.3 million of old notes
in exchange for an equal amount of new notes under the same terms of the
exchange offer which expired on September 27, 2006.

                                       19

<PAGE>


ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
         OF OPERATIONS

The following discussion and analysis of our financial condition and results of
operations should be read in conjunction with our condensed consolidated
financial statements and the related notes thereto appearing elsewhere in this
report and our consolidated financial statements for the year ended December 31,
2005 included in our Annual Report on Form 10-K.

We have made statements in this report which constitute forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. These forward-looking
statements are subject to a number of risks, uncertainties and assumptions about
the Company. Our actual results may differ materially from those anticipated in
these forward-looking statements as a result of many factors, including but not
limited to those set forth above under the heading "Risk Factors" in our Annual
Report on Form 10-K for the year ended December 31, 2005 and in subsequent
Quarterly Reports on Form 10-Q.

You can identify these forward-looking statements by forward-looking words such
as "believe," "may," "could," "will," "estimate," "continue," "anticipate,"
"intend," "seek," "plan," "expect," "should," "would" and similar expressions in
this report.

GENERAL

Integra is a market-leading, innovative medical device company focused on
helping the medical professional enhance the standard of care for patients.
Integra provides customers with clinically relevant, innovative and
cost-effective products that improve the quality of life for patients. We focus
on cranial and spinal procedures, peripheral nerve repair, small bone and joint
injuries, and the repair and reconstruction of soft tissue.

Our distribution channels include two direct sales organizations (Integra
NeuroSciences and Integra Reconstructive Surgery), two networks of
manufacturer's representatives managed by a direct sales organization (JARIT
Surgical Instruments and Miltex) and strategic alliances with market leaders
such as Johnson & Johnson, Medtronic, Inc., Wyeth and Zimmer Holdings, Inc. We
have direct sales forces in the United States, Canada, Germany, the United
Kingdom, the Benelux (Belgium, Netherlands, Luxembourg) region and France.
Elsewhere throughout the world, our products are distributed through a number of
independent distributors. We invest substantial resources and management effort
to develop our sales organizations, and we believe that we compete very
effectively in this aspect of our business.

In 2006, we revised the manner in which we present our revenues. This change
better aligns our product categories by functional product characteristic and
intended use. We now present revenues in two categories: Neurosurgical and
Orthopedic Implants and Medical Surgical Equipment. Our Neurosurgical and
Orthopedic Implants product group includes dural grafts that are indicated for
the repair of the dura matter, dermal regeneration and engineered wound
dressings, implants used in small bone and joint fixation, repair of peripheral
nerves, and hydrocephalus management, and implants used in bone regeneration and
in guided tissue regeneration in periodontal surgery. Our Medical Surgical
Equipment product group includes ultrasonic surgery systems for tissue ablation,
cranial stabilization and brain retraction systems, instrumentation used in
general, neurosurgical, spinal and plastic and reconstructive surgery and dental
procedures, systems for the measurement of various brain parameters, and devices
used to gain access to the cranial cavity and to drain excess cerebrospinal
fluid from the ventricles of the brain.

We manage these product groups and distribution channels on a centralized basis.
Accordingly, we report our financial results under a single operating segment -
the development, manufacturing and distribution of medical devices.

We manufacture many of our products in various plants located in the United
States, Puerto Rico, France, the United Kingdom and Germany. We also manufacture
some of our ultrasonic surgical instruments and source most of our hand-held
surgical instruments through specialized third-party vendors.

We believe that we have a particular advantage in the development, manufacture
and sale of specialty tissue repair products derived from bovine collagen. We
develop and manufacture these products primarily in our facilities in
Plainsboro, New Jersey and Puerto Rico. Products that contain materials derived

                                       20

<PAGE>

from animal sources, including food as well as pharmaceuticals and medical
devices, are increasingly subject to scrutiny from the press and regulatory
authorities. These products comprised 26% and 31% of total revenues in each of
the nine-month periods ended September 30, 2006 and 2005, respectively.
Accordingly, widespread public controversy concerning collagen products, new
regulation, or a ban of the Company's products containing material derived from
bovine tissue, could have a material adverse effect on the Company's current
business or its ability to expand its business.

Our objective is to continue to build a customer-focused and profitable medical
device company by developing or acquiring innovative medical devices and other
products to sell through our sales channels. Our strategy therefore entails
substantial growth in product revenues through internal means - through
launching new and innovative products and selling existing products more
intensively - and by acquiring existing businesses or already successful product
lines.

We aim to achieve this growth in revenues while maintaining strong financial
results. While we pay attention to any meaningful trend in our financial
results, we pay particular attention to measurements that are indicative of
long-term profitable growth. These measurements include revenue growth, derived
through acquisitions and products developed internally, gross margins on total
revenues, operating margins, which we aim to continually expand on as we
leverage our existing infrastructure, and earnings per fully diluted share of
common stock.

ACQUISITIONS

Our strategy for growing our business includes the acquisition of complementary
product lines and companies. Our recent acquisitions of businesses, assets and
product lines may make our financial results for the nine months ended September
30, 2006 not directly comparable to those of the corresponding prior-year
period. See Note 2 to the unaudited condensed consolidated financial statements
for a further discussion. Since the beginning of 2005, we have acquired the
following businesses:

In January 2005, we acquired all of the outstanding capital stock of Newdeal
Technologies SAS ("Newdeal Technologies") for $51.9 million in cash paid at
closing, a $0.7 million working capital adjustment paid in January 2006, and
$0.8 million of acquisition related expenses. Additionally, we agreed to pay the
sellers up to an additional 1.3 million Euros if the sellers were to continue
their employment with us through January 3, 2006. This additional payment was
accrued to selling, general and administrative expense on a straight-line basis
in 2005 over the one-year employment requirement period and was paid in January
2006.

Newdeal is a leading developer and marketer of specialty implants and
instruments specifically designed for foot and ankle surgery. Newdeal's products
include a wide range of products for the forefoot, the mid-foot and the hind
foot, including the Bold(R) Screw, Hallu-Fix(R) plate system and the HINTEGRA(R)
total ankle prosthesis. Newdeal's target physicians include orthopedic surgeons
specializing in injuries of the foot, ankle and extremities, as well as
podiatric surgeons.

On March 3, 2006, Integra acquired certain assets of the Radionics Division of
Tyco Healthcare Group, L.P. for approximately $74.5 million in cash paid at
closing, subject to certain adjustments, and $3.2 million of acquisition related
expenses in a transaction treated as a business combination. Radionics, based in
Burlington, Massachusetts, is a leader in the design, manufacture and sale of
advanced minimally invasive medical instruments in the fields of neurosurgery
and radiation therapy. Radionics' products include the CUSA EXcel(R) ultrasonic
surgical aspiration system, the CRW(R) stereotactic system, the XKnife(R)
stereotactic radiosurgery system, and the OmniSight(R) EXcel image guided
surgery system.

Tyco Healthcare sold Radionics products in over 75 countries, using a network of
independent distributors in the United States and both independent distributors
and Tyco Healthcare affiliates internationally. We are using distributors in
many of the markets in which Tyco Healthcare sold directly to customers. As a
result, we expect that revenue and pre-tax income attributable to the acquired
product lines will be less than the 2005 levels recognized by Tyco. In addition,
because the CUSA Excel ultrasonic aspiration system competes with our existing
line of ultrasonic surgery systems, our sales force may, in some situations,
sell the CUSA system in lieu of our existing ultrasonic aspirator products.

                                       21

<PAGE>

On May 12, 2006, we acquired all of the outstanding capital stock of Miltex
Holdings, Inc. ("Miltex") for $102.7 million in cash paid at closing, subject to
certain adjustments, and $0.6 million of transaction related costs. Miltex,
based in York, Pennsylvania, is a leading provider of surgical and dental hand
instruments to alternate site facilities, which includes physician and dental
offices and ambulatory surgery care sectors. Miltex sells products under the
Miltex(R), Meisterhand(R), Vantage(R), Moyco(R), Union Broach(R), and
Thompson(R) trade names in over 65 countries, using a network of independent
distributors. Miltex operates a manufacturing and distribution facility in York,
Pennsylvania and also operates a leased facility in Tuttlingen, Germany, where
Miltex's staff coordinates design, production and delivery of instruments.

On July 5, 2006, we acquired a direct sales force in Canada through the
acquisition of our longstanding distributor, Canada Microsurgical Ltd. Canada
Microsurgical has eight sales representatives covering each province in Canada.
We paid $5.8 million (6.4 million Canadian dollars) for Canada Microsurgical at
closing and $0.1 million of transaction related costs. In addition, we may pay
up to an additional 2.1 million Canadian dollars over the next three years,
depending on the performance of the business.

On July 31, 2006 we acquired the shares of Kinetikos Medical, Inc. ("KMI") for
$39.5 million in cash, subject to certain adjustments, including future payments
based on the performance of the KMI business after the acquisition. KMI, based
in Carlsbad, California, was a leading developer and manufacturer of innovative
orthopedic implants and surgical devices for small bone and joint procedures
involving the foot, ankle, hand, wrist and elbow. KMI marketed products that
addressed both the trauma and reconstructive segments of the extremities market.
KMI's reconstructive products are largely focused on treating deformities and
arthritis in small joints of the upper and lower extremity, while its trauma
products are focused on the treatment of fractures of small bones most commonly
found in the extremities. The Company has integrated the KMI product line into
its U.S. direct sales force while maintaining seven former KMI independent sales
agencies. The Company plans to increase sales of KMI products internationally
through our well-established Newdeal infrastructure.

IMPACT OF RESTRUCTURING ACTIVITIES

In June 2005, we announced plans to restructure our European operations. The
restructuring plan included closing our Integra ME production facility in
Tuttlingen, Germany and reducing various positions in our production facility
located in Biot, France, both of which were substantially completed in December
2005. We transitioned the manufacturing operations of Integra ME to our
production facility in Andover, UK. We also eliminated some duplicative sales
and marketing positions, primarily in Europe. The Company terminated 68
individuals under the European restructuring plan.

In 2005, we also completed the transfer of the Spinal Specialties assembly
operations from our San Antonio, Texas plant to our San Diego, California plant
and we continue to transfer certain assembly, processing and packaging
operations to our San Diego and Puerto Rico facilities. During the nine months
ended September 30, 2006, the Company terminated four employees in connection
with the transfer of certain manufacturing packaging operations from its plant
in Plainsboro, New Jersey to its plant in Anasco, Puerto Rico. The Company may
terminate approximately ten additional employees over the next nine to twelve
months in connection with this transfer; however no final decision has been
made.

In connection with these restructuring activities, we recorded employee
termination costs of $63,000 and $440,000, respectively, during the three and
nine months ended September 30, 2006.

While we expect to achieve a positive impact from the restructuring and
integration activities, such results remain uncertain. We have reinvested most
of the savings from these restructuring and integration activities into further
expanding our European sales, marketing and distribution organization, and
integrating the Radionics and KMI businesses into our existing sales and
distribution network.

                                       22

<PAGE>

RESULTS OF OPERATIONS

Net income for the three months ended September 30, 2006 was $2.6 million, or
$0.09 per diluted share, as compared to net income of $10.5 million, or $0.33
per diluted share, for the three months ended September 30, 2005.

Net income for the nine months ended September 30, 2006 was $19.3 million, or
$0.64 per diluted share, as compared to a net income of $26.6 million, or $0.82
per diluted share, for the nine months ended September 30, 2005.

These amounts include the following charges (in thousands):

<TABLE>
<CAPTION>
                                                                           Three Months Ended     Nine Months Ended
                                                                              September 30,         September 30,

                                                                             2006       2005       2006       2005
                                                                             ----       ----       ----       ----
<s>                                                                      <c>           <c>       <c>         <c>
Acquisition-related charges:

   Inventory fair market value purchase accounting adjustments .....     $ 1,399     $   --      $ 4,012     $  466
   Acquired in-process research and development.. ..................       5,600        500        5,600        500

Charges associated with convertible debt exchange offer.............       1,792         --        1,879         --

Charges associated with termination of interest rate swap...........       1,425         --        1,425         --

Employee termination and related costs..............................          63        666          440      2,740
Facility consolidation, acquisition integration, manufacturing
     transfer, enterprise business system integration and 
     related costs..................................................         582        492        1,299      1,314
Impairment of inventory and fixed assets related to discontinued
     development project and product lines..........................          --         --        1,578        478
                                                                         -------     ------      -------     ------
Total...............................................................     $10,861     $1,658      $16,233     $5,498
                                                                         =======     ======      =======     ======
</TABLE>


Of these amounts, $5.4 million and $1.8 million were charged to cost of product
revenues in the nine-month periods ended September 30, 2006 and 2005,
respectively, and $7.2 million and $1.0 million was charged to research and
development in the nine months ended September 30, 2006. The remaining amounts
were primarily charged to selling, general and administrative expenses.

We believe that, given our ongoing, active strategy of seeking new acquisitions
and integrating recent acquisitions, our current focus on rationalizing our
existing manufacturing and distribution infrastructure, our recent review of
various product lines in relation to our current business strategy, and a
renewed focus on enterprise business systems integrations, charges similar to
those discussed above could recur with similar materiality in the future. We
believe that the delineation of these costs provides useful information to
measure the comparative performance of our business operations.

Net income for the three and nine months ended September 30, 2006 also includes
approximately $2.6 million and $7.0 million, respectively, net of tax, of
stock-based compensation expense recorded in connection with the adoption of
Statement of Financial Accounting Standards No 123(R) "Shared Based Payment".

                                       23

<PAGE>

Revenues and Gross Margin on Product Revenues

Our revenues and gross margin on product revenues were as follows (in
thousands):

<TABLE>
<CAPTION>
                                                                           Three Months Ended     Nine Months Ended
                                                                              September 30,         September 30,
                                                                             2006      2005       2006        2005
                                                                             ----      ----       ----        ----
<s>                                                                       <c>       <c>         <c>          <c>
Neurosurgical and Orthopedic Implants ...............................     $43,136   $33,516     $118,778     $99,219
Medical Surgical Equipment...........................................      73,511    35,818      175,125     105,732
                                                                          -------   --------    --------     --------

Total revenue .......................................................    $116,647   $69,334     $293,903    $204,951

Cost of product revenues ............................................      47,559    26,394      116,869      78,423
                                                                         --------   -------     --------    --------
Gross margin on total revenues ......................................      69,088    42,940      177,034     126,528
Gross margin as a percentage of total revenues ......................          59%       62%          60%         62%
</TABLE>


THREE MONTHS ENDED SEPTEMBER 30, 2006 AS COMPARED TO THE THREE MONTHS ENDED 
SEPTEMBER 30, 2005

Revenues and Gross Margin

For the quarter ended September 30, 2006, total revenues increased 68% over the
prior-year period to $116.6 million. Domestic revenues increased $35.7 million
to $89.1 million, or 76% of total revenues, as compared to 77% of revenues in
the three months ended September 30, 2005.

In the Neurosurgical and Orthopedic Implants category, sales of our
reconstructive surgery implant products continued to grow strongly. Rapid growth
in nerve and dermal repair products and sales of products for the hand, foot and
ankle accounted for much of the increase in implant product revenues.
INTEGRA(TM) dermal repair product revenues increased 32% over the third quarter
of 2005, nerve repair product revenues increased by 44%, and our hand, foot and
ankle products more than doubled. Revenues from bone graft and collagen dental
products increased by 57% over the third quarter of 2005. KMI products
contributed $1.9 million of sales to the quarter.

In the Medical Surgical Equipment category, increased sales of our JARIT(R)
surgical instrument lines and sales of the recently acquired Radionics and
Miltex products provided the year-over-year growth in equipment product revenues
for the third quarter. Radionics, Miltex and non-Integra distributed products
sold through our former Canadian distributor (all acquired in 2006) contributed
$33.8 million of sales to the quarter.

We have generated our product revenue growth through acquisitions, new product
launches and increased direct sales and marketing efforts both domestically and
in Europe. We expect that our expanded domestic sales force, the recent
conversion of JARIT domestic sales from a distributor billing model to a direct
billing model, the continued implementation of our direct sales strategy in
Europe and sales of internally developed and acquired products will drive our
future revenue growth. We also intend to continue to acquire businesses that
complement our existing businesses and products. Many of our recent acquisitions
involve businesses or product lines that overlap in some way with our existing
products. Our sales and marketing departments are integrating these
acquisitions, and there has been, and we expect there will continue to be, some
cannibalization of sales of our existing products that will affect our internal
growth. Overall, we target our revenues to continue to grow internally and
through acquisitions in the range of 20% to 30% per year.

In 2006, we revised our presentation of cost of product revenues to include
amortization of product technology-based intangible assets. Previously, this
amortization was included in intangible asset amortization in the condensed
consolidated statement of operations. We have revised prior period amounts to
conform to the current year's presentation. This revision increased cost of
product revenues by $673,000 and $379,000 for the three-month period ended
September 30, 2006 and 2005, respectively.

                                       24

<PAGE>

Gross margin on total revenues in the third quarter of 2006 was 59.2%. Strong
sales growth in many higher gross margin products was offset by sales of the
relatively lower-margin Radionics and Miltex products. We recognized $1.4
million in inventory fair value purchase accounting adjustments from
acquisitions as the products were sold, a $1.3 million change in estimate
related to consignment inventory and $582,000 in restructuring and manufacturing
transfer and systems integration costs. These charges reduced our gross margin
in the third quarter of 2006 by approximately 2 percentage points.

We expect that sales of our higher gross margin products will continue to
increase as a proportion of total product revenues, but be offset slightly by
relatively lower gross margin generated from sales of Radionics and Miltex
products. Also, we now invoice hospital customers directly for sales of JARIT
instruments rather than distributors. This has resulted in increased product
revenues as a result of higher selling prices, a higher gross margin, and also
increased selling expenses from commissions paid to distributors.

Other Operating Expenses

The following is a summary of other operating expenses as a percent of total
revenues:

<TABLE>
<CAPTION>  
                                                 Three Months Ended
                                                   September 30,
                                                2006           2005
                                                ----           ----
<s>                                            <c>             <c>
Research and development ....................     9%             4%
Selling, general and administrative .........    37%            33%
Intangible asset amortization ...............     2%             2%
Total other operating expenses ..............    49%            39%
</TABLE>


Total other operating expenses, which consist of research and development
expense, selling, general and administrative expense and amortization expense,
increased $30.4 million, or 113%, to $57.3 million in the third quarter of 2006,
compared to $26.8 million in the third quarter of 2005. The increase is
partially related to a $5.6 million in-process research and development charge
related to the acquisition of KMI, a $3.7 million stock-based compensation
expense associated with the adoption of Statement 123(R) (the majority of which
is included in selling, general and administrative expense) and higher
commission expenses associated with the JARIT direct bill initiative. Expenses
also increased because of the continued expansion of our direct sales and
marketing organizations in our direct selling platforms and increased corporate
staff to support the recent growth in our business and to integrate acquired
businesses. The recently acquired Radionics, Miltex, KMI and our former Canadian
distributor businesses contributed approximately $8.9 million in other operating
expenses in the third quarter 2006.

Research and development expenses in the third quarter of 2006 increased by $7.9
million compared to the prior-year period. Included in research and development
costs were a $5.6 million in-process research and development charge related to
the KMI acquisition, a $0.5 million charge related to an upfront payment
pursuant to a new product development alliance and $168,000 of stock-based
compensation expenses associated with the adoption of Statement 123(R). In
connection with our acquisition of Radionics and KMI, research and development
expenses increased by $1.1 million in the third quarter ended September 30,
2006. There was also an overall increase of $1.5 million associated with product
development initiatives compared to the prior-year period. Our research and
development efforts in 2006 are expected to be focused on clinical activities
directed towards expanding the indications for use of our absorbable implant
technology products, including a multi-center clinical trial suitable to support
an application to the FDA for approval of the DuraGen Plus(TM) Adhesion Barrier
Matrix product, and development of a next-generation ultrasonic aspirator
system.

Selling, general and administrative expenses increased $20.8 million, or 92%, as
compared to the prior-year period to $43.4 million. The increase in selling,
general and administrative expenses includes $3.5 million of stock-based
compensation expense associated with the adoption of Statement 123(R) and higher
commission expenses associated with the JARIT direct bill initiative. Selling,
general and administrative costs also increased in the third quarter of 2006 in
connection with the recently acquired Radionics, Miltex and KMI businesses. We
also continued to expand our direct sales and marketing organizations in our
direct selling platforms and increased corporate staff to support the recent
growth in our business and to integrate acquired businesses. Additionally, we
have incurred higher operating costs in connection with our recent investments
in our infrastructure, including the continued implementation of an enterprise
business system and the relocation and expansion of our domestic and
international distribution capabilities through third-party service providers.
We expect that we will continue to incur costs related to these activities
during the remainder of 2006 and 2007 as we complete these ongoing activities.

                                       25

<PAGE>

Amortization expense increased in the third quarter of 2006 as a result of
amortization of intangible assets from acquisitions completed in 2006.

Non-Operating Income and Expenses

Interest expense primarily relates to the $120 million of 2 1/2% contingent
convertible subordinated notes that we have outstanding and a related interest
rate swap agreement, which was terminated on September 27, 2006 and interest on
the used and unused portion of the $200 million senior secured credit facility
that we established in December 2005. The increase in interest expense in the
third quarter of 2006 is primarily related to the write-off of unamortized debt
issuance costs related to the old notes and interest associated with the credit
facility that was established in December 2005. In the third quarter of 2006, we
made net additional borrowings of $23 million under our credit facility.

On September 27, 2006, the Company exchanged $115.2 million (out of a total of
$120.0 million) of its old contingent convertible notes for the equivalent
amount of new notes. See Note 12 to the unaudited condensed consolidated
financial statements for a further discussion. In connection with the exchange
of our convertible notes, the Company recorded a $1.2 million write-off of the
unamortized debt issuance costs and $0.3 million of fees associated with the old
contingent convertible notes that were exchanged. Our reported interest expense
for the three-month period ended September 30, 2005 included $204,000 of
non-cash amortization of debt issuance costs.

We will pay additional interest on our convertible notes under certain
conditions. The fair value of this contingent interest obligation is marked to
its fair value at each balance sheet date, with changes in the fair value
recorded to interest expense. In the third quarter of 2006, the change in the
estimated fair value of the contingent interest obligation increased interest
expense by $104,000. In the third quarter of 2005, the fair value increased by
$300,000.

On September 27, 2006, we terminated an interest rate swap agreement with a $50
million notional amount to hedge the risk of changes in fair value attributable
to interest rate risk with respect to a portion of our fixed rate convertible
notes. The interest rate swap agreement qualified as a fair value hedge under
SFAS No. 133, as amended "Accounting for Derivative Instruments and Hedging
Activities". The net amount to be paid or received under the interest rate swap
agreement was recorded as a component of interest expense. Interest expense
associated with the interest rate swap for the three months ended September 30,
2006 and 2005 was $345,000 and $100,000, respectively.

The Company paid the counterparty approximately $2.2 million in connection with
the termination of the swap, consisting of a $0.6 million payment of accrued
interest and a $1.6 million payment representing the fair market value of the
interest rate swap on the termination date. The termination payment was already
accrued by the Company. During the three months ended September 30, 2005, the
net fair value of the interest rate swap increased $500,000 to $2.0 million, and
the carrying value of our convertible notes decreased by $512,000. The net
difference between changes in the fair value of the interest rate swap and the
contingent convertible notes represents the ineffective portion of the hedging
relationship, and this amount is recorded in other income/(expense), net.

Our income tax expense was $3.5 million and $5.2 million for the three-month
periods ended September 30, 2006 and 2005, respectively. The overall effective
tax rate for the three months ended September 30, 2006 and 2005 was 57.2% and
33.2 %, respectively. The third quarter of 2006 included a $5.6 million
in-process research and development charge related to the KMI acquisition which
is not deductible for tax purposes. The effective tax rate for the third quarter
of 2006 would have been 29.7% without this charge. The decrease in the effective
income tax rate in 2006 was primarily due to a continued favorable impact of
various planning and reorganization initiatives, a change in the geographic mix
of earnings and losses and our realization of additional deductions related to
qualified production activities income provided for under the American Jobs
Creation Act of 2004.

                                       26

<PAGE>

In 2006, we have used all of our remaining unrestricted and current year
allowable acquired net operating loss carryforwards to offset 2006 taxable
income. At September 30, 2006, several of our subsidiaries had unused net
operating loss carryforwards arising from periods prior to our ownership which
expire through 2010. The Internal Revenue Code limits the timing and manner in
which we may use any acquired net operating losses.

Our effective tax rate may vary from period to period depending on, among other
factors, the geographic and business mix of taxable earnings and losses. We
consider these factors and others, including our history of generating taxable
earnings, in assessing our ability to realized deferred tax assets.


NINE MONTHS ENDED SEPTEMBER 30, 2006 AS COMPARED TO THE NINE MONTHS ENDED 
SEPTEMBER 30, 2005

Revenues and Gross Margin

For the nine months ended September 30, 2006, total revenues increased 43% over
the prior-year period to $293.9 million. Domestic revenues increased $67.8
million to $220.4 million, or 75% of total revenues, as compared to 74% of
revenues in the nine months ended September 30, 2005.

In the Neurosurgical and Orthopedic Implants category, sales of our
Reconstructive Surgery implant products continued to grow strongly. Rapid growth
in the NeuraGen(TM) Nerve Guide, the INTEGRA(TM) dermal repair products and
sales of products for the hand, foot and ankle accounted for much of the
increase in implant product revenues. INTEGRA(TM) dermal repair product revenues
increased approximately 33% over the nine months of 2005, nerve repair product
revenues increased by 40%, and our Newdeal(TM) foot and ankle products increased
approximately 37%.

Sales of Reconstructive Surgery products continued their fast growth, while our
Neurosurgery products, including the DuraGen(R) family of duraplasty products
continued to grow modestly. Increased revenues of the Absorbable Collagen Sponge
that we supply for use in Medtronic's INFUSE(TM) bone graft product and of the
dental products we supply to Zimmer also contributed to the growth in implant
revenues.

In the Medical Surgical Equipment category, increased sales of our JARIT(R)
surgical instrument lines and sales of the recently acquired Radionics and
Miltex products provided the year-over-year growth in equipment product revenues
for the nine months. Sales of Radionics and Miltex products contributed $59.5
million in the nine months ended September 2006.

In 2006, we revised our presentation of cost of product revenues to include
amortization of product technology-based intangible assets. Previously, this
amortization was included in intangible asset amortization in the condensed
consolidated statement of operations. We have revised prior period amounts to
conform to the current year's presentation. This revision increased cost of
product revenues by $1.8 million and $1.1 million for the nine-month periods
ended September 30, 2006 and 2005, respectively.

Gross margin on total revenues in the nine months of 2006 was 60.2%. Although we
had strong sales growth in many higher gross margin products, we recognized $4.0
million in inventory fair value purchase accounting adjustments from
acquisitions as the products were sold and $1.3 million in restructuring and
manufacturing transfer and systems integration costs. These charges reduced our
gross margin by approximately 2%. We recognized the impact of $466,000 of
inventory fair value purchase accounting adjustments in the nine months of 2005.
Additionally, in the second quarter of 2006 we recorded a $1.2 million
impairment charge to cost of product revenues against a range of electrosurgical
generators and accessories sold exclusively in Europe following a review of
on-hand inventory quantities of those products in relation to expected demand
for that product line.

                                       27

<PAGE>

Other Operating Expenses

The following is a summary of other operating expenses as a percent of total
revenues:

<TABLE>
<CAPTION>
                                                 Nine Months Ended
                                                   September 30,

                                                 2006        2005
                                                 ----        ----
<s>                                             <c>          <c>
Research and development ......................   7%          5%
Selling, general and administrative ...........  38%         35%
Intangible asset amortization..................   2%          2%
Total other operating expenses.................  47%         42%
</TABLE>


Total other operating expenses, which consist of research and development
expense, selling, general and administrative expense and amortization expense,
increased $53.1 million, or 62%, to $138.4 million in the nine months of 2006,
compared to $85.3 million in the nine months of 2005. The increase includes
$10.1 million of stock-based compensation expense associated with the adoption
of Statement 123(R) (the majority of which is included in selling, general and
administrative expense). Businesses we acquired in 2006 contributed
approximately $15.0 million of other operating expenses for the nine-month
period ended September 30, 2006.

Research and development expenses increased $11.3 million in the nine months of
2006 and included a $5.6 million in-process research and charge associated with
the KMI acquisition, $452,000 of stock-based compensation expenses associated
with the adoption of Statement 123(R), $2.3 million of research and development
activities from the recently acquired Radionics and KMI businesses, a $1.6
million charge related to the discontinued ultrasonic aspirator development
project and a $0.5 million charge related to an upfront payment pursuant to a
new product development alliance.

Selling, general and administrative expenses increased $39.2 million, or 54%, as
compared to the prior-year period to $111.8 million. This increase is primarily
related to a $9.6 million stock-based compensation expense associated with the
adoption of Statement 123(R), higher commission costs associated with the Jarit
distributor network, and operating costs associated with the recently acquired
Radionics and Miltex businesses. Additionally, we have incurred higher operating
costs in connection with our recent investments in our infrastructure, including
the continued implementation of an enterprise business system, the relocation
and expansion of our domestic and international distribution capabilities
through third-party service providers, the continued expansion of our direct
sales and marketing organizations in our direct selling platforms and increased
corporate staff to support the recent growth in our business and to integrate
acquired businesses also contributed to the increase. We expect that we will
continue to incur costs related to these activities during the remainder of 2006
and 2007 as we complete these ongoing activities.

Amortization expense increased by approximately $2.7 million in the nine months
of 2006 as a result of amortization of intangible assets from the acquisitions
completed in 2006.

Non-Operating Income and Expenses

The increase in interest expense in the nine months of 2006 is primarily related
to an increase in the variable rate that we paid on our $50 million interest
rate swap, which was terminated on September 27, 2006, the write-off of
unamortized debt issuance costs related to the old contingent convertible notes
and interest on the used and unused portion of the $200 million senior credit
facility that was established in December 2005. In the nine months ended
September 30, 2006, we made net borrowings of $87 million under our credit
facility.

On September 27, 2006, the Company exchanged $115.2 million (out of a total of
$120.0 million) of its old contingent convertible notes for the equivalent
amount of new notes. See Note 12 to the unaudited condensed consolidated
financial statements for a further discussion. In connection with the exchange
of our convertible notes, the Company recorded a $1.2 million write-off of the
unamortized debt issuance costs and $0.3 million of fees associated with the old
contingent convertible notes that were exchanged. Our reported interest expense
for the nine-month periods ended September 30, 2006 and 2005 included $599,000
and $611,000, respectively, of non-cash amortization of debt issuance costs.

                                       28

<PAGE>

We will pay additional interest on our convertible notes under certain
conditions. The fair value of this contingent interest obligation is marked to
its fair value at each balance sheet date, with changes in the fair value
recorded to interest expense. Changes in the estimated fair value of the
contingent interest obligation increased interest expense by $271,000 and
$78,000 for the nine months ended September 30, 2006 and 2005, respectively.

On September 27, 2006, we terminated an interest rate swap agreement with a $50
million notional amount to hedge the risk of changes in fair value attributable
to interest rate risk with respect to a portion of our fixed rate convertible
notes. The net amount to be paid or received under the interest rate swap
agreement was recorded as a component of interest expense. Interest expense
associated with the interest rate swap for the nine months ended September 30,
2006 was $827,000. Interest expense for the nine months ended September 30, 2005
included an insignificant benefit associated with the interest rate swap.

The Company paid the counterparty approximately $2.2 million in connection with
the termination of the swap, consisting of a $0.6 million payment of accrued
interest and a $1.6 million payment representing the fair market value of the
interest rate swap on the termination date. The termination payment was already
accrued by the Company. During the nine months ended September 30, 2005, the net
fair value of the interest rate swap increased $0.6 million to $2.0 million, and
this amount was included in other liabilities. The net difference between
changes in the fair value of the interest rate swap and the contingent
convertible notes represents the ineffective portion of the hedging
relationship, and this amount is recorded in other income (expense), net.

Our income tax expense was $11.4 million and $13.7 million for the nine-month
periods ended September 30, 2006 and 2005, respectively. The overall effective
tax rate for the nine months ended September 30, 2006 and 2005 was 37.1% and
34.0%, respectively. The third quarter of 2006 included a $5.6 million
in-process research and development charge which is not deductible for tax
purposes. The effective tax rate for the nine months of 2006 would have been
31.4% without this charge. The decrease in the effective income tax rate in 2006
was primarily due to a continued favorable impact of various planning and
reorganization initiatives, a change in the geographic mix of earnings and
losses and our realization of additional deductions related to qualified
production activities income provided for under the American Jobs Creation Act
of 2004.


INTERNATIONAL PRODUCT REVENUES AND OPERATIONS

Product revenues by major geographic area are summarized below (in thousands):

<TABLE>
<CAPTION>
                                                            United                     Asia       Other
                                                            States        Europe      Pacific     Foreign     Total
                                                            ------        ------      -------     -------     -----
<s>                                                       <c>            <c>         <c>          <c>         <c>
Three months ended September 30, 2006..............       $ 88,740       $ 21,165    $  2,815     $  3,927    $116,647
Three months ended September 30, 2005..............         53,504         10,443       2,662        2,725      69,334

Nine months ended September 30, 2006...............        220,393         56,884       8,809        7,817     293,903
Nine months ended September 30, 2005...............        152,623         36,187       8,443        7,698     204,951
</TABLE>


For the three months ended September 30, 2006, revenues from customers outside
the United States totaled $27.9 million, or 24% of total revenues, of which
approximately 82% were to European customers. Revenues from customers outside
the United States included $22.3 million of revenues generated in foreign
currencies.

In the three months ending September 30, 2005, revenues from customers outside
the United States totaled $15.8 million, or 23% of total revenues, of which
approximately 66% were from European customers. Revenues from customers outside
the United States included $12.0 million of revenues generated in foreign
currencies.

                                       29

<PAGE>

For the nine months ended September 30, 2006, revenues from customers outside
the United States totaled $73.5 million, or 25% of total revenues, of which
approximately 77% were to European customers. Revenues from customers outside
the United States included $52.9 million of revenues generated in foreign
currencies.

In the nine months ending September 30, 2005, revenues from customers outside
the United States totaled $52.3 million, or 26% of total revenues, of which
approximately 69% were from European customers. Revenues from customers outside
the United States included $41.0 million of revenues generated in foreign
currencies.

Because we have operations based in Europe and we generate revenues and incur
operating expenses in Euros and British pounds, we experience currency exchange
risk with respect to those foreign currency denominated revenues or expenses. We
currently do not hedge our exposure to foreign currency risk. We will continue
to assess the potential effects that changes in foreign currency exchange rates
could have on our business. If we believe this potential impact presents a
significant risk to our business, we may enter into derivative financial
instruments to mitigate this risk.

Additionally, we generate significant revenues outside the United States, a
portion of which are U.S. dollar-denominated transactions conducted with
customers who generate revenue in currencies other than the U.S. dollar. As a
result, currency fluctuations between the U.S. dollar and the currencies in
which those customers do business may have an impact on the demand for our
products in foreign countries.

Local economic conditions, regulatory or political considerations, the
effectiveness of our sales representatives and distributors, local competition
and changes in local medical practice all may combine to affect our sales into
markets outside the United States.

Relationships with customers and effective terms of sale frequently vary by
country, often with longer-term receivables than are typical in the United
States.


LIQUIDITY AND CAPITAL RESOURCES

Cash and Marketable Securities

At September 30, 2006, we had cash and cash equivalents totaling approximately
$24.3 million. In the third quarter of 2006, we liquidated the remaining $16.7
million of our current and non-current investments.

Cash Flows

Cash provided by operations has recently been and is expected to continue to be
our primary means of funding existing operations and capital expenditures. We
have generated positive operating cash flows on an annual basis, including $56.8
million for the year ended December 31, 2005 and $50.8 million for the nine
months ended September 30, 2006. Operating cash flows for the nine months ended
September 30, 2005 were $41.9 million. Overall, operating cash flows in the nine
months ended of 2006 were negatively affected by subsequent investments in
working capital made in connection with the Radionics acquisition.

Our principal uses of funds during the nine-month period ended September 30,
2006 were $227.1 million for acquisition consideration, $31.8 million paid for
the purchase of 857,650 shares of our common stock and $7.2 million in capital
expenditures. We received $96.8 million in cash from sales and maturities of
available for sale securities, net of purchases. In addition to the $50.4
million in operating cash flows for the nine months ended September 30, 2006, we
received $9.2 million from the issuance of common stock through the exercise of
stock options during the period and $87.0 million from borrowings under our
credit facility.

Working Capital

At September 30, 2006 we have a negative working capital of $36.3 million
compared to a positive working capital on December 31, 2005 of $234.7 million.
The decrease in working capital is primarily related to the use of $227.1
million for acquisition consideration in the first nine months of 2006. Also

                                       30

<PAGE>

contributing to this decrease is the reclassification of $115.2 million of
contingent convertible notes to current liabilities. Such classification is made
since the closing price of the Company's stock on the issuance date of the new
notes was higher than the market price trigger of the new notes, the holders
have the option to convert their notes into cash, and if applicable, shares of
our common stock at any time.

Convertible Debt and Related Hedging Activities

On September 27, 2006, we concluded an offer to exchange up to $120 million
principal amount of new notes with a "net share settlement" mechanism for our
currently outstanding contingent convertible subordinated notes. As of that
date, an aggregate principal amount of $115,205,000 of old notes was tendered.
See Note 12 to the unaudited condensed consolidated financial statements for a
further discussion. Also on September 27, 2006, we terminated our interest rate
swap agreement with a $50 million notional amount to hedge the risk of changes
in fair value attributable to interest rate risk with respect to a portion of
the notes. See "Results of Operations - Non-Operating Income and Expenses" for a
further discussion.

We pay interest on both our old and new contingent convertible subordinated
notes at an annual rate of 2 1/2% each September 15 and March 15. We will also
pay contingent interest on the notes if, at thirty days prior to maturity, our
common stock price is equal to or greater than $37.56. The contingent interest
will be payable at maturity for each of the last three years the notes remain
outstanding in an amount equal to the greater of (1) 0.50% of the face amount of
the notes and (2) the amount of regular cash dividends paid during each such
year on the number of shares of common stock into which each note is
convertible. Holders of the old notes may convert the notes into shares of our
common stock under certain circumstances, including when the market price of our
common stock on the previous trading day is equal to or greater than $37.56 per
share, based on an initial conversion price of $34.15 per share. Holders of the
new notes may convert their notes into cash, and if applicable, shares of our
common stock under certain circumstances, including when the market price of our
common stock on the previous trading day is equal to or greater than $37.56 per
share. Between September 27 and September 30, 2006, our stock price exceeded
$37.56 and no convertible notes have been converted to cash or common stock.

The notes are general, unsecured obligations of the Company and are subordinate
to any senior indebtedness. We cannot redeem the notes prior to their maturity,
and the notes' holders may compel us to repurchase the notes upon a change of
control. There are no financial covenants associated with the convertible notes.

Share Repurchase Plan

In February 2006, our Board of Directors authorized us to repurchase shares of
our common stock for an aggregate purchase price not to exceed $50 million
through December 31, 2006 and terminated our prior repurchase program. Shares
may be purchased either in the open market or in privately negotiated
transactions.

The Company purchased 456,750 and 400,900 shares of our common stock for a total
purchase price of approximately $16.7 million and $15.1 million during the three
months ended September 30, 2006 and June 30, 2006, respectively under this
repurchase program. No purchases were made under this program during the first
quarter of 2006.

In October 2006, our Board of Directors terminated the repurchase program
approved in February 2006 and adopted a new program that authorizes us to
repurchase shares of our common stock for an aggregate purchase price not to
exceed $75 million through December 31, 2007. Shares may be repurchased either
in the open market or in privately negotiated transactions.

Dividend Policy

We have not paid any cash dividends on our common stock since our formation. Our
credit facility limits the amount of dividends that we may pay. Any future
determinations to pay cash dividends on our common stock will be at the
discretion of our Board of Directors and will depend upon our financial
condition, results of operations, cash flows and other factors deemed relevant
by the Board of Directors.

                                       31

<PAGE>

Requirements and Capital Resources

In December 2005, we established a $200 million, five-year, senior secured
revolving credit facility. The credit facility currently allows for revolving
credit borrowings in a principal amount of up to $200 million, which can be
increased to $250 million should additional financing be required in the future.
We plan to utilize the credit facility for working capital, capital
expenditures, share repurchases, acquisitions and other general corporate
purposes. We have borrowed against this credit facility in 2006 for acquisition
related purposes. As of September 30, 2006, we had $87 million of outstanding
borrowings under our credit facility, and the weighted average interest rate for
this borrowing was 6.58% per annum.

The indebtedness under the credit facility is guaranteed by all but one of our
domestic subsidiaries. The Company's obligations under the credit facility and
the guarantees of the guarantors are secured by a first-priority security
interest in all present and future capital stock of (or other ownership or
profit interest in) each guarantor and substantially all of the Company's and
the guarantors' other assets, other than real estate, intellectual property and
capital stock of foreign subsidiaries.

Borrowings under the credit facility bear interest, at our option, at a rate
equal to (i) the Eurodollar Rate in effect from time to time plus an applicable
rate (ranging from 0.75% to 1.5%) or (ii) the higher of (x) the weighted average
overnight Federal funds rate, as published by the Federal Reserve Bank of New
York, plus 0.5%, and (y) the prime commercial lending rate of Bank of America,
N.A. plus an applicable rate (ranging from 0% to 0.5%). The applicable rates are
based on a financial ratio at the time of the applicable borrowing.

We will also pay an annual commitment fee (ranging from 0.15% to 0.25%) on the
daily amount by which the commitments under the credit facility exceed the
outstanding loans and letters of credit under the credit facility.

The credit facility requires us to maintain various financial covenants,
including leverage ratios, a minimum fixed charge coverage ratio and a minimum
liquidity ratio. The credit facility also contains customary affirmative and
negative covenants, including those that limit the Company's and its
subsidiaries' ability to incur additional debt, incur liens, make investments,
enter into mergers and acquisitions, liquidate or dissolve, sell or dispose of
assets, repurchase stock and pay dividends, engage in transactions with
affiliates, engage in certain lines of business and enter into sale and
leaseback transactions. As of September 30, 2006, we were in compliance with all
of our debt covenants.

Contractual Obligations and Commitments

Under certain agreements, we are required to make payments based on sales levels
of certain products or if specific development milestones are achieved.


OTHER MATTERS

Critical Accounting Estimates

The critical accounting estimates included in our Annual Report on Form 10-K for
the fiscal year ended December 31, 2005 have not materially changed other than
as set forth below.

Recently Adopted Accounting Standard

We adopted Statement of Financial Accounting Standards No. 123(R) "Share-Based
Payment" on January 1, 2006 using the modified prospective method which requires
companies (1) to record the unvested portion of previously issued awards that
remain outstanding at the initial date of adoption and (2) to record
compensation expense for any awards issued, modified or settled after the
effective date of the statement. As a result of the adoption of Statement
123(R), we began expensing stock options in the first quarter of 2006 using the
fair value method prescribed by Statement 123(R). Stock-based compensation cost
is measured at the grant date based on the fair value of an award and is
recognized on a straight-line basis as an expense over the requisite service

                                       32

<PAGE>

period, which is the vesting period. Certain of these costs are capitalized into
inventory and will be recognized as an expense when the related inventory is
sold. Our income before income taxes and net income for the nine months ended
September 30, 2006 were $10.3 million and $7.0 million lower, respectively, than
if we had continued to account for share-based compensation under APB No. 25.

We recognize stock-based compensation expense in the consolidated statement of
operations based on the awards that are expected to vest. Accordingly, we have
adjusted stock-based compensation expense to reflect estimated forfeitures.
Statement 123(R) requires forfeitures to be estimated at the time of grant and
revised, if necessary, in subsequent periods if actual forfeitures differ from
those estimates. We estimate forfeitures based on historical experience.

Statement 123(R) supercedes our previous accounting under Accounting Principals
Boards Opinion No. 25 "Accounting for Stock Issued to Employees" for periods
subsequent to December 31, 2005. In March 2005, the Securities and Exchange
Commission issued Staff Accounting Bulletin No. 107, which provides interpretive
guidance in applying the provisions of Statement 123(R). We have applied the
provisions of SAB 107 in our adoption of Statement 123(R).

Our condensed consolidated statement of operations for the nine months ended
September 30, 2006, includes compensation expense related to (i) stock-based
awards granted prior to, but not fully vested as of, January 1, 2006, based on
grant date fair values estimated in accordance with the pro forma provisions of
Statement of Financial Accounting Standards Statement No 123 "Accounting for
Stock-Based Compensation", and (ii) stock-based awards granted in 2006, based on
grant-date fair values estimated in accordance with Statement 123(R).

We calculate the fair value of our restricted stock awards and restricted stock
unit awards based on the closing market price of our common stock on the date of
the grant. We calculated the fair value of options granted prior to October 1,
2004 using the Black-Scholes model, while we calculate the fair value of options
granted on or after October 1, 2004 using the binomial distribution model. These
models include assumptions regarding the expected term of our option awards,
expected future volatility in the market price of our common stock, future
risk-free interest rates, and future dividends, if any, on our common stock. We
believe that the binomial distribution model is better than the Black-Scholes
model because the binomial distribution model is a more flexible model that
considers the impact of non-transferability, vesting and forfeiture provisions
in the valuation of employee stock options.

The assumptions used in calculating the fair value of stock-based compensation
awards involve inherent uncertainties and the application of management
judgment. If factors were to change, and we used different assumptions,
depending on the level of our future stock-based awards, our stock-based
compensation expense in the future could be materially different from that
reported for the nine months ended September 30, 2006 or pro forma amounts
reported for periods prior to January 1, 2006. In addition, if our actual
forfeiture rate varies significantly from our current estimate, the amount of
stock-based compensation expense recognized in future periods will be affected.

Recently Issued Accounting Standards

In September 2006, the Financial Accounting Standards Board (FASB) issued SFAS
No. 158, Employer's Accounting for Defined Benefit Pension and Other
Postretirement Plans--an amendment of FASB Statements No. 87, 88, 106 and 132(R)
. SFAS No. 158 requires the Company to (a) recognize a plan's funded status in
its statement of financial position, (b) measure a plan's assets and its
obligations that determine its funded status as of the end of the employer's
fiscal year, and (c) recognize changes in the funded status of a defined
postretirement plan in the year in which the changes occur through other
comprehensive income. The requirement to recognize the funded status of a
benefit plan and the disclosure requirements are effective for the Company for
the fiscal year ending December 31, 2006. The Company does not believe the
implementation of this provision will have a material impact on its financial
position or results of operations.

In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements. This
Statement defines fair value, establishes a framework for measuring fair value
in generally accepted accounting principles (GAAP), and expands disclosures
about fair value measurements. SFAS No. 157 is effective for financial
statements issued for fiscal years beginning after November 15, 2007. The
Company is currently assessing the impact this provision may have on its
financial position or results of operations. 

                                       33

<PAGE>

In September 2006, the SEC issued Staff Accounting Bulletin No. 108, Considering
the Effects of Prior Year Misstatements when Quantifying Misstatements in
Current Year Financial Statements (SAB 108), to address diversity in practice in
quantifying financial statement misstatements. SAB 108 requires the
quantification of misstatements based on their impact to both the balance sheet
and the income statement to determine materiality. The guidance provides for a
one-time cumulative effect adjustment to correct for misstatements for errors
that were not deemed material under a company's prior approach but are material
under the SAB 108 approach. SAB 108 is effective for the fiscal year ending
December 31, 2006. The Company does not believe the implementation of this
provision will have a material impact on its financial position or results of
operations.

In July 2006, the FASB issued FASB Interpretation 48, "Accounting for
Uncertainty in Income Taxes - An Interpretation of FASB Statement No. 109" (FIN
48). FIN 48 clarifies the accounting for uncertainty in income tax recognition
in a company's financial statements in accordance with FASB Statement No. 109,
Accounting for Income Taxes, by defining the criterion that an individual tax
position must meet in order to be recognized in the financial statements. FIN 48
requires that the tax effects of a position be recognized only if it is
"more-likely-than-not" to be sustained based solely on the technical merits as
of the reporting date. FIN 48 further requires that interest that the tax law
requires to be paid on the underpayment of taxes should be accrued on the
difference between the amount claimed or expected to be claimed on the return
and the tax benefit recognized in the financial statements. FIN 48 also requires
additional disclosures of unrecognized tax benefits, including a reconciliation
of the beginning and ending balance. The provisions of FIN 48 are effective
January 1, 2007. The Company is currently assessing the impact that the adoption
of FIN 48 will have on its financial position or results of operations.

                                       34

<PAGE>




I
TEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to various market risks, including changes in foreign currency
exchange rates and interest rates that could adversely impact our results of
operations and financial condition. To manage the volatility relating to these
typical business exposures, we may enter into various derivative transactions
when appropriate. We do not hold or issue derivative instruments for trading or
other speculative purposes.

Foreign Currency Exchange Rate Risk

A discussion of foreign currency exchange risks is provided under the caption
"International Product Revenues and Operations" under "Management's Discussion
and Analysis of Financial Condition and Results of Operations."

Interest Rate Risk - Marketable Securities

We are exposed to the risk of interest rate fluctuations on the fair value and
interest income earned on our cash and cash equivalents and investments in
available-for-sale marketable debt securities. A hypothetical 100 basis point
movement in interest rates applicable to our cash and cash equivalents and
investments in marketable debt securities outstanding at September 30, 2006
would increase or decrease interest income by approximately $243,000 on an
annual basis. We are not subject to material foreign currency exchange risk with
respect to these investments.

Interest Rate Risk - Senior Secured Credit Facility

We are exposed to the risk of interest rate fluctuations on the interest paid
under the terms of our senior secured credit facility. A hypothetical 100 basis
point movement in interest rates applicable to this credit facility would
increase or decrease interest expense by approximately $870,000 on an annual
basis.

                                       35

<PAGE>




ITEM 4.  CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that
information required to be disclosed in our Exchange Act reports is recorded,
processed, summarized and reported within the time periods specified in the
Securities and Exchange Commission's rules and forms and that such information
is accumulated and communicated to our management, including our principal
executive officer and principal financial officer, as appropriate, to allow for
timely decisions regarding required disclosure. Disclosure controls and
procedures, no matter how well designed and operated, can provide only
reasonable assurance of achieving the desired control objectives, and management
is required to apply its judgment in evaluating the cost-benefit relationship of
possible controls and procedures. Management has designed our disclosure
controls and procedures to provide reasonable assurance of achieving the desired
control objectives.

As required by Rule 13a-15(b) under the Exchange Act, we have carried out an
evaluation, under the supervision and with the participation of our management,
including our principal executive officer and principal financial officer, of
the effectiveness of the design and operation of our disclosure controls and
procedures as of the end of the period covered by this report. Based on the
foregoing, our principal executive officer and principal financial officer
concluded that our disclosure controls and procedures were effective at the
reasonable assurance level.

Changes in Internal Control over Financial Reporting

No changes in our internal control over financial reporting (as defined in Rules
13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the quarter
ended September 30, 2006, that have materially affected, or are reasonably
likely to materially affect, our internal control over financial reporting.

On March 3, 2006 and May 12, 2006 the Company completed the purchases of
Radionics and Miltex, respectively, and is in the process of integrating the
operations and related controls of both businesses within the Company. On July
5, 2006 and July 31, 2006 the Company completed the purchases of Canada
Microsurgical Ltd. And Kinetikos Medical, Inc., respectively, and is in the
process of integrating the operations and related controls of these businesses
within the Company. See Note 2, "Business Acquisitions", to the unaudited
interim condensed consolidated financial statements included in this Quarterly
Report on Form 10-Q for a discussion of the acquisitions and related financial
data.

Internal control over financial reporting cannot provide absolute assurance of
achieving financial reporting objectives because of its inherent limitations.
Internal control over financial reporting is a process that involves human
diligence and compliance and is subject to lapses in judgment and breakdowns
resulting from human failures. Internal control over financial reporting also
can be circumvented by collusion or improper management override. Because of
such limitations, there is a risk that material misstatements may not be
prevented or detected on a timely basis by internal control over financial
reporting. However, these inherent limitations are known features of the
financial reporting process. Therefore, it is possible to design into the
process safeguards to reduce, though not eliminate, this risk.

                                       36

<PAGE>




PART II. OTHER INFORMATION


ITEM 1.  LEGAL PROCEDINGS

Various lawsuits, claims and proceedings are pending or have been settled by the
Company. The most significant of those are described below.

In May 2006, Codman & Shurtleff, Inc., a division of Johnson & Johnson,
commenced an action in the United States District Court for the District of New
Jersey for declaratory judgment against Integra LifeSciences Corporation with
respect to United States Patent No. 5,997,895 (the "'895 Patent") held by
Integra. Integra's patent covers dural repair technology related to Integra's
Duragen(R) family of duraplasty products.

The action seeks declaratory relief that Codman's DURAFORM(TM) product does not
infringe Integra's patent and that Integra's patent is invalid and
unenforceable. Codman does not seek either damages from Integra or injunctive
relief to prevent Integra from selling the Duragen(R) Dural Graft Matrix.
Integra has filed a counterclaim against Codman, alleging that Codman's
DURAFORM(TM) product infringes the '895 Patent, seeking injunctive relief
preventing the sale and use of DURAFORM(TM), and seeking damages, including
treble damages, for past infringement.

In July 1996, the Company sued Merck KGaA, a German corporation, seeking damages
for patent infringement. The patents in question are part of a group of patents
granted to The Burnham Institute and licensed by Integra that are based on the
interaction between a family of cell surface proteins called integrins and the
arginine-glycine-aspartic acid ("RGD") peptide sequence found in many
extracellular matrix proteins.

The case has been tried, appealed and returned to the trial court. Most
recently, in September 2004, the trial court ordered Merck KgaA to pay Integra
$6.4 million in damages. Merck KGaA filed a petition for a writ of certiorari
with the United States Supreme Court seeking review of the Circuit Court's
decision, and the Supreme Court granted the writ in January 2005.

On June 13, 2005, the Supreme Court vacated the June 2003 judgment of the
Circuit Court. The Supreme Court held that the Circuit Court applied an
erroneous interpretation of 35 U.S.C. ss.271(e)(1) when it rejected the
challenge of Merck KGaA to the jury's finding that Merck KGaA failed to show
that its activities were exempt from claims of patent infringement under that
statute. On remand, the Circuit Court was to have reviewed the evidence under a
reasonableness test that does not provide categorical exclusions of certain
types of activities. The hearing before the Circuit Court occurred in June 2006,
and a ruling is expected this year. Further enforcement of the trial court's
order has been stayed. We have not recorded any gain in connection with this
matter, pending final resolution and completion of the appeals process.

In addition to these matters, we are subject to various claims, lawsuits and
proceedings in the ordinary course of its business, including claims by former
employees, distributors and competitors and with respect to our products. In the
opinion of management, such claims are either adequately covered by insurance or
otherwise indemnified, or are not expected, individually or in the aggregate, to
result in a material adverse effect on our financial condition. However, it is
possible that our results of operations, financial position and cash flows in a
particular period could be materially affected by these contingencies.

                                       37


<PAGE>


ITEM 1A.  RISK FACTORS

The Risk Factors included in the Company's Annual Report on Form 10-K for the
fiscal year ended December 31, 2005 (as modified by the subsequent Quarterly
Report on Form 10-Q) have not materially changed other than the modifications to
the risks factors as set forth below.

Certain Of Our Products Contain Materials Derived From Animal Sources And May
Become Subject To Additional Regulation.

Certain of our products, including our dermal regeneration products, our
duraplasty products and our nerve repair products, contain material derived from
bovine tissue. Products that contain materials derived from animal sources,
including food as well as pharmaceuticals and medical devices, are increasingly
subject to scrutiny in the press and by regulatory authorities. Regulatory
authorities are concerned about the potential for the transmission of disease
from animals to humans via those materials. This public scrutiny has been
particularly acute in Japan and Western Europe with respect to products derived
from animal sources, because of concern that materials infected with the agent
that causes bovine spongiform encephalopathy, otherwise known as BSE or mad cow
disease, may, if ingested or implanted, cause a variant of the human
Creutzfeldt-Jakob Disease, an ultimately fatal disease with no known cure.
Recent cases of BSE in cattle discovered in Canada and the United States have
increased awareness of the issue in North America.

We take great care to provide that our products are safe and free of agents that
can cause disease. In particular, the collagen used in the products that Integra
manufactures is derived only from the deep flexor tendon of cattle less than 24
months old from New Zealand, a country that has never had a case of BSE, or the
United States. The collagen used in a product that we sell, but do not
manufacture, is derived from bovine pericardium. We are also qualifying sources
of collagen from other countries that are considered BSE-free. The World Health
Organization classifies different types of cattle tissue for relative risk of
BSE transmission. Deep flexor tendon and bovine pericardium are in the lowest
risk categories for BSE transmission (the same category as milk, for example),
and are therefore considered to have a negligible risk of containing the agent
that causes BSE (an improperly folded protein known as a prion). Nevertheless,
products that contain materials derived from animals, including our products,
may become subject to additional regulation, or even be banned in certain
countries, because of concern over the potential for prion transmission.
Significant new regulation, or a ban of our products, could have a material
adverse effect on our current business or our ability to expand our business.

In addition, we have been notified that Japan has issued new regulations
regarding medical devices that contain tissue of animal origin. Among other
regulations, Japan requires that the tendon used in the manufacture of medical
devices sold in Japan originate in a country that has never had a case of BSE.
Currently, we purchase our tendon from the United States and New Zealand. We
received approval in Japan for the use of New Zealand sourced tendon in the
manufacturing of our products sold in Japan. If we cannot continue to use or
qualify a source of tendon from New Zealand or another country that has never
had a case of BSE, we will not be permitted to sell our collagen hemostatic
agents and products for oral surgery in Japan. We do not currently sell our
dural or skin repair products in Japan.

Lack Of Market Acceptance For Our Products Or Market Preference For Technologies
That Compete With Our Products Could Reduce Our Revenues And Profitability.

We cannot be certain that our current products or any other products that we may
develop or market will achieve or maintain market acceptance. Certain of the
medical indications that can be treated by our devices can also be treated by
other medical devices or by medical practices that do not include a device. The
medical community widely accepts many alternative treatments, and certain of
these other treatments have a long history of use. For example, the use of
autograft tissue is a well-established means for repairing the dermis, and it
competes for acceptance in the market with the INTEGRA(R) Dermal Regeneration
Template. In addition, we face similar competition for acceptance of our Newdeal
and Kinetikos Medical products, which previously were distributed by third
parties.

We cannot be certain that our devices and procedures will be able to replace
those established treatments or that either physicians or the medical community
in general will accept and utilize our devices or any other medical products
that we may develop.

                                       38

<PAGE>

In addition, our future success depends, in part, on our ability to develop
additional products. Even if we determine that a product candidate has medical
benefits, the cost of commercializing that product candidate may be too high to
justify development. Competitors may develop products that are more effective,
achieve more favorable reimbursement status from third-party payors, cost less
or are ready for commercial introduction before our products. If we are unable
to develop additional commercially viable products, our future prospects could
be adversely affected.

Market acceptance of our products depends on many factors, including our ability
to convince prospective collaborators and customers that our technology is an
attractive alternative to other technologies, to manufacture products in
sufficient quantities and at acceptable costs, and to supply and service
sufficient quantities of our products directly or through our distribution
alliances. In addition, unfavorable reimbursement methodologies or
determinations of third-party payors could harm acceptance or continued use of
our products. The industry is subject to rapid and continuous change arising
from, among other things, consolidation and technological improvements. One or
more of these factors may vary unpredictably, which could have a material
adverse effect on our competitive position. We may not be able to adjust our
contemplated plan of development to meet changing market demands.

We Are Exposed To A Variety Of Risks Relating To Our International Sales And
Operations, Including Fluctuations In Exchange Rates, Local Economic Conditions
And Delays In Collection Of Accounts Receivable.

We generate significant revenues outside the United States in Euros, British
pounds and in U.S. dollar-denominated transactions conducted with customers who
generate revenue in currencies other than the U.S. dollar. For those foreign
customers who purchase our products in U.S. dollars, currency fluctuations
between the U.S. dollar and the currencies in which those customers do business
may have an impact on the demand for our products in foreign countries where the
U.S. dollar has increased in value compared to the local currency.

Because we have operations based in Europe and we generate revenues and incur
operating expenses in Euros and British pounds, we experience currency exchange
risk with respect to those foreign currency-denominated revenues and expenses.
We also experience currency exchange risk with respect to the yen.

Currently, we do not use derivative financial instruments to manage operating
foreign currency risk. As the volume of our business transacted in foreign
currencies increases, we expect to continue to assess the potential effects that
changes in foreign currency exchange rates could have on our business. If we
believe that this potential impact presents a significant risk to our business,
we may enter into derivative financial instruments to mitigate this risk.

In general, we cannot predict the consolidated effects of exchange rate
fluctuations upon our future operating results because of the number of
currencies involved, the variability of currency exposure and the potential
volatility of currency exchange rates.

Our international operations subject us to customs and import-export laws. These
laws restrict, and in some cases prohibit, United States companies from directly
or indirectly selling goods, technology or services to people or entities in
certain countries. These laws also prohibit transactions with certain designated
persons.

Our sales to foreign markets also may be affected by local economic conditions,
legal, regulatory or political considerations, the effectiveness of our sales
representatives and distributors, local competition and changes in local medical
practice. Relationships with customers and effective terms of sale frequently
vary by country, often with longer-term receivables than are typical in the
United States.

Our Current Strategy Involves Growth Through Acquisitions, Which Requires Us To 
Incur Substantial Costs And Potential Liabilities For Which We May Never Realize
The Anticipated Benefits.

In addition to internal growth, our current strategy involves growth through
acquisitions. Since 1999, we have acquired 24 businesses or product lines at a
total cost of approximately $335 million.

                                       39

<PAGE>

We may be unable to continue to implement our growth strategy, and our strategy
ultimately may be unsuccessful. A significant portion of our growth in revenues
has resulted from, and is expected to continue to result from, the acquisition
of businesses complementary to our own. We engage in evaluations of potential
acquisitions and are in various stages of discussion regarding possible
acquisitions, certain of which, if consummated, could be significant to us. Any
new acquisition can result in material transaction expenses, increased interest
and amortization expense, increased depreciation expense and increased operating
expense, any of which could have a material adverse effect on our operating
results. Certain businesses that we acquire may not have adequate financial,
regulatory or quality controls at the time we acquire them. As we grow by
acquisition, we must integrate and manage the new businesses to bring them into
our systems for financial, regulatory and quality control, realize economies of
scale, and control costs. In addition, acquisitions involve other risks,
including diversion of management resources otherwise available for ongoing
development of our business and risks associated with entering new markets with
which our marketing and sales force has limited experience or where experienced
distribution alliances are not available. Our future profitability will depend
in part upon our ability to develop further our resources to adapt to these new
products or business areas and to identify and enter into satisfactory
distribution networks. We may not be able to identify suitable acquisition
candidates in the future, obtain acceptable financing or consummate any future
acquisitions. If we cannot integrate acquired operations, manage the cost of
providing our products or price our products appropriately, our profitability
could suffer. In addition, as a result of our acquisitions of other healthcare
businesses, we may be subject to the risk of unanticipated business
uncertainties, regulatory matters or legal liabilities relating to those
acquired businesses for which the sellers of the acquired businesses may not
indemnify us.

                                       40

<PAGE>




ITEM 2.  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

In February 2006, our Board of Directors authorized us to repurchase shares of
our common stock for an aggregate purchase price not to exceed $50 million
through December 31, 2006. Shares may be purchased either in the open market or
in privately negotiated transactions.

The following table summarizes our repurchases of our common stock during the
quarter ended September 30, 2006 under this program:

<TABLE>
<CAPTION>
                                                                                                        Approximate
                                                                                                        Dollar Value
                                                                                       Total Number          of
                                                                                         of Shares      Shares that
                                                                                       Purchased as         May
                                                                                          Part of          Yet be
                                                        Total Number      Average        Publicly        Purchased
                                                         of Shares      Price Paid       Announced       Under the
Period                                                   Purchased       per Share        Program         Program
------                                                   ---------       ---------        -------         -------
<s>                                                       <c>            <c>              <c>           <c>
July 1, 2006 - July 31, 2006                                55,300       $  37.93          55,300       $32,715,891
August 1, 2006 - August 31, 2006                           401,450          36.26         401,450        18,161,013
September 1, 2006 - September 30, 2006                          --            --               --        18,161,013
                                                           -------                        -------

     Total                                                 456,750       $  36.46         456,750       $18,161,013
                                                           =======                        =======
</TABLE>


In October 2006, our Board of Directors terminated the repurchase program
approved in February 2006 and adopted a new program that authorizes us to
repurchase shares of our common stock for an aggregate purchase price not to
exceed $75 million through December 31, 2007. Shares may be repurchased either
in the open market or in privately negotiated transactions.

                                       41

<PAGE>




ITEM 6.  EXHIBITS

4.1      Indenture, dated as of September 29, 2006, between Integra
         LifeSciences Holdings Corporation and Wells Fargo Bank, N.A.
         (Incorporated by reference to Exhibit 4.1 to the Company's Current 
         Report on Form 8-K filed on October 5, 2006)

4.2      Form of 2 1/2% Contingent Convertible Subordinated Note due 2008 
         (Incorporated by reference to Exhibit 4.2 to the Company's Current 
         Report on Form 8-K filed on October 5, 2006)

10.1     Integra LifeSciences Holdings Corporation Management Incentive 
         Compensation Plan.

10.2     Fourth  Amendment to Sublease, dated as of August 15,  2006, by and 
         between  Sorrento  Montana,  L.P. and Integra LifeSciences  Corporation
         (Incorporated  by reference to Exhibit 10.1 to the  Company's Current
         Report on Form 8-K filed on August 17, 2006).

10.3     Lease Contract, dated April 1, 2005, between the Puerto Rico Industrial
         Development Company and Integra CI, Inc. (executed on September 15, 
         2006)

31.1     Certification of Principal Executive Officer Pursuant to Section 302 of
         the Sarbanes-Oxley Act of 2002

31.2     Certification of Principal Financial Officer Pursuant to Section 302 of
         the Sarbanes-Oxley Act of 2002

32.1     Certification of Principal Executive Officer Pursuant to Section 906 of
         the Sarbanes-Oxley Act of 2002

32.2     Certification of Principal Financial Officer Pursuant to Section 906 of
         the Sarbanes-Oxley Act of 2002

                                       42


<PAGE>




                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

                    INTEGRA LIFESCIENCES HOLDINGS CORPORATION

    Date:     November 9, 2006             /s/  Stuart M. Essig
                                           -------------------
                                           Stuart M. Essig
                                           President and Chief Executive Officer

    Date:     November 9, 2006             /s/ Maureen B. Bellantoni
                                           -------------------
                                           Maureen B. Bellantoni
                                           Executive Vice President and Chief
                                           Financial Officer


                                       43


<PAGE>



Exhibits

4.1      Indenture, dated as of September 29, 2006, between Integra
         LifeSciences Holdings Corporation and Wells Fargo Bank, N.A.
         (Incorporated by reference to Exhibit 4.1 to the Company's Current 
         Report on Form 8-K filed on October 5, 2006)

4.2      Form of 2 1/2% Contingent Convertible Subordinated Note due 2008 
         (Incorporated by reference to Exhibit 4.2 to the
         Company's Current Report on Form 8-K filed on October 5, 2006)

10.1     Integra LifeSciences Holdings Corporation Management Incentive 
         Compensation Plan.

10.2     Fourth Amendment to Sublease, dated as of August 15, 2006, by and 
         between  Sorrento  Montana,  L.P. and Integra LifeSciences Corporation 
         (Incorporated  by reference to Exhibit 10.1 to the Company's Current
         Report on Form 8-K filed on August 17, 2006).

10.3     Lease Contract, dated April 1, 2005, between the Puerto Rico Industrial
         Development  Company and Integra CI, Inc. executed on September 15, 
         2006)

31.1     Certification of Principal Executive Officer Pursuant to Section 302 of
         the Sarbanes-Oxley Act of 2002

31.2     Certification of Principal Financial Officer Pursuant to Section 302 of
         the Sarbanes-Oxley Act of 2002

32.1     Certification of Principal Executive Officer Pursuant to Section 906 of
         the Sarbanes-Oxley Act of 2002

32.2     Certification of Principal Financial Officer Pursuant to Section 906 of
         the Sarbanes-Oxley Act of 2002

                                       44



<PAGE>












                    INTEGRA LIFESCIENCES HOLDINGS CORPORATION


                     MANAGEMENT INCENTIVE COMPENSATION PLAN






<PAGE>





                    INTEGRA LIFESCIENCES HOLDINGS CORPORATION

                     MANAGEMENT INCENTIVE COMPENSATION PLAN


1.       Purpose

         The purpose of the Plan is to enhance the ability of Integra to offer
incentive compensation to Key Associates by rewarding the achievement of
corporate goals and specifically measured individual goals which are consistent
with and support the overall corporate goals of Integra. More specifically,
through this Plan, Integra intends to (i) reinforce strategically important
operational objectives; (ii) establish goals relating to revenue and
profitability; (iii) provide rewards based on achieving significant Employer,
departmental and individual goals and objectives; (iv) provide incentives that
result in behavior that is consistent with shareholders' desires of building a
stronger company with a higher potential for increased profitability; and (v)
incorporate an incentive program in the Integra overall compensation program to
help attract and retain Key Associates.

2.       Definitions

         (a)  "Administrator"  shall mean Integra's head of its human  resources
department, whose duties are set forth in Section
 4.

         (b) "Award"  shall mean the  incentive  award earned by a Key Associate
under the Plan for any Performance Period.

         (c) "Base Salary" shall mean the Key Associate's annual base salary
rate in effect at the end of a Performance Period. Base Salary does not include
Awards under this Plan or any other short-term or long-term incentive plan;
imputed income from such programs as group-term life insurance; or non-recurring
earnings, such as moving expenses, but is based on salary earnings before
reductions for such items as deferrals under Employer-sponsored deferred
compensation plans, contributions under Code section 401(k) and contributions to
flexible spending accounts under Code section 125.

         (d) "Board" shall mean Integra's Board of Directors as constituted from
time to time.

         (e) "CEO" shall mean the Chief Executive Officer of Integra.

         (f) "Code" shall mean the Internal Revenue Code of 1986, as amended or
any successor statute thereto.

         (g) "Committee" shall mean the Compensation Committee of the Board.

         (h) "Effective Date" shall mean August 11, 2006.

         (i) "Employee" shall mean an employee of the Employer (including an
officer or director who is also an employee) and any individual characterized as
a "leased employee" within the meaning of Code section 414(n) who works
full-time for the Employer, but excluding any individual (i) employed in a
casual or temporary capacity (i.e., those hired for a


<PAGE>

specific job of limited duration); (ii) whose terms of employment are
governed by a collective bargaining agreement that does not provide for
participation in this Plan; (iii) characterized as a "leased employee" within
the meaning of Code section 414 who does not work full-time for the Employer; or
(iv) classified by the Employer as a "contractor" or "consultant," no matter how
characterized by the Internal Revenue Service, other governmental agency or a
court. Any change of characterization of an individual by any court or
government agency shall have no effect upon the classification of an individual
as an Employee for purposes of this Plan, unless the Committee determines
otherwise.

         (j) "Employer" shall mean Integra and any United States subsidiary of
Integra.

         (k) "Integra" shall mean Integra LifeSciences Holdings Corporation.

         (l) "Key Associate" for any Performance Period, shall mean (i) a Senior
Officer designated by the Committee to participate in the Plan or otherwise
included in the employee grade levels set forth in the definition of "Target
Award Percentage" (defined below), and (ii) each other Employee designated by
the Administrator to participate in the Plan; and who meets the eligibility
requirements described in Section 3 below. Notwithstanding the foregoing, no
Employees of Integra California, Inc., Miltex Holdings, Inc. (and any subsidiary
thereof) and Integra Radionics, Inc., and no member of any sales force of the
Employer who, as part of his or her compensation, receives commission payments,
shall be a "Key Associate."

         (m) "Performance Goals" for any Performance Period, shall mean the
performance goals of Integra and/or the Employer, as specified by the
Administrator in consultation with Integra's Executive Committee, based on the
achievement of corporate EBITDA targets relating to Integra and/or the
Employer's operating plan and global sales. In addition, performance goals for a
Performance Period will relate to the individual Key Associate's attainment of
performance goals that are specified for such Key Employee. The Performance
Goals may be weighted as to corporate and individual goals for each Key
Associate, as determined at the beginning of the Performance Period or, if
later, at the time of the Key Associate's participation in the Plan.

         (n) "Performance Period" shall mean the fiscal year of Integra or any
other period designated by the Committee with respect to which an Award may be
earned. The first Performance Period for the Plan shall be the period between
July 1, 2006 and December 31, 2006.

         (o) "Plan" shall mean this Integra LifeSciences Holdings Corporation
Management Incentive Compensation Plan, as from time to time amended and in
effect.

         (p) "Senior Officer" shall mean an executive office of Integra as
determined under applicable securities laws.

         (q) "Target Award Percentage" shall mean with respect to any
Performance Period, the percentage of the Key Associate's Base Salary that the
Key Associate would earn as an Award for that Performance Period if the targeted
level of performance was achieved for each of the Performance Goals for that Key
Associate for the Performance Period. Unless otherwise specified prior to the
Performance Period (or, if later, at

                                       2

<PAGE>

the time of the Key Associate's participation in the Plan), Target Award 
Percentages will be based on a Key Associate's grade level as follows:


<TABLE>
<CAPTION>
    Grade Level             Management Group            Percent of Base Salary
<s>                    <c>                          <c>                 
--------------------- ----------------------------  ---------------------------
         12                       SVP                           16.25%
--------------------- ----------------------------  ---------------------------
         10                 Vice Presidents                     13.75%
--------------------- ----------------------------  ---------------------------
         8                      Director                        6.25%
--------------------- ----------------------------  ---------------------------
         7                 Directors/Managers                     5%
--------------------- ----------------------------  ---------------------------
         6                 Directors/Managers                     5%
--------------------- ----------------------------  ---------------------------
</TABLE>


Notwithstanding the foregoing, if any Key Associate held more than one grade
level during the Performance Period, then the Committee may designate different
Target Award Percentages with respect to each grade level and the Award will be
pro-rated to reflect (to the nearest semi-monthly increment) the period during
which such Key Associate had each Target Award Percentage.

         (r) "Target Award" for any Key Associate with respect to any
Performance Period, shall mean the dollar amount based on the Key Associate's
Target Award Percentage that the Key Associate would be eligible to earn as an
Award for that Performance Period.

3.       Eligibility

         Subject to the approval by the Administrator or the Committee, all
exempt Employees employed by an Employer in a Grade Level 6 or above position,
as of January 1 of each Performance Period, shall be eligible to participate in
the Plan. In addition, exempt Employees who are newly hired to a Grade Level 6
or above position after January 1 of a Performance Period, but prior to October
1 of such Performance Period, will, subject to the approval of the Administrator
or the Committee, be eligible to participate in the Plan for the Performance
Period of their hiring on a pro rata basis that is tied to their first day of
employment. Any exempt Employee who is either (i) promoted to a Grade Level 6 or
above position, or (ii) a participant in the Plan but is promoted to a higher
Grade Level position, in either case after January 1 of a Performance Period,
but prior to October 1 of such Performance Period, will, subject to the approval
of the Administrator or the Committee, be eligible to participate in the Plan
for the remaining portion of the Performance Period after the promotion on a pro
rata basis that is tied to the date of the promotion.

         An exempt Employee who is hired into a Grade Level 6 or above position
on or after October 1 of a Performance Period shall not be eligible to
participate in the Plan for such Performance Period. An exempt Employee who is
not participating in the Plan for a Performance Period and is subsequently
promoted to a Grade Level 6 or above position on or after October 1 of a
Performance Period shall also not be eligible to participate in the Plan. An
exempt Employee who is participating in the Plan for a Performance Period and is
subsequently promoted to a higher position on or after October 1 of a
Performance Period shall continue at the participation level for the Performance
Period prior to the promotion.

                                       3

<PAGE>

         Except as otherwise provided in this Plan, any individual participating
in the Plan during a Performance Period who ceases to be an Employee during such
Performance Period shall cease to be eligible to participate in the Plan.

4.       Administration

         The administration of the Plan shall be consistent with the purpose and
the terms of the Plan. The Plan shall be administered by the Administrator,
subject to oversight by the Committee. The Administrator shall have full
authority to establish the rules and regulations relating to the Plan, to
interpret the Plan and those rules and regulations, to select Key Associates to
participate in the Plan, to determine each Key Associate's Target Award
Percentage, to approve all of the Awards, to decide the facts in any case
arising under the Plan and to make all other determinations, including factual
determinations, and to take all other actions necessary or appropriate for the
proper administration of the Plan, including the delegation of such authority or
power, where appropriate; provided, however, that with respect to Senior
Officers, the Committee shall have final decision-making authority. All powers
of the Administrator and of the Committee shall be executed in their sole
discretion, in the best interest of Integra, not as a fiduciary, and in keeping
with the objectives of the Plan and need not be uniform as to similarly situated
individuals. The CEO, other than with respect to himself, also has the powers of
the Administrator and of the Committee with respect to selecting Key Associates
in the Plan and determining each Key Associate's Target Award Percentage.

         All Awards shall be made conditional upon the Key Associate's
acknowledgement, in writing or by acceptance of the Award, that all decisions
and determination of the Administrator shall be final and binding on the Key
Associate, his or her beneficiaries and any other person having or claiming an
interest under such Award. Awards need not be uniform as among Key Associates.
The Administrator's administration of the Plan, including all such rules and
regulations, interpretations, selections, determinations, approvals, decisions,
delegations, amendments, terminations and other actions, shall be final and
binding on Integra, the Employer and all Employees of the Employer, including,
the Key Associates and their respective beneficiaries.

5.       Determination of Awards

         (a) Setting Target Awards. Except as noted below for 2006, prior to the
beginning of the Performance Period (or after the beginning of the Performance
Period for any Employee who becomes newly eligible or has a promotion), the
Administrator (or, as appropriate, the Committee) shall determine the Employees
who shall be Key Associates during that Performance Period and determine each
Key Associate's Target Award Percentage, each of which shall be documented by
the Administrator. The Administrator's written records shall set forth (i) the
Key Associates during that Performance Period (which may be amended during the
Performance Period for new Key Associates), (ii) each Key Associate's Target
Award Percentage for that Performance Period, and (iii) the Performance Goal or
Goals (and how they are weighted, if applicable) for that Performance Period.
The Employer shall notify each Key Associate of the Key Associate's Target Award
Percentage and the applicable Performance Goals for the Performance Period as
soon as administratively practicable after the time the Target Award Percentage
and Performance Goals are established for such Performance Period. The
         
                                       4

<PAGE>

Performance Goals that are established may be (but need not be) different each
Performance Period and different Performance Goals may be applicable to
different Key Associates. for 2006, the determination of Key Associates and the
Target Award Percentages for Employees eligible to participate in the Plan on
the Effective Date shall be made prior to the Effective Date.

         (b) Earning An Award. Generally, a Key Associate earns an Award for a
Performance Period based on the level of achievement of the Performance Goals
established for that period. The amount of the Award may be increased as much as
50% above the Target Award based on the extent to which the level of achievement
of the Performance Goals exceeds the target level for that Performance Period
(to a maximum of 120% of the Target Performance Goals), as specified at the time
the Performance Goals are set for that Performance Period. An Award may also be
reduced below the Target Award to the extent the level of achievement of the
Performance Goals is below target, but at or above the minimum level for that
Performance Period, at the time the Performance Goals are established. A Key
Associate will receive no Award if the level of achievement of all Performance
Goals is below the minimum required to earn an Award for the applicable
Performance Period (i.e., 90% of the Target Performance Goals), as specified at
the time the Performance Goals are established.

6.       Changes to the Target

         The Administrator (or, with respect to Senior Officers, the Committee)
may at any time prior to the final determination of Awards change the Target
Award Percentage of any Key Associate or assign a different Target Award
Percentage to a Key Associate to reflect any change in the Key Associate's
responsibility level or position during the course of the Performance Period.

         In addition, the Committee may at any time prior to the final
determination of Awards, change the performance measures or Performance Goals to
reflect a change in corporate capitalization, such as a stock split or stock
dividend, or a corporate transaction, such as a merger, consolidation,
separation, reorganization or partial or complete liquidation, or to equitably
reflect the occurrence of any extraordinary event, any change in applicable
accounting rules or principles, any change in Integra's or the Employer's method
of accounting, any change in applicable law, any change due to any merger,
consolidation, acquisition, reorganization, stock split, stock dividend,
combination of shares or other changes in Integra's or the Employer's corporate
structure or shares, or any other change of a similar nature.

7.       Payment of Awards

         After the end of the Performance Period, all financial information for
the Performance Period will be accumulated and the Audit Committee of the Board
will certify Integra's and/or the Employer's financial results for the relevant
Performance Period. After such certification, the Administrator will determine
and approve the Awards, if any, that will be paid based on the financial results
for the Performance Period, along with each Key Associates attainment of his or
her individual Performance Goals for the Performance Period. The Administrator
will announce the Awards that will be paid under the Plan for the Performance
Period to each Key Associate as soon as administratively practicable following
such approval by the Administrator. Subject to the provisions of Section 8,
payment of the Awards shall be made, in a single lump sum cash payment, as soon

                                       5

<PAGE>

as administratively practicable following the close of such Performance Period,
but in no event later than March 15 of the calendar year following the
Performance Period; provided, however, that such payment may be delayed past
March 15 of such calendar year if the Committee determines that, as a result of
unforeseen circumstances beyond Integra's control, it is administratively
impracticable to make the payment by such date or that making the payment by
such date would jeopardize the solvency of Integra, then the payment will be
made as soon as administratively practicable after March 15.

8.       Limitations on Rights to Payment of Awards

         (a) Employment. No Key Associate shall have any right to receive
payment of an Award under the Plan for a Performance Period unless the Key
Associate remains in the employ of the Employer through the date of payment of
such Award; provided, however, that if a Key Associate's employment with the
Employer terminates prior to the end of the Performance Period, the
Administrator may provide that the Key Associate shall remain eligible to
receive a prorated portion of any earned Award, based on the number of days that
the Key Associate was actively employed and performed services during such
Performance Period in such circumstances as are deemed appropriate and provided,
further, however, that no Key Associate shall have the right to receive payment
of an Award under the Plan if (a) that Key Associate's employment has been
terminated prior to the end of the Performance Period, (b) that Key Associate
has an employment agreement with Employer and (c) the employment agreement
provides for a payment to the Key Associate upon his/her termination.

         (b) Leaves of Absence/Partial Year of Participation. If a Key Associate
is on an authorized leave of absence during the Performance Period, or first
becomes eligible to participate in the Plan after the first day of the
Performance Period, such Key Associate shall be eligible to receive a prorated
portion of any Award that would have been earned, based on the number of days
that the Key Associate was actively employed and performed services during such
Performance Period. If payments are to be made under the Plan after a Key
Associate's death, such payments shall be made to the personal representative of
the Key Associate's estate.

         (c) Accelerated Payment. Unless the Administrator determines otherwise,
in no event will payment be made to any Key Associate with respect to an Award
prior to the end of the Performance Period to which it relates.

9.       Amendments

         The Board or the Committee may at any time amend (in whole or in part)
this Plan. No such amendment which adversely affects any Key Associate's rights
to or interest in an Award earned prior to the date of the amendment shall be
effective unless the Key Associate shall have agreed thereto.

10.      Termination

         The Board or the Committee may terminate this Plan (in whole or in
part) at any time.

                                       6

<PAGE>

11.      Miscellaneous Provisions

         (a) No Employment Right. This Plan is not a contract between Integra or
the Employer and the Employees or the Key Associates. Neither the establishment
of this Plan, nor any action taken hereunder, shall be construed as giving any
Employee or any Key Associate any right to be retained in the employ of Integra
or the Employer. Integra is under no obligation to continue the Plan. Nothing
contained in the Plan shall limit or affect in any manner or degree the normal
and usual powers of management, exercised by the officers and the Board or
committees thereof, to change the duties or the character of employment of any
Employee of the Employer or to remove the individual from the employment of the
Employer at any time, all of which rights and powers are expressly reserved.

         (b) No Assignment. A Key Associate's right and interest under the Plan
may not be assigned or transferred, except as provided in Section 8 of the Plan
in the event of death, and any attempted assignment or transfer shall be null
and void and shall extinguish, in Integra's sole discretion, Integra's
obligation under the Plan to pay Awards with respect to the Key Associate.

         (c) Unfunded Plan. The Plan shall be unfunded. Neither Integra nor any
Employer shall be required to establish any special or separate fund, or to make
any other segregation of assets, to assure payment of Awards.

         (d) Withholding Taxes. The Employer shall have the right to deduct from
Awards paid any taxes or other amounts required by law to be withheld.

         (e) Type of Plan. This Plan is intended solely to be an annual bonus
plan and is not intended to be a plan subject to the requirements of the
Employee Retirement Income Security Act of 1974, as amended.

         (f) Governing Law. The validity, construction, interpretation and
effect of the Plan shall exclusively be governed by and determined in accordance
with the law of the State of New Jersey.

                                       7

 
                   PUERTO RICO INDUSTRIAL DEVELOPMENT COMPANY
                P.O.Box 362350, San Juan, Puerto Rico 00936-2350


                                 LEASE CONTRACT


                             PROJECT NOS. T-0994-0-70, T-0810-0-68, T-0810-1-02,
                             T-0810-2-03, and L-154-2-62

                             LOCATION: Anasco, Puerto Rico


         THIS AGREEMENT ENTERED into on April 1, 2005 by:
AS "LANDLORD", THE PUERTO RICO INDUSTRIAL  DEVELOPMENT COMPANY, AND AS "TENANT",
INTEGRA CI, INC., doing business as "INTEGRA NEUROSCIENCES PR"

                                   WITNESSETH:

         WHEREAS, LANDLORD is the owner of certain landsite and buildings,
identified herein above, and hereinafter referred to as the "Premises"; and,

         WHREAS, this Lease Contract supersedes the Construction Lease Contract
entered into on April 11, 2003 by and between LANDLORD and Integra NeuroSciences
P.R., Inc.;

         WHEREAS, TENANT is the successor in interest of Integra NeuroSciences,
P.R., Inc., the original Tenant of the Premises, pursuant to a merger
consummated on December 31, 2005.

         NOW THEREFORE, in consideration of the foregoing premises, the parties
herein agree to this Lease, subject to the following:

                              TERMS AND CONDITIONS

         ONE: LANDLORD hereby demises and lets unto TENANT, and TENANT hereby
leases from LANDLORD the Premises which are fully described in Schedule "A"
hereto annexed and made a part hereof.

     The Premises are subject to
 the encumbrances, liens and/or restrictions, if
any, that may appear from said Schedule "A". Furthermore, the air rights of the
Premises, are excepted and reserved to LANDLORD.


<PAGE>

         TWO: The Premises shall be used and occupied exclusively by TENANT in
the manufacture of medical products and medical devices and Biomaterials (SIC
#3841). Lot Number 6 will be used for parking.

         THREE: TENANT shall hold the Premises for a period of fifteen (15)
years, commencing on April 1st, 2005 for Project Nos. T-0810-0-68, T-0810-1-01,
and T-0810-2-03 and Lot No. 6, and commencing on December 1, 2005 for Project
No. T-0994-0-70; ending on March 31, 2020.

         FOUR: Commencing on May 1st, 2005 for Project Nos. T-0810-0-68,
T-0810-1-02, and T-0810-2-03 and Lot No. 6, and on December 1st, 2005 for
Project T-004-0-70, TENANT shall pay to LANDLORD an annual rent in the following
manner:

<TABLE>
<CAPTION>
                                     Total Area       Rent Per Sq. Ft.    Monthly Basic Rent      Annual Basic Rent
    <s>                         <c>                   <c>                 <c>                      <c>
    --------------------------- ---------------------------------------------------------------- ------------------
    (a)    T-0810-0-68           11,425.30 sq. ft.
           T-0810-1-02            5,430.00 sq. ft.
           T-0810-2-03            7,036.26 sq. ft.
    --------------------------- ------------------- ------------------ ---------------------- ----------------------
            180 months           23,891.56 sq. ft.        $3.85              $7,665.21             $91,982.52
    --------------------------- ------------------- ------------------ ---------------------- ----------------------
    (b)    Lot  6                                          ---                 $958.34                  ---
    --------------------------- ------------------- ------------------ ---------------------- ----------------------
    (c)    T-0994-0-70             22,445.75 sq. ft.      $3.25              $6,079.00             $72,948.72
    --------------------------- ------------------- ------------------ ---------------------- ----------------------
</TABLE>

         The monthly installments for rent specified herein, shall be paid in
advance on the first day of each month at LANDLORD'S office, or at any other
place that LANDLORD may notify. In the event that the date of commencement does
not fall on the first of the month, TENANT further agrees to pay the first
partial monthly installments, prior to, or on the date of commencement.

         FIVE:  TENANT  shall  deposit with  LANDLORD the amount of  $19,791.25,
distributed as follows:
              a) $3,016.28  previously  deposited by TENANT as a reservation fee
                 of Project Num. T-0810-0-68, on June 30, 1994; and,
              b) $8,021.62 previously deposited by TENANT with LANDLORD; and,
              c) $8,753.85  previously  deposited by TENANT as a reservation fee
                 for Project No. T-0994-0-70.

                                       2

<PAGE>

         This deposit shall guarantee the compliance by TENANT of its
obligations, under this Contract, particularly, but not limited to, the payment
of rent, the compliance of the environmental clauses herein included and the
return of the Premises in proper condition at the termination of this Lease. On
said termination, if TENANT is not in default of any of the terms and conditions
of this Contract, LANDLORD will return to TENANT the sum of money, if any, held
pursuant to this provision, after LANDLORD's Environmental Office certifies that
there are no environmental deficiencies as a result of TENANT's manufacturing
operation on the demised Premises.

         SIX: TENANT agrees to have on the date of commencement of the term of
this Lease a capitalization of $500,000.00. Likewise TENANT agrees to install
within six (6) months from the same date manufacturing machinery and equipment
with a value of at least $1,900,899.00. This shall not include the cost of
transportation and installation thereof, or its ordinary depreciation after
installation; and within eighteen (18) months from the date of commencement of
the term, to employ a minimum of one hundred forty five (145) production
workers. The aforementioned levels, shall be maintained throughout the term of
this Lease or any extension thereof.

         SEVEN: All notices, demands, approvals, consents and/or communications
herein required or permitted shall be in writing. If by mail should be certified
and to the following addresses, to LANDLORD: PO BOX 362350, SAN JUAN, PUERTO
RICO 00936-2350. To TENANT:

    Mr. Joseph Celusak, General Manager    Parent Company: Integra LifeSciences
    P.O. Box 167, Anasco, P.R. 00610                       311 Enterprise Drive 
    Phone (787) 826-2329                                   Plainsboro, NJ 08536
                                            Att: Senior VP-Operations and Law 
                                                 Department

         EIGHT: Net Lease - This Lease shall be interpreted as a net lease; it
being the exclusive responsibility of TENANT to pay for all operating expenses,
utilities, maintenance, expenses, insurance, taxes or any other costs, expenses
or charges of any nature not specifically assumed by LANDLORD hereunder.

         NINE: Warranty as to use - LANDLORD does hereby warrant that at the
time of the commencement of the term of this Lease, the Premises may be used by
TENANT for the manufacturing purposes herein intended which are deemed
consistent with the design and construction in accordance with the corresponding
plans and specifications.

                                       3

<PAGE>

         TEN: Alterations - TENANT shall make no alterations, additions or
improvements to the Premises without the prior consent of LANDLORD and all such
alterations, additions or improvements made by or for TENANT, shall be at
TENANT'S own cost and expenses and shall, when made, be the property of LANDLORD
without additional consideration and shall remain upon and be surrendered with
the Premises as a part thereof at the expiration or earlier termination of this
Lease, subject to any right of LANDLORD to require removal or to remove as
provided for hereinafter.

         In the event TENANT asks for LANDLORD'S consent for any alteration;
LANDLORD may at its option, require from TENANT to submit plans and
specifications for said alteration. Before commencing any such work, said plans
and specifications, if required, shall be filed with and approved by all
governmental agencies having jurisdiction thereof, and the consent of any
mortgagee having any interest in or lien upon this Lease shall be procured by
TENANT and delivered to LANDLORD if required by the term of the mortgage.

         Before commencing any such work, TENANT shall at TENANT'S own cost and
expense, deliver to LANDLORD a General Accident Liability Policy more
particularly described in Article THIRTY (30) hereof, but said policy shall
recite and refer to such work, and in addition thereto, if the estimated cost of
such work is more than FIVE THOUSAND DOLLARS ($5,000.00), TENANT shall, at
TENANT'S own cost and expense, deliver to LANDLORD a surety bond, or a
performance bond from a company acceptable to LANDLORD, or a similar bond or
other security satisfactory to LANDLORD, in an amount equal to the estimated
cost of such work, guaranteeing the completion of such work within a reasonable
time, due regard being had to conditions, free and clear of materialmen liens,
mechanics liens or any other kind of lien, encumbrances, chattel mortgages and
conditional bills of sale and in accordance with said plans and specifications
submitted to and approved by LANDLORD. At LANDLORD'S option TENANT shall provide
a blanket written guarantee in an amount sufficient to satisfy LANDLORD as to
all alterations, changes, additions and improvements to the Premises in lieu of
separate guarantee for each such project.

         TENANT shall pay the increased premium, if any, charged by the
insurance companies carrying insurance policies on said building, to cover the
additional risk during the course of such work.

                                       4

<PAGE>

         ELEVEN: Power Substation - If required by TENANT'S operations, TENANT
shall, at its own cost and expense, construct and/or install a power substation
and connect it to the PUERTO RICO ELECTRICAL POWER AUTHORITY (PREPA)
distribution lines, for voltages up to 13.2 KV; and to PREPA transmission lines
for voltages of 38 KV, all in conformity to PREPA'S requirements. Such
construction shall, in no event, be undertaken by TENANT until after LANDLORD
has approved the location thereof, as well as the routing of the power line
extension.

         TWELVE: Repairs and Maintenance - TENANT shall, at its own cost and
expense, put, keep and maintain in thorough repair and good order and safe
condition the building and improvements standing upon the Premises at the
commencement of the term hereon or thereafter erected upon the premises, or
forming part of the Premises, and their full equipment and appurtenances, the
side walks areas, sidewalk hoists, railings, gutters, curbs and the like in from
of the adjacent to the Premises, and each and every part thereof, both inside
and outside, extraordinary and ordinary, and shall repair the whole and each and
every part thereof in order to keep the same at all times during the term hereof
in through repair and good order and safe conditions, whenever the necessity or
desirability therefor may occur, and whether or not the same shall occur, in
whole or in part, by wear, tear, obsolescence or defects, and shall use all
reasonable precautions to prevent waste, damage or injury, except as provided
hereinafter.

         LANDLORD and not TENANT, shall be responsible for and shall promptly
correct any defects in the building on the Premises which are due to faulty
design, or to errors of construction not apparent at the time the Premises were
inspected by TENANT for purposes of occupancy by TENANT; this shall not be
interpreted to relieve TENANT of any responsibility or liability herein
otherwise provided, including among others, for structural failure due to the
fault or negligence of TENANT.

         TENANT shall also, at TENANT'S own cost and expense, maintain the
landsite in thoroughly clean condition; free from solid waste (which includes
liquid and gaseous as defined by the Resource Conservation and Recovery Act),
and the Regulation on Hazardous and Non-Hazardous Waste of the Environmental
Quality Board, as amended, rubbish, garbage and other obstructions.
Specifically, TENANT shall not use said landsite, nor permit it to be used, as a
deposit or as dump for raw materials, waste materials, hazardous, toxic or
non-toxic substances, or substances of whichever nature. TENANT shall neither
make any excavation for the purpose of storing, putting away and/or concealing
raw materials or waste materials of any kind. Underground storage of hazardous
and/or toxic substances is specifically prohibited.

                                       5

<PAGE>

         TENANT shall not do or cause to be done, nor permit on the Premises
anything deemed extra hazardous, nor shall it store in the Premises flammable or
toxic products of any class or kind without taking the proper precautions and
complying with applicable federal and Commonwealth laws and regulations.

         In case TENANT needs to store in the landsite raw materials of a
hazardous and/or toxic nature or hazardous and/or toxic wastes, TENANT shall
notify LANDLORD and secure its prior authorization. LANDLORD shall be furnished
with a copy of any permit issued for such storage.

         Although it is not intended that TENANT shall be responsible for any
decrease in value of the Premises due to the mere passing of time, or for
ordinary wear and tear of surfaces and other structural members of the building,
nevertheless TENANT shall: (i) replace, with like kind and quality, doors,
windows; electrical, sanitary and plumbing, fixtures; building equipment and/or
other facilities or fixtures in the Premises which through TENANT's use, fault
or negligence, become too worn out to repair during the life of this Lease, (ii)
paint the property inside and outside as required.

         In addition to the foregoing, TENANT shall indemnify and safe harmless
LANDLORD from and against any and all cost, expenses, claims, losses, damages,
or penalties, including counsel fees, because of or due to TENANT'S failure to
comply with the foregoing, and TENANT shall not call upon LANDLORD for any
disbursement or outlay of money whatsoever, and hereby expressly releases and
discharges LANDLORD of and from any liability or responsibility whatsoever in
connection therewith.

         THIRTEEN: Roof Care - TENANT, without the prior consent of LANDLORD,
shall not: (i) erect or cause to be erected on the roof any bill board, aerial
sign, or structure of any kind, (ii) place any fixture, equipment or any other
load over the roof, (iii) drill any hole on the roof for whichever purpose, (iv)
use the roof for storage, nor (v) correct any leaks whatsoever, this being
LANDLORD'S sole responsibility. Furthermore, TENANT shall take all reasonable
precautions to insure that the drainage facilities of the roof are not clogged
and are in good and operable conditions at all times.

                                       6

<PAGE>

         FOURTEEN: Floor Loads - TENANT hereby acknowledges that it has been
informed by LANDLORD that the maximum floor load of the Premises herein demised
is 150 pounds per sq. ft. Therefore, TENANT hereby agrees that in the event the
load of the machinery and equipment to be installed thereat exceeds such maximum
load, it shall, at its own cost and expense, carry out any improvements to the
floor of the Premises which may be necessary to support such additional load; it
being further agreed and understood that construction and/or installation of
such improvements shall not be commenced until after LANDLORD'S approval of the
plans to be prepared therefor by TENANT and thereafter, after completion of
construction and/or installation of said facilities, they shall be deemed
covered by and subject to the applicable provisions of this Contract; it being
further specifically agreed and understood that upon termination of this Lease,
such facilities shall be removed by TENANT, at its own cost and expense, or in
the alternative, and upon request by LANDLORD, they shall remain as part of the
Premises with no right whatsoever on the part of TENANT to be reimbursed and/or
compensated therefor.

         FIFTEEN: Fixtures - TENANT shall not affix to the ceiling, nor to its
supporting joists or columns, nor to any of its walls, any air conditioning
unit, nor any other fixture, without the prior consent of LANDLORD.

         SIXTEEN: Environmental Protection and Compliance - TENANT agrees, as a
condition hereof, that it will not discharge its solid, liquid or gaseous
industrial and/or sanitary effluent or discharges, either into the sewer system
and/or into any other place until after required authorizations therefor has
been obtained from the Puerto Rico Aqueduct and Sewer Authority, and/or the
Department of Health of Puerto Rico and/or Environmental Quality Board, and/or
any other governmental agency having jurisdiction thereof and TENANT further
agrees and undertakes to pre-treat any such effluent, prior to discharge thereof
as required by the said Authority, Department and/or governmental agency with
jurisdiction, and/or to install any equipment or system required, and to fully
abide by and comply with any and all requisites imposed thereby, and upon
request by LANDLORD to submit evidence of such compliance; it being agreed that
non-compliance thereof by TENANT for a period of ninety (90) days after notice,
shall be deemed an additional event of default under the provisions hereof.
Provided, that no construction and/or installation shall be made until LANDLORD
has approved of it.

                                       7

<PAGE>

         TENANT shall also, at TENANT'S own cost and expense, construct and
maintain Premises, processes and/or operating procedures in compliance with the
terms, conditions and commitments specified in any Environmental Impact
Statement, Environmental Assessment or any other analogous document produced by
the Commonwealth of Puerto Rico, Economic Development Administration /LANDLORD
as lead agency/ or by any other governmental agency in connection with the
approval or operation of the project.

         TENANT shall also serve LANDLORD with a copy of any lawsuit, notice of
violation, order to show cause or any other regulatory or legal action against
TENANT in any environmental-related case or issue.

         TENANT shall also serve LANDLORD with a copy of any permit granted to
TENANT for air emissions, water discharge, solid waste generation, storage,
treatment and/or disposal, and for any hazardous and/or toxic waste raw
materials or by-products used or generated, stored, treated and/or disposed or
any other endorsement, authorization or permit required to be obtained by
TENANT.

         TENANT shall also serve LANDLORD with a copy of any filing or
notification to be filed by TENANT with any regulatory agency or any
environmentally related case or issue, especially in any situation involving
underground or surface water pollution, hazardous and/or toxic waste spillage
and ground contamination. The notification to LANDLORD shall take place not
later than the actual filing of the pertinent documents with the regulatory
agency.

         SEVENTEEN: Improper Use - TENANT, during the term of this Lease and of
any renewal or extension thereof, agrees not to use or keep or allow the leased
Premises or any portion thereof to be used or occupied for any unlawful purpose
or in violation of this Lease or of any certificate of occupancy or certificate
of compliance covering or affecting the use of the Premises or any portion
thereof, and will not suffer any act to be done or any condition to exist on the
Premises or any portion thereof, or any article to be brought thereon, which may
be dangerous, unless safeguarded as required by law, or which may in law,
constitute a nuisance, public or private, or which may made void or voidable any
insurance then in force on the leased Premises.

                                       8

<PAGE>

         EIGHTEEN: Government Regulations - TENANT agrees and undertakes to
abide by and comply with any and all rules, regulations and requirements of the
Planning Board of Puerto Rico, the Department of Health, the Environmental
Quality Board, the Environmental Protection Agency (EPA), where applicable
and/or of any other governmental agency, having jurisdiction thereon applicable
to TENANT'S operations at the Premises and/or products to be manufactured
thereat, and if requested by LANDLORD, TENANT shall submit evidence of such
compliance; it being agreed and understood that noncompliance with any and all
such rules, regulations and requisites shall be deemed an additional event of
default under the provisions of this Contract, unless remedied within thirty
(30) days after receipt of notice thereof.

         Any and all improvements to the Premises required by any governmental
agency, having jurisdiction thereon so as to carry TENANT'S operations in
accordance with the regulations and requisites thereof, shall be at TENANT'S own
cost and expense, except for any improvements that may be required as a result
of any violation by LANDLORD that may exist at the effective date hereof other
than violations caused by TENANT or TENANT'S agents.

         TENANT further agrees and undertakes to install in the Premises, at its
own costs and expense, such devices as may be necessary to prevent any hazard,
which may be caused or created by its operations from affecting the
environmental integrity of the landsite or causing any nuisance to adjacent
TENANTS and/or the community in general; it being agreed and understood that
creating or causing any such nuisance, shall be deemed an additional event of
default under the provisions of this Contract.

         TENANT further agrees and undertakes to abide by and comply with any
and all rules, regulations and requisites of the Fire Department relative to the
use and storage of raw materials, finished products and/or inflammable
materials, and/or of any other governmental agency, having jurisdiction thereon
applicable to TENANT'S operations at the Premises, and if requested by LANDLORD,
TENANT shall submit evidence of such compliance; it being agreed and understood
that noncompliance by TENANT with any of the aforementioned rules, regulations
and requisites shall be deemed, in each of such cases, an additional event of
default under the provisions of this Contract, unless remedied within thirty
(30) days after receipt of notice thereof.

                                       9

<PAGE>

         If as a consequence of the foregoing dispositions, TENANT need to make
alterations to the Premises, the same shall be done subject to the dispositions
of Article TEN hereof.

         NINETEEN: Use Permit - TENANT agrees to abide by and comply with any
and all conditions and requisites included in the Use Permit which may be issued
by the Puerto Rico Permits and Regulations Administration (ARPE), and if
requested by LANDLORD, shall submit evidence of such compliance; it being agreed
and understood that noncompliance by TENANT with any and all such conditions and
requisites and/or the cancellation of the said Use Permit shall, in each of such
cases, be deemed an additional event of default under the provisions of this
Contract.

         TWENTY: Inspection - TENANT shall permit LANDLORD or LANDLORD'S agents
to enter the Premises at all reasonable time for the purpose of inspecting the
same, or of making repairs that TENANT has neglected or refused to make as
required by the terms, covenants and conditions of this Lease, and also for the
purpose of showing the Premises to persons wishing to purchase the same, and
during the year next preceding the expiration of this Lease, shall permit
inspection thereof by or on behalf of prospective TENANTS. If, at a reasonable
time, admission to the Premises for the purposes aforesaid cannot be obtained,
or if at any time an entry shall be deemed necessary for the inspection or
protection of the property, or for making any repairs, whether for the benefit
of TENANT or LANDLORD, LANDLORD'S agents or representatives may enter the
Premises by force, or otherwise, without rendering LANDLORD, or LANDLORD'S
agents or representative liable to any claim or cause of action or damage by
reason thereof, and accomplish such purpose.

         The provisions contained in this Article are not to be construed as an
increase of LANDLORD'S obligations under this Lease; it being expressly agreed
that the right and authority hereby reserved does not impose, nor does LANDLORD
assume, by reason thereof, any responsibility or liability whatsoever for the
repair, care of supervision of the Premises, or any building, equipment or
appurtenance on the Premises.

         TWENTY ONE: LANDLORD'S entry for repairs and alterations - LANDLORD
reserves the right to make such repairs, changes alterations, additions or
improvements in or to any portion of the building and the fixtures and equipment
which are reputed part thereof as it may deem necessary or desirable and for the
purpose of making the same, to use the street entrances, halls, stairs and
elevators of the building provided that there be no unnecessary obstruction of
TENANT'S right of entry to and peaceful enjoyment of the Premises, and TENANT
shall make no claim for rent abatement compensation or damages against LANDLORD
by reason of any inconvenience or annoyance arising therefrom.

                                       10

<PAGE>

         TWENTY TWO: LANDLORD excused in certain instances - If, by reason of
inability to obtain and utilized labor, materials or supplies, or by reason of
circumstances directly or indirectly the result of any state of war, or of
emergency duly proclaimed by the corresponding governmental authority, or by
reason of any laws, rules orders, regulations or requirements of any
governmental now or hereafter in force or by reason of strikes or riots, or by
reason of accidents, in damage to or the making of repairs, replacements or
improvements to the building or any of the equipment thereof, or by reason of
any other cause reasonable beyond the control of LANDLORD, LANDLORD shall be
unable to perform or shall be delayed in the performance of any covenant to
supply any service, such non-performance or delay in performance shall not be
ground to any claim against LANDLORD for damages or constitute a total or
partial eviction, constructive or otherwise.

         TWENTY THREE: Quiet Enjoyment - TENANT on paying the full rent and
keeping and performing the conditions and covenants herein contained, shall and
may peaceably and quietly enjoy the Premises for the term aforesaid, subject,
however, to the terms of this Lease and to the mortgages hereinafter mentioned.

         TWENTY FOUR: Leasehold Improvements - If leasehold improvements made by
or for the benefit of TENANT in the Premises at his request or other personal
property to TENANT are assessable or taxable and a tax liability is imposed to
TENANT or LANDLORD, it is understood that it shall be the sole responsibility of
TENANT to pay such taxes and in no event shall such taxes be the liability of or
be transferable to LANDLORD. In the event that by operation of law, such taxes
became a liability of LANDLORD, TENANT shall pay such taxes as they become due
and payable and shall promptly reimburse LANDLORD for any payments or expenses
incurred or disbursed by LANDLORD by reasons of any such assessment. Said amount
shall be due and payable, as additional rent, with the next installment of rent.
In the event that TENANT fails to make this payment when due, it shall be
subject to the dispositions of Article THIRTY SEVEN hereof.

                                       11

<PAGE>

         TWENTY FIVE: Stoppage of Operations - It is understood by the parties
hereto that this Lease is made by LANDLORD in furtherance of the
industrialization plans of the Commonwealth of Puerto Rico, and it is
accordingly understood that TENANT will use all reasonable efforts while this
Lease is in effect to maintain a manufacturing operation upon the Premises, but
nothing contained in this paragraph shall be deemed to require TENANT to
maintain such an operation otherwise than in accordance with sound principles of
business management, or (without limiting the generality of the foregoing) to
prevent TENANT from curtailing such operation or from shutting it down, whenever
and as often as TENANT may, in the exercise of sound business judgment, deem
such action advisable. However, TENANT shall give to LANDLORD notice of any
necessary or convenient curtailment and/or shut-down, at least seven (7) days
prior to the date fixed therefor except in cases of an emergency shut-down, in
which case such notice shall be given at the earliest possible time. No
curtailment of operations or shut-down in accordance with the provisions of this
paragraph shall constitute a default under the provisions of this Contract which
will enable LANDLORD to terminate it, unless such plants shall have been
shut-down for a period of six (6) consecutive months. A shutdown on account of
unforeseeable event or events which although foreseeable could not be prevented,
shall not constitute a breach of this agreement. Nothing in this paragraph
contained shall relieve TENANT from the payment of rent during the period of any
shutdown or curtailments of operations.

         TWENTY SIX: Assignment and Subletting - TENANT shall not assign, this
Lease nor let or sublet the Premised or any part thereof except to its parent
company, to a wholly owned subsidiary, to an affiliate of TENANT, wholly owned
by TENANT'S parent company or to a corporation to be organized by TENANT. In any
of these cases, TENANT shall promptly notify LANDLORD of said assignment or
subletting, it being agreed and understood that no such assignment or subletting
shall: (i) reduce or, in any way, affect the obligations of TENANT under this
Lease, nor (ii) release TENANT from liability under this Lease.

         TWENTY SEVEN: Successors in Interest - This Lease Contract and every
provision thereof, shall bind and inure to the benefit of the legal
representatives, successors and assigns on the parties. However, the term
"LANDLORD", as used in this Contract, so far as any covenants or obligations on
the part of LANDLORD under this Lease are concerned, shall be limited to mean
and include only the owner or lessor, at the time in question, of the Premises,
so that in the event hereafter of a transfer of the title to the Premises,
whether any such transfer be voluntary or by operation of law or otherwise, the
person, natural or juridical, by whom any such transfer is made, shall be and
hereby is entirely freed and relieved of all personal liability as respects the
performance of the covenants and obligations of LANDLORD under this Lease from
and after the date of such transfer.

                                       12

<PAGE>

         TWENTY EIGHT: No Representation by LANDLORD - LANDLORD, LANDLORD'S
agents, executives or employees, have made no representations or promises with
respect to the Premises except as herein expressly set forth and no rights,
easements or licenses are acquired by TENANT by implication or otherwise except
as expressly set forth in the provisions of this Contract. The taking possession
of the Premises by TENANT, shall be conclusive evidence, as against TENANT, that
TENANT accepts same "AS IS" and that said Premises, particularly the building
which forms a part of the same, were in good and satisfactory conditions at the
time such possession was so taken.

         TWENTY NINE: Damages - LANDLORD shall not be responsible for any latent
defect or change of conditions in the Premises resulting in damage to the same,
or the property or person therein, except to the extent of LANDLORD'S gross
negligence, and provided such claims or loss is not covered by insurances herein
required from TENANT. TENANT shall promptly notify LANDLORD of any damage to or
defects in the Premises, particularly in any part of the building's sanitary,
electrical, air conditioning or other systems located in our passing through the
Premises, and the damage or defective conditions, subject to the provisions of
Article TWENTY ONE (21) hereof, shall be remedied by LANDLORD with reasonable
diligence.

         THIRTY: General Liability Insurance - TENANT shall indemnify, have
harmless and defend LANDLORD and agents, servants and employees of LANDLORD
against and from any and all liability, fines, suits, claims, demands, expenses,
including attorneys' fees, and actions of any kind or nature arising by reason
of injury to person or property including the loss of use resulting thereof or,
violation of law occurring in the Premises occasioned in whole or in part by any
negligent act or omission on the part of TENANT or an employee (whether or not
acting within the scope of his employment), servant, agent, licensee, visitor,
assignor or under tenant of TENANT, or by any neglectful use or occupancy of the
Premises or any breach, violation or non-performance of any covenant in this
Lease on the part of TENANT to be observed or performed.

                                       13

<PAGE>

         Pursuant to the foregoing, TENANT shall, maintain during the term of
this lease, at its own cost and expense, a Comprehensive General Liability
Policy. Said policy shall: (i) be for a combined single limit of no less than
$1,000,000.00 per accident, (ii) hold LANDLORD harmless against any and all
liability as hereinbefore stated, and (iii) the care, custody & control
exclusion shall be deleted from this coverage. LANDLORD may require additional
reasonable limits of public liability insurance and coverage, when changing
circumstances so require.

         THIRTY ONE: Property Insurance - TENANT recognizes that the rent
provided for herein does not include any element to indemnify, repair, replace
or make whole TENANT, his employees, servants, agents, licensees, visitors,
assignees, or under tenant for any loss or damage to any property or injury to
any person in the Premises.

         Accordingly, during the term of this Lease, TENANT shall keep the
building standing upon the Premises at the commencement of the term hereof or
thereafter erected upon the Premises, including all equipment appurtenant to the
Premises and all alterations, changes, additions and improvements, insured for
the benefit of LANDLORD and TENANT, as their respective interest may appear, in
an amount at least equal to the percentages stated below (as LANDLORD may from
time to time determine). The basis of the Property Insurance shall be
Replacement Cost and the coverage an "All Risks" Property Insurance Policy.
Coverage included in the All Risks Form:

           1. Fire - "Building & Contents Form"

              (a) Building  - 100% of insurable value exclusive of foundations

              (b) Contents - All equipment appurtenant to the Premises (State 
                  value of Policy)

           2. Additional Coverage under the Fire Policy

              (a) Extended Coverage Endorsement - 100% of insurable value 
                  exclusive of foundations

              (b) Earthquake - 100% of insurable value including foundations

              (c) Vandalism and Malicious Mischief Endorsement

              (d) Improvements and Betterments - For all alterations, changes, 
                  additions and improvements

                                       14

<PAGE>

           3. Landsite and Flood whenever applicable and/or necessary

           4. Boiler and Machinery (if any) - 100% of insurable value

           5. Pollution Liability Policy - if necessary.

         THIRTY TWO: Multifactory Building Specific Dispositions - In the event
that the Premises constitute a section or sections of an industrial building and
landsite in which other operations are conducted by other TENANTS: (i) the
insurance coverage herein required, shall be acquired by LANDLORD for the whole
of the industrial building and TENANT shall reimburse LANDLORD, for its
proportionate share in the total cost of said policies, (ii) if, because of
anything done, caused or permitted to be done, permitted or omitted by TENANT,
the premium rate for any kind of insurance affecting the Premises shall be
increased, TENANT shall pay to LANDLORD the additional amount which LANDLORD may
be thereby obligated to pay for such insurance, and if LANDLORD shall demand
that TENANT remedy the condition which cause the increase in the insurance
premiums rate, TENANT will remedy such conditions within five (5) days after
such demand, and (iii) the insurance policies required in the preceding Articles
THIRTY (30) & THIRTY ONE (31) shall be endorsed to include a waiver of
subrogation against TENANT. All amounts to be reimbursed by TENANT under this
Article, shall be due and payable, as additional rent, with the next installment
of rent. In the event that TENANT fails to make this payment, when due, it shall
be subject to the dispositions of Article THIRTY SEVEN (37) hereof.

         THIRTY THREE: Additional Dispositions about Insurance - All the
Insurance policies herein required from TENANT, shall be taken in form and
substance acceptable to LANDLORD with insurance companies duly authorized to do
business in Puerto Rico, having a "A" and a higher financial fatting according
to Best's Insurance Report; and shall include LANDLORD as additional insured.
TENANT shall instruct the corresponding insurer to deliver such policies or
certified copies of Certificates of Insurance, in lieu of, directly to LANDLORD.
LANDLORD reserves the right not to deliver possession of the Premises to TENANT,
unless, and until two (2) days after such original policies, or certified copies
or certificates have been deposited with LANDLORD.

         Furthermore, said policies, shall: (i) provide that they may not be
cancelled by the insurer for nonpayment of premium or otherwise, until at least
thirty (30) days after services of notice by registered or certified mail of the
proposed cancellation upon LANDLORD, and (ii) be promptly renewed by TENANT upon
expiration and TENANT shall, within thirty (30) days after such renewal, deliver
to LANDLORD adequate evidence of the payment of premiums thereon. If such
premiums or any of them shall not be so paid, LANDLORD may procure the same in
the manner set forth for governmental agencies, and TENANT shall reimburse
LANDLORD any amount so paid. This reimbursement being due and payable with the
next installment of rent. In the event that TENANT fails to make this payment

                                       15

<PAGE>

when due, it shall be subject to the dispositions of Article THIRTY SEVEN (37)
hereof. It is expressly agreed and understood, that payment by LANDLORD of any
such premiums shall not be deemed to waive or release the default in the payment
thereof by TENANT nor the right of LANDLORD to take such action as may be
available hereunder as in the case of default in the payment of rent.

         Upon the commencement of the term hereof, TENANT shall pay to LANDLORD
the apportioned unearned premiums on all such policies of insurance then carried
by LANDLORD in respect of the Premises in the event TENANT continues with the
insurance policies placed in LANDLORD.

         TENANT shall not violate nor permit to be violated any of the
conditions or provisions of any of said policies, and TENANT shall so perform
and satisfy the requirements of the companies writing such policies that at all
times companies of good standing and acceptable to LANDLORD shall be willing to
write and continue such insurance.

         TENANT shall cooperate with LANDLORD in connection with the collection
of any insurance monies that may be due in the event of loss and shall execute
and deliver to LANDLORD such proofs of loss and other instruments that may be
required for the purpose of facilitating the recovery of any such insurance
monies, and in the event that TENANT shall fail or neglect so to cooperate or to
execute, acknowledge and deliver any such instrument, LANDLORD, in addition to
any other remedies, may as the agent or attorney-in fact of TENANT, execute and
deliver any proof of loss or any other instruments as may seem desirable to
LANDLORD and any mortgagee for the collection of such insurance monies. This
shall not be interpreted as any waiver of the obligations of TENANT under
Articles THIRTY, THIRTY ONE, THIRTY TWO and THIRTY THREE hereof or exclusively
in favor of LANDLORD under Article THIRTY NINE hereof.

                                       16

<PAGE>

         THIRTY FOUR: Waivers - The receipt by LANDLORD of the rent, additional
rent, or any other sum or charges payable by TENANT with or without knowledge of
the breach of any covenant of this Contract, shall not be deemed a waiver of
such breach. No act or omission of LANDLORD or its agent during the term of this
Lease shall be deemed an acceptance of a surrender of the Premises and no
agreement to accept a surrender of the Premises shall be valid unless it be made
in writing and subscribed by LANDLORD. This Contract contains all the agreements
and conditions made between the parties hereto with respect to the Premises and
it cannot be changed orally. Any additions to, or charges in this Lease must be
in writing, signed by the party to be charged.

         Failure on the part of LANDLORD to act or complain of any action or
nonaction on the part of TENANT shall not be deemed to be a waiver of any of its
respective rights hereunder nor constitute a waiver at any subsequent time of
the same provision. The consent or approval by LANDLORD to, or of any action by
the other requiring consent or approval, shall not be deemed to waive or render
unnecessary the consent or approval by LANDLORD of any subsequent similar act.

         THIRTY FIVE: Reinstatement - No receipt of monies by LANDLORD for
TENANT after the termination or cancellation hereof in any lawful manner shall
reinstate, continue or extend the term hereof, or affect any notice theretofore
given to TENANT, or operate as a waiver of the right of LANDLORD to enforce the
payment of rent, additional rent, or other charges then due or thereafter
falling due, or operate as a waiver of the right of LANDLORD to recover
possession of the Premises by proper suit, action, proceeding or remedy; it
being agreed that, after the service of notice to terminate or cancel this
Lease, and the expiration of the time therein specified, if the default has not
been cured in the meantime, or after the commencement of suit, action or summary
proceedings or of any other remedy, or after a final order, warrant of judgment
of the possession of the Premises, LANDLORD may demand, receive and collect any
monies then due, or thereafter becoming due, without in any manner affecting
such notice, proceeding, suit, action, order, warrant or judgment; and any and
all such monies so collected shall be deemed to be payments for the use and
occupation of the Premises, or at the election of LANDLORD, on account of
TENANT'S liability hereunder. Delivery or acceptance of the keys to the
Premises, or any similar act, by the LANDLORD, or its agents or employees,
during the term hereof, shall not be deemed to be a delivery or an acceptance of
a surrender of the Premises unless LANDLORD shall explicitly consent to it, in
the manner set forth hereinbefore.

                                       17

<PAGE>

         THIRTY SIX: Subordination and Attornment - This Lease is and shall be
subject and subordinate to all liens, or mortgages which may now or hereafter
affect the Premises and to all renewals, modifications, consolidations,
replacements and extensions thereof and, although this subordination provision
shall be deemed for all purposes to be automatic and effective without any
further instrument on the part of TENANT, TENANT shall execute any further
instrument requested by LANDLORD to confirm such subordination.

         TENANT further covenants and agrees that if by reason of a default upon
the part of LANDLORD of any mortgage affecting the Premises, the mortgage is
terminated or foreclosed by summary proceedings or otherwise, TENANT will attorn
to the mortgagee or the purchaser in foreclosure proceedings, as the case may
be, and will recognize such mortgage or purchaser, as the TENANT'S landlord
under this Lease. TENANT agrees to execute and deliver, at any time and from
time to time, upon the request of LANDLORD or of the mortgagee or the purchaser
in foreclosure proceedings, as the case may be, any reasonable instrument which
may be necessary or appropriate to evidence such attornment. TENANT further
waives the provision of any statute or rule of law now or hereafter in effect
which may give or purport to give TENANT any right of election to terminate this
lease or to surrender possession of the Premises demised hereby in the event any
such proceeding is brought by the holder of any such mortgage, and TENANT'S
obligations hereunder shall not be affected in any way whatsoever by any such
proceeding.

         TENANT, covenants and agrees, upon demand of the holder of any mortgage
duly recorded or recordable in the corresponding Registry of the Property or of
any receiver duly appointed by the foreclose any such mortgage, to pay to the
holder of any such mortgage or to such receiver, as the case may be, all rent
becoming due under this Lease after such demand, provided such holder of any
such mortgage or any such receiver complies with the obligations of LANDLORD
under this Lease.

         TENANT, upon request of LANDLORD or any holder of any mortgage or lien
affecting the Premises, shall from time to time, deliver or cause to be
delivered to LANDLORD or such lien holder or mortgagee, within ten (10) working
days from date of demand a certificate duly executed and acknowledged in form
for recording, without charges, certifying, if true, or to extent true, that
this Lease is valid and subsisting and in full force and effect and LANDLORD is
not in default under any of the terms of this Lease.

                                       18

<PAGE>

         THIRTY SEVEN: Late Payments and Payment by LANDLORD - In the event that
(i) TENANT makes late payment, or fails to make payments to LANDLORD, in whole
or in part, of the rent, or of the additional rent, or of any of the other
payments of money required to be paid by TENANT to LANDLORD, as stipulated in
this Lease, when and as due and payable; or if (ii) LANDLORD, without assuming
any obligation to do so, after any notice or grace period provided hereunder,
performs or causes to be performed, at the cost and expense of TENANT, any of
the acts or obligations agreed to be performed by TENANT, as stipulated in this
Lease, and TENANT fails to refund LANDLORD any amounts of money paid or incurred
by LANDLORD in performing of causing the performance of such acts or
obligations, when and as due and payable, TENANT undertakes and agrees to pay
LANDLORD as additional rent, interest on such lately paid or unpaid rents,
additional rent, and/or on such other payments of money required to be paid,
and/or on any such amounts of money required to be refunded, from and after the
date when payment thereof matured or became due and payable, until full payment,
at the rate of twelve (12%) per cent per annum, or if such 12% interest, is
unlawful, then and in such event, at the highest maximum prevailing rate of
interest on commercial unsecured loans as fixed by the Board of Regulatory Rates
of Interest and Financial Charges, created under Law #1, approved October 15,
1973 (10 LPRA 998), as amended, or by any successor statute or regulation
thereof.

         THIRTY EIGHT: Abatement - If any substantial service or facility to be
provided by LANDLORD is unavailable for a period exceeding thirty (30) days and
LANDLORD has been notified of the same, should time unavailability of such
service render all or any portion of the Premises untenable, TENANT after the
aforesaid thirty (30) days, shall be entitled to an abatement of a portion of
the rent that shall reflect that portion of the Premises which is untenable,
provided the damage to the service or facility is not attributable to the act or
neglect of TENANT or the employees, servants, licensees, visitors, assigns or
under tenants of TENANT.

         THIRTY NINE: Fire or other Casualty - If before or during the term of
this Lease, the Premises shall be damaged by fire or other casualty, LANDLORD
after written notice thereof is given by TENANT, shall repair the same with
reasonable dispatch after notice to it of the damage, due allowances being made
for any delay due to causes beyond the LANDLORD'S reasonable control, provided,
however, that LANDLORD shall not be required to repair or replace any furniture,
furnishings or other personal property which TENANT may have placed or installed
or which it may be entitled or required to remove from the Premises. LANDLORD
shall proceed with due diligence to obtain the corresponding insurance
adjustment of the loss and TENANT shall fully cooperate with LANDLORD and assist
in the adjustment of the loss. Until such repairs are completed, and provided
such damage or other casualty is not attributable to the act or neglect of
TENANT or the employees, servants, licensees, visitors, assigns or under tenants
of TENANT, the rent required to be paid pursuant to Article FOUR hereof, shall

                                       19

<PAGE>

be abated in proportion to the part of the Premises which are untenable. If the
building, be so damaged that LANDLORD shall decide to demolish and/or to
reconstruct the building, in whole or in part, LANDLORD may terminate this Lease
by notifying TENANT within a reasonable time after such damage of LANDLORD'S
election to terminate this Lease, such termination to be effective immediately
if the term shall not have commenced or on a date to be specified in such notice
if given during the term. In the event of the giving of such notice during the
term of this Lease, the rent shall be apportioned and paid up to the time of
such fire or other casualty if the Premises are damaged, or up to the specified
date of termination if the Premises are not damaged and LANDLORD shall not be
otherwise liable to TENANT for the value of the unexpired term of this Lease.

         FORTY: Default Provisions - If, during the term of this Lease, TENANT
shall: (i) apply for or consent in writing to, the appointment of a receiver,
trustee or liquidator of TENANT or of all or substantially all of its assets or
(ii) seek relief under the Bankruptcy Act, or admit in writing its inability to
pay its debts as they become due, or (iii) make a general assignment for the
benefit of this creditors, or (iv) file a petition case or an answer seeking
relief (other than a reorganization not involving the liabilities of TENANT) or
arrangement with creditors, or take advantage of any insolvency law, or (v) file
an answer admitting the material allegations of a case filed against it in any
bankruptcy, reorganization or insolvency proceeding or, if an order, judgment or
decree shall be entered by any court of competent jurisdiction on the
application of TENANT or creditor adjudicating TENANT a bankrupt or insolvent,
or approving a petition seeking reorganization of TENANT (other than a
reorganization not involving the liabilities of TENANT) or appointment of a
receiver, trustee or liquidator of TENANT, or of all or substantially all its
assets, and such order, judgment or decree, shall continue stayed and in effect
for any period of sixty (60) consecutive days, the term of this Lease and all
right, title and interest of TENANT hereunder shall expire as fully and
completely as if that day were the date herein specifically fixed for the
expiration of the term, and TENANT will then, quit and surrender the Premises to
LANDLORD, but TENANT shall remain liable as hereinafter provided.

                                       20

<PAGE>

         If, during the term of this Lease: (i) TENANT shall default in
fulfilling any of the covenants of this Lease (other than the covenants for the
payment of rent or additional rent), or of any other standing contract with
LANDLORD or (ii) if, during the term of this Lease TENANT shall abandon, vacate,
or remove from the Premises the major portion of the goods, wares, equipment, or
furnishings usually kept on said premises, of (iii) this Lease, without the
prior consent of LANDLORD, shall be encumbered, assigned or transferred in any
manner in whole or in part or shall, by operation of law, pass to or devolve
upon any third party, except as herein provided, or (iv) if TENANT is in
violation of laws, rules and regulations regarding minimum wages of its
employees, or of any other law, rules and regulations applicable to his
operations, but which have not been specifically mentioned in this Lease,
LANDLORD may give to TENANT notice of any such default or the happening of any
event referred to above and if at the expiration of thirty (30) days after the
service of such a notice the default or event upon which said notice was based
shall continue to exist, or in the case of a default which cannot with due
diligence be cured within a period of thirty (30) days, if TENANT fails to
proceed promptly after the service of such notice and with all due diligence to
cure the same and thereafter to prosecute the curing of such default with all
due diligence (it being intended that in connection with a default not
susceptible of being cured with due diligence within thirty (30) days that the
time of TENANT within which to cure the same shall be extended for such period
as may be necessary to complete the same with all due diligence), LANDLORD may
give to TENANT a notice of expiration of the term of this Lease as of the date
of the service of such second notice, and upon the giving of said notice of
expiration the term of this Lease and all right, title and interest of TENANT
hereunder shall expire as full and completely as if that day were the date
herein specifically fixed for the expiration of the term, and TENANT or any
party holding under his will then quit and surrender the Premises to LANDLORD,
but TENANT shall remain liable as hereinafter provided.

         If, (i) TENANT shall default in the payment of the rent, the additional
rent, or of any other payment as required under this Lease and such default
shall continue for ten (10) working days after notice thereof by LANDLORD, of
(ii) if the default of the payment of the rent, continues for thirty (30) days
from the date any such payment became due and payable (AUTOMATIC DEFAULT
TERMINATION), or (iii) if this Lease shall terminate as in Paragraph one and two
of this Article provided, this Lease shall terminate and TENANT will then quit
and surrender the Premises to LANDLORD, but TENANT shall remain liable as
hereinafter provided, LANDLORD or LANDLORD's agents and servants may immediately
or at any time thereafter re-enter the Premises and remove all persons and all
or any property therefrom, whether by summary dispossess proceedings or by any

                                       21

<PAGE>

suitable action or proceeding at law, or with the license and permission of
TENANT, which shall under this Contract be deemed given upon expiration of the
strict thirty (30) days notice period of subdivision of paragraph Two of this
Article, without LANDLORD being liable to indictment, prosecution or damages
therefor and repossess and enjoy the Premises with all additions, alterations
and improvements.

         If TENANT shall fail to take possession of the Premises within ten (10)
days after the commencement of the term of this Lease, or if TENANT shall vacate
and abandon the Premises, LANDLORD shall have the right, at LANDLORD'S option,
to terminate this Lease and the term hereof, as well as all the right, title and
interest of TENANT hereunder, by giving TENANT five (5) days notice in writing
of such intention, and upon the expiration of the time fixed in such latter
notice, if such default be not cured prior thereto, this lease and the term
hereof, as well as all the right, title and interest of TENANT hereunder, shall
wholly cease and expire in the same manner and with the same force and effect
(except as to TENANT'S liability) as if the date fixed by such latter notice
were the expiration of the term herein originally granted; and TENANT shall
immediately quit and surrender to LANDLORD the Premises and each and every part
thereof and LANDLORD may enter into or repossess the Premises, either by force,
summary proceedings or otherwise. The right granted to LANDLORD in this Article
or any other Article of this Lease to terminate this Lease, shall apply to any
extension or renewal of the term hereby granted, and the exercise of any such
right by LANDLORD during the term hereby granted, shall terminate any extension
or renewal of the term hereby granted and any right on the part of TENANT
thereto.

         Upon the termination of this Lease by reason of any of the foregoing
event, or in the event of the termination of this Lease by summary dispossess
proceedings or under any provisions of law, now or at any time hereafter, in
force by reason of, or based upon, or arising out of a default under or breach
of this Lease on the part of TENANT, or upon LANDLORD recovering possession of
the Premises in the manner or in any of the circumstances hereinbefore
mentioned, or in any other manner or circumstances whatsoever , whether with or
without legal proceedings, by reason of, or based upon, or arising out of a
default under or breach of this Lease on the part of TENANT, LANDLORD, at its
option, but without assuming any obligation to do so in any case, may at any
time, and from time to time, relet the Premises or any part or parts thereof for
the account of TENANT or otherwise on such terms as LANDLORD may elect,
including the granting of concessions, and receive and collect the rents
therefor, applying the same at a rental not higher than the one stipulated in
this Contract, first to the payment of such reasonable expenses as LANDLORD may
have incurred in recovering possession of the Premises, including reasonable
legal expenses, and for putting the same into good order or condition or
preparing or altering the same for re-rental, and expenses, commissions and

                                       22

<PAGE>

charges paid, assumed, or incurred by LANDLORD in and about the reletting of the
Premises or any portion thereof and then to the fulfillment of the covenants of
TENANT hereunder. Any such reletting herein provided for, may be for the
remainder of the term of this Lease or for a longer or shorter period or at a
higher or lower rental. In any such case, whether or not, the Premises or any
part thereof be relet, TENANT shall pay to LANDLORD the rent required to be paid
by TENANT up to the time of such termination of this Lease, and/or the full rent
provided for in the agreement for any holdover of such period after termination
and up to the surrender or recovery of possession of the Premises by LANDLORD,
as the case may be, and thereafter TENANT covenants and agrees, to pay to
LANDLORD until the end of the term of this Lease as originally demised the
equivalent of any deficiency amount of all the rent reserved herein, less the
net avails of reletting, if any, as specified hereinabove in this Article and
the same shall be due and payable by TENANT to LANDLORD as provided herein, that
is to say, TENANT shall pay to LANDLORD the amount of any deficiency then
existing.

         FORTY ONE: LANDLORD'S Remedies - In the event TENANT shall default in
the performance of any of the terms, covenants or provisions herein contained,
LANDLORD may, but without the obligation to do so, perform the same for the
account of TENANT and any amount paid or expense incurred by LANDLORD in the
performance of the same shall be repaid by TENANT on demand. In the event of a
breach or threatened breach by TENANT or any subtenant or other person holding
or claiming under TENANT of any of the covenants, conditions or provisions
hereof, LANDLORD shall have the right of injunction to restrain the same, and
the right to invoke any remedy allowed by law or in equity as if specific
remedies, indemnity or reimbursement were not herein provided for. The rights
and remedies given to LANDLORD in this Lease are distinct, separate and
cumulative, and no one of them, whether or not exercised by LANDLORD, shall be
deemed to be a waiver, or an exclusion of any of the others.

         FORTY TWO: Notice of Default - Anything in this Lease to the contrary
notwithstanding, it is specifically agreed that there shall be no enforceable
default against LANDLORD under any provisions of this Lease, unless notice of
such default be given by TENANT to LANDLORD in which TENANT shall specify the
default or omission complained of, and LANDLORD shall have thirty (30) days
after receipt of such notice in which to remedy such default, or if said default
or omission shall be of such a nature that the same cannot be cured within said

                                       23

<PAGE>

period, then the same shall not be an enforceable default if LANDLORD shall have
commenced taking the necessary steps to cure or remedy said default within the
said thirty (30) days and diligently proceeds with the correction thereof.

         FORTY THREE: Capitalization - For the purpose of this Contract,
specifically of Article SIX, Capitalization includes the total of owner's equity
sources (preferred stock, common stock and surplus accounts) plus long-term
debts, it being agreed and understood that the amortization of any such debt
shall in no way diminish the amount originally determined as capitalization.

         FORTY FOUR: Disclosure of Information - TENANT agrees to furnish to
LANDLORD within ninety (90) days after the expiration of each fiscal year of
TENANT, an annual statement certified by an independent Certified Public
Accountant showing as of the end of each such fiscal year: (i) TENANT'S paid-in
capital, (ii) long-term debts and capitalization as required by Articles SIX and
FORTY THREE hereof, (iii) investment in machinery and its capacity to provide
employment, (iv) taxes (including Social Security taxes) paid, and (v) any other
information as required by this Lease.

         In the event such statement is not filed with LANDLORD as herein
provided, LANDLORD may obtain such information from TENANT at TENANT'S expense,
and for such purpose TENANT shall make available to LANDLORD'S designated
representatives, its books of accounts and other necessary data and facilities,
all of which shall be provided and made available at TENANT'S principal office
in Puerto Rico.

         FORTY FIVE: Automatic Renewal - In the event TENANT does not vacate the
Premises in the manner and under the conditions hereinbefore provided, within
ninety (90) days after the normal expiration of the term hereof, LANDLORD shall
have the option to be exercised at any time thereafter, to notify TENANT that
the lease herein has been renewed for an additional term of five (5) years from
the date of the last normal expiration of the term hereof and, in such event,
the parties agree that this Contract shall be held to have been renewed and to
continue in full force and effect for such additional term of five (5) years
upon the mere mailing of such notice by LANDLORD to TENANT. This provision shall
in no way prejudice, affect or deny any right which LANDLORD may otherwise have
because, or at the time, of any such termination of the term hereof,

                                       24

<PAGE>

particularly whenever LANDLORD does not exercise such option; it being agreed
and understood that such renewal shall be upon the same terms and conditions
contained herein except that the rental rate to be charged shall be the rate
then currently being charged by LANDLORD for similar building in the area, but
in no event shall it be less than the rate herein stipulated.

         FORTY SIX: Partial Invalidity and Applicable Law - If any term or
provisions of this Lease or the application thereof to any person or
circumstances shall, to any extent, be invalid or unenforceable, the remainder
of this Lease and the application of such term or provision to persons or
circumstances other than those as to which it is held invalid or unenforceable,
shall not be affected thereby, and each term and provision of this Lease shall
be valid and be enforceable to the fullest extent permitted by law. This
Contract is entered into and shall be interpreted in accordance with the laws of
the Commonwealth of Puerto Rico.

         FORTY SEVEN: Lease Termination and Holding Over - Upon the expiration
or termination of this Lease:

         (i) TENANT shall inform LANDLORD in writing of TENANT'S activities
affecting each or any environmental area of concern during the period of
TENANT'S operation, including a description from an environmental standpoint of
the physical conditions of the premises and landsite. TENANT shall also inform
to LANDLORD in writing of any environmental regulatory violations, compliance
plans, permits, closure plans, clean-up actions or any other regulatory
procedures related to the operation. In the event that the information reveals
TENANT'S noncompliance of any of the above, or in the event that a physical
inspection of the Premises and adjacent areas by LANDLORD, or any other source
of information reveal the possibility of contamination, in that event, TENANT
shall, at LANDLORD'S request submit a plan of action with the appropriate
financial provisions to execute it. LANDLORD shall hold TENANT responsible for
any and all environmental damage, or any damage to third parties as a result of
any environmental damage, or any remedial action (including monitoring) to be
performed at landsite or otherwise as a result of TENANT'S operations after
termination of Lease and until such a time as complete remediation or
fulfillment of TENANT'S obligations is effected. In case TENANT fails to comply
with the foregoing provisions, LANDLORD may elect to effect them at TENANT'S
expense and responsibility.

                                       25

<PAGE>

         (ii) TENANT shall remove all hazardous and toxic substances belonging
to TENANT or to a third party. TENANT shall also remove all other property of
TENANT and that of any third party and failing so to do, TENANT hereby appoints
LANDLORD its agent so that LANDLORD may cause all of the said property to be
removed at the expense and risk of TENANT. TENANT covenants and agrees to give
full and timely observance and compliance to this covenant to remove all its
property and surrender the Premises broom clean. TENANT hereby agrees to pay all
reasonable necessary cost and expenses thereby incurred by LANDLORD. If, as the
sole result of the removal of TENANT'S property any portion of the Additional
Premises or of the building of which they are a part, are damaged, TENANT shall
pay to LANDLORD the reasonable cost of repairing such damages unless due to the
gross negligence of LANDLORD, its agents, servants, employees and contractors.
TENANT'S obligation to observe or perform this covenant shall survive the
expiration or other termination of the term of this Lease.

         FORTY EIGHT: Change of Address - TENANT shall promptly notify LANDLORD
of any change in the addresses other than those required from it in Article
SEVEN hereof.

         FORTY NINE: TENANT will indemnify LANDLORD for any and all liability,
loss, damages, expenses, penalties and/or fines, and any additional expenses
including any attorney fees LANDLORD may suffer as a result of claims, lawsuits,
demands, administrative orders, costs, resolutions or judgements against it
arising out of negligence and/or failure of TENANT or those acting under TENANT
to conform to the statutes, ordinances, or other regulations or requirements of
any governmental authority, be it Federal, of the Commonwealth of Puerto Rico,
its instrumentalities or public corporations, in connection with the performance
of this Lease.

         FIFTY: Inasmuch as TENANT is currently in possession of Project No.
T-0810-0-68 pursuant to a Lease Contract dated June 30, 1994 and Project No.
T-0994-0-70 pursuant to a Supplement and Amendment to Lease Contract dated
October 4, 2005 entered into between LANDLORD and Integra NeuroSciences PR,
Inc., TENANT accepts Project Nos. T-0810-0-68, T-0810-1-02, T-0810-2-03, Lot No.
6 of L-154-2-62, and Project No. T-0994-0-70 in their respective present
conditions.

                                       26

<PAGE>

         FIFTY ONE: Anything contained in this Contract to the contrary
notwithstanding, in the event that TENANT requires additional volume of water
and/or pressure as is now available within the area wherein the demised premises
are located, it shall be at its own cost and expense the construction and/or
installation of such improvements and/or facilities as may be necessary to or
convenient and/or required by the Puerto Rico Aqueduct and Sewer Authority to
increase such volume and/or pressure; it being agreed and understood, however,
that such construction and/or installation shall in no event be commenced until
after LANDLORD'S written approval has first been requested and obtained.

         FIFTY TWO: TENANT hereby acknowledges that in the industrial park there
are other industries; therefore TENANT hereby specifically agrees and undertakes
to take such steps and install such equipment as may be necessary to prevent
that any hazard and/or noise which may be created by its operations may in any
way or manner unduly affect the operations of the other industries and therefore
TENANT hereby releases and saves LANDLORD harmless from any and all claims or
demands arising therefrom or in connection therewith.

         FIFTY THREE: TENANT shall, at its own cost and expense, install a fire
protection system and shall obtain the endorsement and approval from said Fire
Department for such installation. TENANT must also provide security measures to
prevent or reduce fire hazard due to the storage of inflammable materials and
products.

         FIFTY FOUR: TENANT shall procure and obtain a permit for the operation
of a solid waste emission source from the Environmental Quality Board and
authorization for the Office of Solid Waste and/or from the Municipality of
Anasco for the final disposition of wastes.

         FIFTY FIVE: TENANT, at its own cost and expense, shall implement the
necessary measures and install the control equipment to maintain the atmospheric
air quality levels in compliance with the environmental laws and regulations of
the Environmental Quality Board and the Environmental Protection Agency, as
promulgated by any succeeding law or regulations.

                                       27

<PAGE>

         FIFTY SIX: It is hereby agreed and understood that TENANT shall take
the necessary steps to comply with the regulations and law requirements of the
PUERTO RICO OCCUPATIONAL SAFETY AND HEALTH OFFICE (PROSHO).

         FIFTY SEVEN: TENANT shall, at is own cost and expense, construct and/or
install all necessary equipment required to connect the building's electrical
system to the Puerto Rico Electrical Power Authority's electrical distribution
lines, such connection to be made in compliance with the requirement of PREPA.

         FIFTY EIGHT: TENANT must comply with the rules and regulations of
pre-treatment established by the Puerto Rico Aqueduct and Sewer Authority, the
Environmental Quality Board and the Environmental Protection Agency related to
the effluent industrial discharge in the sanitary sewer system and their final
disposition. Also, any improvement necessary to provide pre-treatment facilities
for the above mentioned effluents shall be at TENANT'S own cost and expense and
in coordination and with the approval of LANDLORD's Engineering and Maintenance
Departments.

         FIFTY NINE: It is hereby agreed and understood that TENANT, at its own
cost and expense, shall install an air conditioning system in the demised
premises, in the event TENANT needs to use and/or install it in his process.
Such air conditioning system shall be considered as a special facility from
LANDLORD, and it shall be installed in coordination with LANDLORD'S Engineering
and Maintenance Departments.

         SIXTY: TENANT agrees to submit to LANDLORD within thirty (30) days from
the date of execution of this Contract: (a) evidence of its registration in the
Department of State of the Commonwealth of Puerto Rico and the name and address
of its resident agent; and (b) a certificate of a resolution of its Board of
Directors either authorizing or ratifying the execution of this Contract.

         SIXTY ONE: TENANT certifies and guarantees that at the date of
subscribing this Contract it has submitted the Corporate Tax Returns Forms
during the last five (5) years and does not have any tax debt pending with the
Commonwealth of Puerto Rico, or is complying with the terms of a payment plan
duly approved.

                                       28

<PAGE>

         TENANT also certifies and guarantees that at the date of execution of
this contract it has paid unemployment insurance compensation, temporary
disability insurance, and the driver's social security (as applicable); or is
complying with a payment plan duly approved.

         TENANT acknowledges that this is an essential condition of the Contract
and if the above certification is incorrect in any of its parts, LANDLORD may
cancel this contract.

         SIXTY TWO: LANDLORD reserves the right to audit the leased premises
from time to time during the term of this contract, as LANDLORD may deem
necessary, in order to assess all aspects of the environmental condition of said
premises and TENANT's compliance with all environmental legislation and
regulations, under Commonwealth and federal law; TENANT hereby agrees to provide
access to all areas and structures of the premises for these purposes, upon
LANDLORD's request, and to also provide access to all books, records, documents
and instruments which LANDLORD may deem necessary in order to fully audit the
premises as herein stated.

         SIXTY THREE: TENANT shall furnish to LANDLORD, in addition to any other
Information, documents or instruments that may be required in this contract:

        a) Prompt written notice of the occurrence of any event that by law or
        regulation would require any oral, telephonic or written notice or
        communication to the US Environmental Protection Agency and/or to the
        Puerto Rico Environmental Quality Board, or any successor agency, and
        copies of all orders, notices or other communications and reports
        received, made or given in connection with any such event, and any
        enforcement action taken against TENANT or against any property owned,
        occupied or used by TENANT;

        b) Quarterly certifications subscribed by an authorized representative
        designated by TENANT, as to the environmental condition of the leased
        premises, containing the information required by LANDLORD, which is
        specified in the form included as Schedule "B" of this contract, or any
        subsequent modification thereto;

        c) Any other information and documents relating to TENANT's compliance
        with environmental legislation and regulations under federal and
        commonwealth laws.

                                       29

<PAGE>

         SIXTY FOUR: TENANT hereby guarantees to LANDLORD that, neither he, or
any of its stockholders, in case of a corporation, owes any money to LANDLORD
under its corporate name or any other corporate name and/or person.

         SIXTY FIVE: TENANT shall not transfer, lease, burden or dispose of in
any way of the equipment used on its operations without prior written notice to
LANDLORD, except in the ordinary course of business.

         SIXTY SIX: TENANT shall not sell, lease or transfer in any way its
operations to any other tenant without the previous written consent of LANDLORD,
except as established on clause Twenty Six.

         SIXTY SEVEN: TENANT recognizes and accepts that this Lease Contract is
subject to the endorsements of the Puerto Rico Aqueduct and Sewer Authority
(PRASA). Said endorsements have been obtained by LANDLORD and TENANT.

         SIXTY EIGHT: LANDLORD agrees to indemnify and save harmless TENANT,
TENANT's successors and assigns and TENANT's present and future officers,
directors, employees and agents (collectively "Indemnitees") from and against
any and all liabilities, penalties, fines, forfeitures, demands, damages,
losses, claims, causes of action, suits, judgments, and costs and expenses
incidental thereto (including cost of defense, settlement, reasonable attorney's
fees, reasonable consultant's fees and reasonable expert fees), which TENANT or
any or all of the Indemnitees may hereafter suffer, incur, be responsible for or
disburse as a result of Environmental Liabilities directly or indirectly cause
by LANDLORD when the premises were in its control (collectively "Environmental
Liabilities") directly or indirectly caused by or arising out of any
Environmental Hazards existing on or about the premises except to the extent
that any such existence is caused by TENANT's activities on the premises. The
term "Environmental Hazardous" shall be defined as hazardous substances,
hazardous wastes, pollutants, asbestos, polycholinated biphenyls (PCBs),
petroleum or other fuels (including crude oil or any faction or derivative
thereof) and underground storage tanks. The term "hazardous substances" shall be
as defined in the Comprehensive Environmental Response, Compensation, and
Liability Act (42 U.S.C. Section 9601 et sq) (CERCLA), and any regulations
promulgated pursuant thereto. The term "hazardous wastes" shall be as defined in
the Resource Conservation and Recovery Act (42 U.S.C. Section 6901 et seq)
(RCRA), and any regulations promulgated pursuant thereto. The term "pollutants"
shall be as defined in the Clean Water Act (33 U.S.C. Section 1251 et seq), and
any regulations promulgated pursuant thereto. This provision shall survive
termination of the lease.

                                       30

<PAGE>

         TENANT agrees to indemnify and save harmless LANDLORD, LANDLORD's
successors and assigns and LANDLORD'S present and future officers, directors,
employees and agents (collectively "Indemnities") from and against any and all
liabilities, penalties, fines forfeitures, demands, damages, losses, claims,
causes of action, suits, judgments, and costs and expenses incidental thereto
(including cost of defense, settlement, reasonable attorney's fees, reasonable
consultant fees and reasonable expert fees), which LANDLORD or any or all of the
Indemnitees may hereafter suffer, incur, be responsible for or disburse as a
result of any Environmental Liabilities directly or indirectly caused by or
arising out of any Environmental Hazardous existing on or about the premises but
only to the extent that any such existence is caused by TENANT's activities on
the premises. This provision shall survive termination of the Lease.

         In the event any Environmental Hazards are found at any time to be in
existence or about the premises other than any Environmental Hazards whose
existence is caused by TENANT's activities on the premises, TENANT shall have
the right to terminate this Lease by so notifying LANDLORD in writing.
Notwithstanding anything to the contrary contained herein, TENANT shall not be
required to pay for any environmental Liability as operating expenses,
additional rental or otherwise if TENANT is not responsible for such expenses
pursuant to this paragraph.

         SIXTY NINE: TENANT agrees to be responsible for certain special
facilities located in Project T-0994-0-70, and to remove the same upon the
request of the LANDLORD upon the expiration or sooner termination of the lease
term, in accordance with the terms and conditions of the Lease Contract,
including the following:

         1. Fluorescent lamps throughout building. 

         2. Metal Halide exterior lamps. 

         3. Fire alarm system.

         4. Electrical Power System.

         5. Air conditioning system throughout the building, including seven
            (7) air conditioning units, with ducts and flashing.

         6. Water sprinkler system.

                                       31

<PAGE>
         

         SEVENTY: On June 7, 2005, the TENANT executed an agreement with Caribe
GE International of Puerto Rico, Inc., in order to share the entranceway and
guard services to the Additional Leased Premises, and the TENANT agrees to be
bound by the terms of that agreement, identified as Exhibit C hereof.

         Furthermore, the TENANT agrees to comply with the accords contained in
the letters dated November 23, 2004, May 23, 2005 and July 8, 2005, identified
as Exhibit II hereof.

         IN WITNESS WHEREOF, LANDLORD and TENANT have respectively signed upon
proper authority this Construction and Lease Contract, this 1 day of April, 2005

                   PUERTO RICO INDUSTRIAL DEVELOPMENT COMPANY
                                 SSP #66-0292871

                          [unreadable]
                     BY:------------------------------------
                          [unreadable]



                 INTEGRA CI, INC. D/B/A INTEGRA NEUROSCIENCES PR
                                      SSP# 98-0476814


                     BY:/s/ David B. Holtz
                        -------------------------------------
                            David B. Holtz
                            Vice President, Finance

                                       32


<PAGE>




                                  SCHEDULE "A"


DESCRIPTION OF PARCEL OF LAND
LOT NO. 6 LOCATED AT URBAN ZONE INDUSTRIAL AREA
ANASCO, PUERTO RICO
SITE FOR PROJECT NO. L-154-2-62

================================================================================

         Parcel of land, Lot No. 6, located at urban Zone Industrial Area, 
         Anasco, Puerto Rico.

         It bounds: by the North with Street "A" of the same industrial area, by
the south with Lot No. 6-1 of the same industrial area, by the East with State
Road No. 402; and by the West with Lot No. 8 of the same industrial area.

         It has an approximate surface area of 2,518.59 square meters equivalent
to 0.6408 cuerdas.

         It is affected by a 5.0 feet wide strip in favor of PREPA, running
along the western boundary.



DESCRIPTION OF PARCEL OF LAND, LOT NUMBER 8
LOCATED AT URBAN ZONE INDUSTRIAL AREA
ANASCO, PUERTO RICO
SITE FOR PROJECT NO. T-0994-0-70

===============================================================================

GENERAL:

         Parcel of land, lot number 8, located at Urban Zone Industrial Area,
Anasco, Puerto Rico.

         It bounds: By the North, with Street A of the same industrial area; by
the South, with land owned by Sucn. Arraras; by the East, with Lot number 6 and
8-1 of the same industrial area; and by the West, with land owned by Sucn.
Arraras.

         It has an approximate surface area of 9,459.68 square meters,
equivalent to 2.4068 cuerdas.

         It is affected by the following right of way:

             o A 5' - 0"feet wide strip in favor of PREPA running along the 
               Eastern boundary.

                                       33

<PAGE>



DESCRIPTION OF BUILDING T-0994-0-70
AT ANASCO, PUERTO RICO

================================================================================

         This is a pitched roof type building consisting of reinforced concrete
foundations, structural steel columns and girders supporting 30 feet long steel
joists which in turn support gauge #22 standard galvanized steel deck, covered
by 1.3" isocianurate insulation and a 3 plies built up roofing. Roof ventilators
are provided.

         The structure consists of a main floor 181'- 0"x 120'- 6"out to out
dimension for an area 21,810.50 of sq. ft. of manufacturing space, a lean-to
60'-0"x 10'- 0" for an area of 635.25 sq. ft. This amounts to the total area of
22,445.75 sq. ft. of covered space.

         The floor consists of a 3 1/2" thick reinforced concrete slab. Designed
for a live load of 150 pounds per square feet.

         Exterior walls are of concrete blocks, plastered and painted on both
         sides.

         Interior walls at the lean-to area plastered and painted.

         The wainscoat is 6'- 1"high sprayed-on glazed finished.

         Windows are Miami aluminum type throughout the building.

         Interior doors are made of plywood and exterior doors are industrial
         metal type.

         Clearance in the manufacturing area from finish floor to lowest part of
beams at the side's eaves is 12'- 9".

                                       34


<PAGE>



DESCRIPTION PROJECT NO. T-0810-2-03
ANASCO, P.R.

================================================================================

This is a pitched roof type building consisting of reinforced concrete
foundations, columns & girders supporting 15'- 11"; 17'- 11"1/2 & 23'- 09"feet
long steel joists, which in turn support gauge #22 standard galvanized steel
deck covered by an 2 inches rigid board insulation with 2 plies cold
weatherproofing system. Four exhaust fans are installed.

The structure consist of a main floor (34'- 10"x 129'- 07"& 38'- 04 1/2"x 54"-
10 1/2") for an area of 6,619.56 sq. ft. of manufacturing space; a lean-to 14'-
07"for an area of 416.70 sq. ft. This amounts to a total area of 7,036.26 sq.
ft.

The floor consists of a five (5) inches thick concrete slab with a monolithic
cement finish. Floor slab is designed for a live load of 150 psf. Exterior walls
are six (6) and eight (8) inches thick reinforced concrete plastered and with
spray on and painted. Interior walls at lean-to area plastered and painted with
epoxy.

Metal deck ceiling is painted throughout the building. Windows are glass ones.
Exterior doors area industrial type. One rolling door 14'- 00"x 12'- 00"is
provided at loading area.

Clearance at the manufacturing area from finish floor to lowest part of beams at
the side eaves is 27'- 00".

                                       35

<PAGE>



DESCRIPTION OF BUILDING T-0810-1
AT ANASCO, P.R.

================================================================================

This is a pitched roof type building consisting of reinforced concrete
foundations, steel columns and steel girders supporting 30 feet long steel
joists which in turn support gage #22 standard galvanized steel deck covered by
1.3# isocianurate insulation and a 3 plies built-up roof.

The structure consists of a main floor 60'- 0"x 90'- 6"out to out dimension for
an area of 5,430 sq. ft. This amounts to a total area of 5,430 sq. ft. of
covered floor space.

The floor consists of a 3 1/2"thick reinforced concrete slab designed for a load
capacity of 150 pounds p.s.f. with monolithic cement finish.

Exterior walls are of concrete blocks, plastered and painted on both sides.

Exterior walls are of concrete blocks, plastered and painted on both sides.
Exterior doors are industrial.

Clearance in the manufacturing area from finish floor to lowest part of beams at
the side's eaves is 16'- 0".

                                       36

<PAGE>



DESCRIPTION OF BUILDING T-0810-0-68
AT ANASCO, PUERTO RICO

================================================================================

This is a pitched roof type building consisting of reinforced concrete
foundations, steel columns and steel girders supporting 30 feet long steel
joists which in turn support gage #22 standard galvanized steel deck covered by
1.3# isocianurate insulation and a 3 plies built-up roof.

The structure consists of a main floor 120'- 11"x 90'- 6"out to out dimension
for an area of 10,943.26 sq. ft. of manufacturing space. A lean-to area 30'- 8"x
10'- 6"for an area of 322.04 sq. ft. for sanitary facilities and a loading
platform 16-0"x 10'- 0"for an area of 160 sq. ft. This amounts to a total area
of 11,425.30 sq. ft. of covered floor space.

The floor consists of a 3 1/2" thick reinforced concrete slab designed for a
load capacity of 150 pounds p.s.f. with monolithic cement finish.

Exterior walls are of concrete blocks, plastered and painted on both sides.

Ceiling is rubbed and painted throughout the building.

Interior walls at the lean-to are plastered and painted.

Windows are Miami louvers throughout the building.

Interior doors are made of plywood and exterior ones are industrial type metal.

Clearance in the manufacturing area from finish floor to lowest part of beams at
the side's eaves is 12'- 2".

                                       37

<PAGE>



                                  SCHEDULE "B"

                                                COMPLIANCE REPORT OF WITH
                                                ENVIRONMENTAL REQUIREMENTS



                                    In the period of ___________ to ___________


I.    PERMITS



PERMITS NUMBER                     EXPIRATION                   RENEWAL DATE
                                                                DATE (IF APPLY)



II.   COMPLIANCE ACTIONS


REFERENCE/CASE NUMBER                 DATE                      RESPONSE OF
                                                                    DATE OF


III.  CERTIFICATION

         I certify, under penalty of law, that this document was prepared under
my supervision and direction; and that was based in my investigation by the
persons directly responsible of gathering the information, that the information
here submitted is, according to my best judgment, certain, complete and precise.


                                              ----------------------------------
                                       38

                  Certification of Principal Executive Officer
            Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Stuart M. Essig, certify that:

1.       I have reviewed this quarterly report on Form 10-Q of Integra
         LifeSciences Holdings Corporation;

2.       Based on my knowledge, this report does not contain any untrue
         statement of a material fact or omit to state a material fact necessary
         to make the statements made, in light of the circumstances under which
         such statements were made, not misleading with respect to the period
         covered by this report;

3.       Based on my knowledge, the financial statements, and other financial
         information included in this report, fairly present in all material
         respects the financial condition, results of operations and cash flows
         of the registrant as of, and for, the periods presented in this report;

4.       The registrant's other certifying officer and I are responsible for
         establishing and maintaining disclosure controls and procedures (as
         defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal
         control over financial reporting (as defined in Exchange Act Rules
         13a-15(f) and 15d-15(f)) for the registrant and we have:

         (a)      designed such disclosure controls and procedures, or caused
                  such disclosure controls
 and procedures to be designed under
                  our supervision, to ensure that material information relating
                  to the registrant, including its consolidated subsidiaries, is
                  made known to us by others within those entities, particularly
                  during the period in which this report is being prepared;

         (b)      designed such internal control over financial reporting, or
                  caused such internal control over financial reporting to be
                  designed under our supervision, to provide reasonable
                  assurance regarding the reliability of financial reporting and
                  the preparation of financial statements for external purposes
                  in accordance with generally accepted accounting principles;

         (c)      evaluated the effectiveness of the registrant's disclosure
                  controls and procedures and presented in this report our
                  conclusions about the effectiveness of the disclosure controls
                  and procedures, as of the end of the period covered by this
                  report based on such evaluation; and

         (d)      disclosed in this report any change in the registrant's
                  internal control over financial reporting that occurred during
                  the registrant's most recent fiscal quarter (the registrant's
                  fourth fiscal quarter in the case of an annual report) that
                  has materially affected, or is reasonably likely to materially
                  affect, the registrant's internal control over financial
                  reporting; and

5.       The registrant's other certifying officer and I have disclosed, based
         on our most recent evaluation of internal control over financial
         reporting, to the registrant's auditors and the audit committee of
         registrant's board of directors (or persons performing the equivalent
         functions):

         (a)      all significant deficiencies and material weaknesses in the
                  design or operation of internal control over financial
                  reporting which are reasonably likely to adversely affect the
                  registrant's ability to record, process, summarize and report
                  financial information; and

         (b)      any fraud, whether or not material, that involves management
                  or other employees who have a significant role in the
                  registrant's internal control over financial reporting.



Date: November 9, 2006                    /s/ Stuart M. Essig
                                          -------------------------------------
                                          Stuart M. Essig
                                          President and Chief Executive Officer


                  Certification of Principal Financial Officer
            Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Maureen B. Bellantoni, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Integra LifeSciences
Holdings Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a
material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as
of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial
reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
registrant and we have:

         (a)      designed such disclosure controls and procedures, or caused
                  such disclosure
 controls and procedures to be designed under
                  our supervision, to ensure that material information relating
                  to the registrant, including its consolidated subsidiaries, is
                  made known to us by others within those entities, particularly
                  during the period in which this report is being prepared;

         (b)      designed such internal control over financial reporting, or
                  caused such internal control over financial reporting to be
                  designed under our supervision, to provide reasonable
                  assurance regarding the reliability of financial reporting and
                  the preparation of financial statements for external purposes
                  in accordance with generally accepted accounting principles;

         (c)      evaluated the effectiveness of the registrant's disclosure
                  controls and procedures and presented in this report our
                  conclusions about the effectiveness of the disclosure controls
                  and procedures, as of the end of the period covered by this
                  report based on such evaluation; and

         (d)      disclosed in this report any change in the registrant's
                  internal control over financial reporting that occurred during
                  the registrant's most recent fiscal quarter (the registrant's
                  fourth fiscal quarter in the case of an annual report) that
                  has materially affected, or is reasonably likely to materially
                  affect, the registrant's internal control over financial
                  reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our
most recent evaluation of internal control over financial reporting, to the
registrant's auditors and the audit committee of registrant's board of directors
(or persons performing the equivalent functions):

         (a)      all significant deficiencies and material weaknesses in the
                  design or operation of internal control over financial
                  reporting which are reasonably likely to adversely affect the
                  registrant's ability to record, process, summarize and report
                  financial information; and

         (b)      any fraud, whether or not material, that involves management
                  or other employees who have a significant role in the
                  registrant's internal control over financial reporting.


Date: November 9, 2006                              /s/ Maureen B. Bellantoni
                                                    ----------------------------
                                                    Maureen B. Bellantoni
                                                    Executive Vice President and
                                                    Chief Financial Officer



<PAGE>






                  Certification of Principal Executive Officer
            Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

I, Stuart M. Essig, President and Chief Executive Officer of Integra
LifeSciences Holdings Corporation (the "Company"), hereby certify that, to my
knowledge:

1.   The Quarterly Report on Form 10-Q of the Company for the quarter ended
     September 30, 2006 (the "Report") fully complies with the requirement of
     Section 13(a) or Section 15(d), as applicable, of the Securities Exchange
     Act of 1934, as amended; and

2.   The information contained in the Report fairly presents, in all material
     respects, the financial condition and results of operations of the Company.

Date: November 9, 2006                     /s/ Stuart M. Essig
                                           -------------------
                                           Stuart M. Essig
                                           President and Chief Executive Officer




48



                  Certification of Principal Financial Officer
            Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

I, Maureen B. Bellantoni, Executive Vice President and Chief Financial Officer
of Integra LifeSciences Holdings Corporation (the "Company"), hereby certify
that, to my knowledge:

1.   The Quarterly Report on Form 10-Q of the Company for the quarter ended
     September 30, 2006 (the "Report") fully complies with the requirement of
     Section 13(a) or Section 15(d), as applicable, of the Securities Exchange
     Act of 1934, as amended; and

2.   The information contained in the Report fairly presents, in all material
     respects, the financial condition and results of operations of the Company.

Date: November 9, 2006                              /s/ Maureen B. Bellantoni
                                                    ---------------------
                                                    Maureen B. Bellantoni
                                                    Executive Vice President and
                                                    Chief Financial Officer